<?xml version="1.0" encoding="UTF-8" standalone="yes"?><trialRecordsOutput><serviceExecutionTime>373</serviceExecutionTime><Trial id="105389"><TitleDisplay>Steroid Therapy for Autistic Children</TitleDisplay><TitleOfficial>Double-blind, Randomized, Placebo-Controlled Clinical Trial of Corticosteroids for the Autistic Spectrum Disorder</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">CAAE 0136.258.000-07</Identifier><Identifier type="Secondary Organisational">RBR-7nq8m7</Identifier><Identifier type="Secondary Organisational">167/07</Identifier><Identifier type="Trial Acronym">CAST</Identifier></Identifiers><Indications><Indication id="423">Autism</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>prednisolone</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1077738" type="Company"><TargetEntity id="5038051434" type="organizationId">Hospital Universitario Antonio Pedro</TargetEntity></SourceEntity><SourceEntity id="423" type="ciIndication"><TargetEntity id="F84.0" type="ICD10"/><TargetEntity id="10003805" type="MEDDRA"/><TargetEntity id="D001321" type="MeSH"/><TargetEntity id="-1744075483" type="omicsDisease"/><TargetEntity id="39" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1077738">Hospital Universitario Antonio Pedro</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2010-05-01T00:00:00Z</DateStart><DateChangeLast>2013-01-22T20:27:17Z</DateChangeLast><DateAdded>2013-01-22T20:27:17Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Hospital Universitario Antonio Pedro</Affiliation><Email>adri.r.brito@gmail.com</Email><Name>Adriana Brito</Name><Phone>(5521) 8565-1212</Phone></Contact><Contact type="Public contact"><Affiliation>Hospital Universitario Antonio Pedro</Affiliation><Email>mmdvascon@gmail.com</Email><Name>Marcio Vasconcelos</Name><Phone>(5521) 8741-6187</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male&lt;/li&gt;&lt;li&gt;Aged 3 to 7 years&lt;/li&gt;&lt;li&gt;Autistic spectrum disorder diagnosed using Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition-Text Revision (DSM-IV-TR)&lt;/li&gt;&lt;li&gt;Parental consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Epilepsy&lt;/li&gt;&lt;li&gt;Neurodegenerative disease&lt;/li&gt;&lt;li&gt;Cerebral malformations&lt;/li&gt;&lt;li&gt;History of meningitis or encephalitis&lt;/li&gt;&lt;li&gt;Mass lesion in the central nervous system&lt;/li&gt;&lt;li&gt;Any other neurologic disorder&lt;/li&gt;&lt;li&gt;Gestational history suggestive of fetal or perinatal distress&lt;/li&gt;&lt;li&gt;Not fully meeting  the diagnostic criteria of autism&lt;/li&gt;&lt;li&gt;Patient's parents or caretakers do not give informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>ABFW (Language Assessment Test)</Description></Measure><Measure><Description>ADL (Language Development Assessment)</Description></Measure><Measure><Description>PEABODY (Picture Vocabulary Test, Third Edition)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>subject score at CARS (Childhood Autism Rating Scale)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This double-blind, randomized, placebo-controlled study was to assess the use of corticosteroids for autistic spectrum disorder [&lt;ulink linkType="Reference" linkID="1358932"&gt;1358932&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive placebo or oral prednisolone 1 mg/kg/day daily for 8 weeks and on alternate days from week 9 to 16. Treatment would be reduced by 10% of the initial dose every week from weeks 17 to 20 and would be reduced by 15% per week from weeks 21 to 24 [&lt;ulink linkType="Reference" linkID="1358932"&gt;1358932&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Brazil"><Sites><Site><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Autism</Disease><PatientSegments><PatientSegment><PatientSegment id="10454">Subjects with Asperger's Syndrome</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10455">Subjects with Autistic Disorder</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10456">Subjects with Pervasive Developmental Disorders (NOS)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1020">Brazilian Clinical Trials Registry (ReBec)</Name><Identifiers><Identifier type="Secondary Organisational">RBR-7nq8m7</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Autism" id="18912"><Endpoint>Assessment of the Symptoms of Autism</Endpoint><SubEndpoints><SubEndpoint disease="Autism" id="18917">Assessment of impairment in communication</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Autism" id="18919"><Endpoint>Assessment of Autism Symptoms by Protocol Specified Scales</Endpoint><SubEndpoints><SubEndpoint disease="Autism" id="18922">Assessment by Childhood Autism Rating Scale(CARS)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Autism" id="16847"><Criterion>Subjects with Autism Spectrum Disorders</Criterion></Inclusion><Inclusion disease="Autism" id="16851"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion><SubCriteria><SubCriterion disease="Autism" id="16852">Diagnosed by Diagnostic and Statistical Manual (DSM IV) criteria</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Autism" id="16889"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Autism" id="16897">Subjects with history /scheduled to receive investigational agent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Autism" id="14355"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Autism" id="14356">Subjects with central nervous system diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-01-22T20:27:17Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="106929"><TitleDisplay>An Open-label Trial to Evaluate the Use of Mycophenolate Mofetil in Treatment of Resistant Membranous Nephropathy</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="3441">Membranous glomerulonephritis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mycophenolate mofetil</Name><Drug id="3669">mycophenolate mofetil</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3669">mycophenolate mofetil</Drug><IndicationsPioneer/><Companies><Company><Company id="20559">Columbia University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3669" type="Drug"><TargetEntity id="144096" type="siDrug">Mycophenolate mofetil</TargetEntity></SourceEntity><SourceEntity id="20559" type="Company"><TargetEntity id="4296376980" type="organizationId">Columbia University</TargetEntity></SourceEntity><SourceEntity id="3441" type="ciIndication"><TargetEntity id="10018372" type="MEDDRA"/><TargetEntity id="D015433" type="MeSH"/><TargetEntity id="-1005518329" type="omicsDisease"/><TargetEntity id="3085" type="siCondition"/></SourceEntity><SourceEntity id="629" type="Action"><TargetEntity id="439" type="Mechanism">Inosine 5'-Monophosphate Dehydrogenase (IMPDH) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20559">Columbia University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="11778">PurH purine biosynthesis protein inhibitor</Action><Action id="629">Inosine monophosphate dehydrogenase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="396">Immunosuppressant</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="751">Film coating</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>16</PatientCountEnrollment><PatientCountEvaluable>16</PatientCountEvaluable><DateStart>2013-02-01T00:00:00Z</DateStart><DateChangeLast>2013-02-04T09:41:12Z</DateChangeLast><DateAdded>2013-02-04T09:41:12Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with idiopathic membranous nephropathy previously resistant to steroids, cytotoxic agents or ciclosporin who had nephrotic proteinuria&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of an open-label trial was to evaluate the use of &lt;ulink linkType="Drug" linkID="3669"&gt;mycophenolate mofetil&lt;/ulink&gt; in treatment of resistant membranous nephropathy [&lt;ulink linkType="Reference" linkID="1361573"&gt;1361573&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2000, results published that &lt;ulink linkType="Drug" linkID="3669"&gt;mycophenolate mofetil&lt;/ulink&gt; appeared to reduce proteinuria in some patients with idiopathic resistant membranous nephropathy [&lt;ulink linkType="Reference" linkID="1361573"&gt;1361573&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="3669"&gt;mycophenolate mofetil&lt;/ulink&gt; 250 to 1000 mg/d po bid for 8 months (mean) (dose titrated according to leukocyte count and side effects) [&lt;ulink linkType="Reference" linkID="1361573"&gt;1361573&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-04T09:41:12Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="107951"><TitleDisplay>A Double-blind, Multicenter,Placebo-controlled, Randomized to Assess Enoxaparin in Venous Thromboembolism</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="325">Thromboembolism</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>enoxaparin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="325" type="ciIndication"><TargetEntity id="D013923" type="MeSH"/><TargetEntity id="-338631668" type="omicsDisease"/><TargetEntity id="306" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1078503">Istituto di Medicina Interna e Medicina Vascolare</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>307</PatientCountEnrollment><PatientCountEvaluable>307</PatientCountEvaluable><DateStart>1998-07-09T00:00:00Z</DateStart><DateChangeLast>2013-02-07T13:04:23Z</DateChangeLast><DateAdded>2013-02-07T13:04:22Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients undergoing elective neurosurgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this double-blind, multicenter, placebo-controlled, randomized study to assess &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin&lt;/ulink&gt; in venous thromboembolism [&lt;ulink linkType="Reference" linkID="1359636"&gt;1359636&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In July 1998 the results were published. &lt;ulink linkType="Drug" linkID="13928"&gt;Enoxaparin&lt;/ulink&gt; combined with compression stockings was more effective than compression stockings alone and did not cause excess bleeding [&lt;ulink linkType="Reference" linkID="1359636"&gt;1359636&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="13928"&gt;enoxaparin&lt;/ulink&gt;, 40 mg s.c. o.d. x 8 d (first dose given within 24 h after surgery ) + compression stockings (on the morning of surgery and until discharge) (n= 153); placebo + compression stockings (on the morning of surgery and until discharge) (n= 154) [&lt;ulink linkType="Reference" linkID="1359636"&gt;1359636&lt;/ulink&gt;]&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><ChangeHistory><Change type="added"><Date>2013-02-07T13:04:22Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="111261"><TitleDisplay>A study to determine the efficacy of direct renin inhibitors with aliskiren added to angiotensin receptor blockers (ARBs) on home blood pressure (BP) and cardiorenal biomarkers in Japanese hypertensive patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="106" role="Therapeutic effect marker" type="Proteomic">N-terminal Pro Brain Natriuretic Peptide</BiomarkerName><BiomarkerName id="120" role="Therapeutic effect marker" type="Genomic;Proteomic">Cystatin C</BiomarkerName><BiomarkerName id="122" role="Therapeutic effect marker" type="Genomic;Proteomic">Renin</BiomarkerName><BiomarkerName id="2586" role="Therapeutic effect marker" type="Physiological">Blood pressure</BiomarkerName><BiomarkerName id="2864" role="Therapeutic effect marker" type="Biochemical">Aldosterone</BiomarkerName><BiomarkerName id="4139" role="Therapeutic effect marker" type="Physiological">Urinary albumin excretion rate</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>aliskiren</Name><Drug id="29717">aliskiren</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="29717">aliskiren</Drug><IndicationsPioneer/><Companies><Company><Company id="26092">Jichi Medical School</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="29717" type="Drug"><TargetEntity id="267580" type="siDrug">Aliskiren hemifumarate</TargetEntity></SourceEntity><SourceEntity id="26092" type="Company"><TargetEntity id="5035524352" type="organizationId">Jichi Medical University</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity><SourceEntity id="343" type="Action"><TargetEntity id="484" type="Mechanism">Renin Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="26092">Jichi Medical School</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="343">Renin inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2657">Antihypertensive</Class><Class id="2667">Antiarteriosclerotic</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="742">Pellet</Technology><Technology id="667">Peptidomimetic</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Japanese Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>51</PatientCountEnrollment><PatientCountEvaluable>51</PatientCountEvaluable><DateStart>2012-05-20T00:00:00Z</DateStart><DateChangeLast>2013-02-21T05:44:10Z</DateChangeLast><DateAdded>2013-02-21T05:44:10Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Japanese hypertensive patients, with office BP   &gt;/= 140/90 mmHg&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Office and home morning and evening BP levels</Description><Timeframe>Before and after 3 months of add-on therapy with aliskiren</Timeframe></Measure><Measure><Description>Plasma RAAS activity (plasma renin activity, PRA; plasma renin concentration, PRC; and aldosterone)</Description><Timeframe>Before and after 3 months of add-on therapy with aliskiren</Timeframe></Measure><Measure><Description>Cardiorenal biomarkers (urinary albumin excretion [UAE], circulating N-terminal B-type natriuretic peptide [NT ProBNP] and cystatin C)</Description><Timeframe>Before and after 3 months of add-on therapy with aliskiren</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This  study was to determine the efficacy of direct renin inhibitors with &lt;ulink linkType="Drug" linkID="29717"&gt;aliskiren&lt;/ulink&gt; added to angiotensin receptor blockers  (ARBs) on home blood pressure (BP) and cardiorenal biomarkers in Japanese hypertensive patients  [&lt;ulink linkType="Reference" linkID="1295304"&gt;1295304&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In May 2012, results were presented. A significant decrease in     office systolic/diastolic BP (158/81 to 139/74 mmHg), morning BP (157/80 to 143/73 mmHg), and evening BP (148/74 to 132/67 mmHg) (all  p  &amp;lt; 0.001) was observed with &lt;ulink linkType="Drug" linkID="29717"&gt;aliskiren&lt;/ulink&gt; add-on therapy, without an increase in pulse rate. At the end of the study, a significant reduction was observed in the PRA (median, 1.0 to 0.3 pg/ml), estimated glomerular filtration rate (eGFR) (mean, 69 to 65 ml/min/1.73 m2), and UAE and NT proBNP levels  (median, 30 to 17 mg/g·Cr and 95 to 90 pg/ml, respectively), whereas PRC was increased (median, 6.3 to 41.0 ng/ml/h; all  p  &amp;lt; 0.01 by paired t-test or Wilcoxon test). There were no significant changes   observed in levels of plasma aldosterone (mean, 71 versus 65 pg/ml) or cystatin C (mean, 1.01 versus 1.03 ng/ml). The treatment-induced changes in UAE and NT proBNP were not associated with office BP,  home morning and evening systolic BP changes, whereas the treatment-induced reduction of eGFR was positively associated with home morning systolic BP change (p  = 0.001)   [&lt;ulink linkType="Reference" linkID="1295304"&gt;1295304&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients   received add-on therapy with &lt;ulink linkType="Drug" linkID="29717"&gt;aliskiren&lt;/ulink&gt; (150 mg qd)  [&lt;ulink linkType="Reference" linkID="1295304"&gt;1295304&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="267862">aliskiren</Intervention><Treatments><Treatment><Dose>150 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-02-21T05:44:10Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="115574"><TitleDisplay>An open-label study to evaluate the effect of mupirocin in the prevention of infections with Staphylococcus aureus in liver transplantation</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="308">Staphylococcus aureus infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>mupirocin</Name><Drug id="3665">mupirocin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3665">mupirocin</Drug><IndicationsPioneer/><Companies><Company><Company id="26104">US Department of Veterans Affairs</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3665" type="Drug"><TargetEntity id="115070" type="siDrug">Mupirocin</TargetEntity></SourceEntity><SourceEntity id="26104" type="Company"><TargetEntity id="8589934520" type="organizationId">US Department of Veterans Affairs</TargetEntity></SourceEntity><SourceEntity id="308" type="ciIndication"><TargetEntity id="4176" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="26104">US Department of Veterans Affairs</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="523">Isoleucyl tRNA synthetase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15186">Topical dermatological antibacterial product</Class><Class id="1538">Bacterial protein synthesis inhibitor</Class><Class id="1594">Antibacterial</Class><Class id="439">RNA synthesis inhibitor</Class></Class><Technologies><Technology id="615">Aerosol formulation dermatological</Technology><Technology id="66">Antibiotic</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="619">Nasal formulation local</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Prevention</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEvaluable>31</PatientCountEvaluable><DateStart>2003-01-27T00:00:00Z</DateStart><DateChangeLast>2013-03-13T05:02:55Z</DateChangeLast><DateAdded>2013-03-13T05:02:55Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with end-stage liver disease who were candidates for liver transplantation and liver transplant recipients with pretransplant nostril culture positive for Staphylococcus aureus&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this open-label study was to evaluate the effect of &lt;ulink linkType="Drug" linkID="3665"&gt;mupirocin&lt;/ulink&gt; in the prevention of infections with Staphylococcus aureus in liver transplantation [&lt;ulink linkType="Reference" linkID="1376476"&gt;1376476&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results published in January 2003, showed that &lt;ulink linkType="Drug" linkID="3665"&gt;mupirocin&lt;/ulink&gt; 2% was effective in decolonizing Staphylococcus aureus nasal carriage, but it did not prevent Staphylococcus aureus infections in patients undergoing liver transplantation [&lt;ulink linkType="Reference" linkID="1376476"&gt;1376476&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received &lt;ulink linkType="Drug" linkID="3665"&gt;mupirocin&lt;/ulink&gt; 2% top. b.i.d. x 5 d [&lt;ulink linkType="Reference" linkID="1376476"&gt;1376476&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-03-13T05:02:55Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="124309"><TitleDisplay>The effects of ginger on type 2 diabetes</TitleDisplay><TitleOfficial>The effects of ginger on hypertension in patients with type 2 diabetes</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT201111306278N2</Identifier><Identifier type="Other">پ/17/1/105713</Identifier></Identifiers><Indications><Indication id="178">Hypertension</Indication></Indications><BiomarkerNames><BiomarkerName id="330" role="Therapeutic effect marker" type="Physiological">Systolic blood pressure</BiomarkerName><BiomarkerName id="332" role="Therapeutic effect marker" type="Physiological">Diastolic blood pressure</BiomarkerName><BiomarkerName id="2095" role="Therapeutic effect marker" type="Physiological">Mean arterial pressure</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ginger</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1041540" type="Company"><TargetEntity id="5035559685" type="organizationId">Shahid Sadoghi University of Medical Science</TargetEntity></SourceEntity><SourceEntity id="178" type="ciIndication"><TargetEntity id="10020772" type="MEDDRA"/><TargetEntity id="D006973" type="MeSH"/><TargetEntity id="-369992864" type="omicsDisease"/><TargetEntity id="240" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1041540">Shahid Sadoughi University of Medical Sciences and Health Services</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>84</PatientCountEnrollment><DateStart>2011-04-21T00:00:00Z</DateStart><DateChangeLast>2018-01-11T22:05:15Z</DateChangeLast><DateAdded>2013-04-26T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>University of Medical Sciences and Health Services ;  Bahonar sq.Yazd Yazd Yazd Iran, Islamic Republic Of</Affiliation><Email>mozaffari.kh@gmail.com</Email><Name>Hassan Mozaffari</Name><Phone>983517240171</Phone></Contact><Contact type="Public contact"><Affiliation>University of Medical Sciences and Health Services ,Yazd ; Yazd ; Yazd ; Iran, Islamic Republic Of ;</Affiliation><Email>b.talaei@ssu.ac.ir b_talaei@hotmail.com</Email><Name>Behrouz Soflaei</Name><Phone>983517240171</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with type 2 diabetes&lt;/li&gt;&lt;li&gt;Patients newly diagnosed diabetes to  ten years&lt;/li&gt;&lt;li&gt;FBS&amp;lt; 180, 2 Hpp &amp;lt; 250 &lt;/li&gt;&lt;li&gt;Using estrogen or progesterone&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Using insulin&lt;/li&gt;&lt;li&gt;Pregnancy and lactation&lt;/li&gt;&lt;li&gt;Vitamin and mineral supplementation&lt;/li&gt;&lt;li&gt;Thyroid, kidney, CVD diseases&lt;/li&gt;&lt;li&gt;Using TG and cholesterol lowering drugs&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Systol Hypertention: mmHg</Description><Timeframe>Before - every two weeks during the intervention and after intervention</Timeframe></Measure><Measure><Description>Diastole Hypertention: mmhg</Description><Timeframe>Before - every two weeks during the intervention and after intervention</Timeframe></Measure><Measure><Description>Mean arterial pressure: mmHg</Description><Timeframe>Before - every two weeks during the intervention and after intervention</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of the study was to study the effects of ginger on hypertension in patients with type 2 diabetes  [&lt;ulink linkType="Reference" linkID="1410077"&gt;1410077&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive capsules of either ginger 1 g tid  or placebo (microcristalline cellulose) for   2 months [&lt;ulink linkType="Reference" linkID="1410077"&gt;1410077&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Yazd Diabetes Research Center</Name><Address1>Yazd</Address1><Address2>Yazd</Address2><CountrySubDivision>Yazd</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Behrouz Talaei Khales soflaei</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT201111306278N2</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1543"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Non-insulin dependent diabetes" id="1547">Hypertension</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Non-insulin dependent diabetes" id="1580"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Non-insulin dependent diabetes" id="581"><Criterion>Subjects with Diabetes Mellitus</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="584">Subjects with type 2 diabetes mellitus</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Non-insulin dependent diabetes" id="837"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="891"><Criterion>Subjects co-morbid with heart disorders/diseases</Criterion></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="946"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="957">Subjects on/treated with insulin</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="963"><Criterion>Subjects with History of/Current Use of a Prohibited Medication</Criterion><SubCriteria><SubCriterion disease="Non-insulin dependent diabetes" id="5063">Subjects on/treated with dietary supplements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Non-insulin dependent diabetes" id="5070"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2011-06-30T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>2.35 Months</EnrollmentPeriod><EnrollmentRate>35.74 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-04-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change><Change type="updated"><Date>2017-07-13T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="127742"><TitleDisplay>Randomized, Controlled Trial to Evaluate the Efficiency of Absorbable Barbed Suture (V-Loc180) During Laparoscopic Myomectomy</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000007591</Identifier></Identifiers><Indications><Indication id="347">Wound healing</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Polysorb</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>V-Loc180</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1040210" type="Company"><TargetEntity id="5035543254" type="organizationId">Juntendo University Hospital</TargetEntity></SourceEntity><SourceEntity id="17111" type="Company"><TargetEntity id="5000142555" type="organizationId">Covidien Ltd</TargetEntity></SourceEntity><SourceEntity id="347" type="ciIndication"><TargetEntity id="D014945" type="MeSH"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1040210">Juntendo University Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="17111">Covidien plc</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>60</PatientCountEnrollment><DateStart>2012-04-30T00:00:00Z</DateStart><DateChangeLast>2014-01-29T08:27:07Z</DateChangeLast><DateAdded>2013-05-07T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tel Aviv Medical Center; Tel Aviv; Israel</Affiliation><Email>hiroaki.kato@covidien.com</Email><Name>Hiroaki Kato</Name></Contact><Contact type="Public contact"><Affiliation>Juntendo UniversityHospital Department of Obstetrics and Gynecology , Hongo 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan</Affiliation><Name>Iwaho Kikuchi</Name></Contact><Contact type="Public contact"><Affiliation>Juntendo UniversityHospital, Department of Obstetrics and Gynecology; Hongo 3-1-3, Bunkyo-ku, Tokyo 113-8431, Japan</Affiliation><Name>Iwaho Kikuchi </Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Interstitial myoma of the uterus&lt;/li&gt;&lt;li&gt;Myomas can be closed with single layer suture&lt;/li&gt;&lt;li&gt;Within three uterine fibroids&lt;/li&gt;&lt;li&gt;Within a 10 cm uterine fibroid in diameter&lt;/li&gt;&lt;li&gt;No history of gynecological surgery (myomectomy, cystectomy)&lt;/li&gt;&lt;li&gt;Healthy organ function&lt;/li&gt;&lt;li&gt;Obtained the written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Active bacterial infection or fungal infection&lt;/li&gt;&lt;li&gt;Under continuing systemic administration (iv or oral) of steroids&lt;/li&gt;&lt;li&gt;Complicated condition with uncontrolled diabetes mellitus (HbA1c&amp;gt; 8.0%)&lt;/li&gt;&lt;li&gt;Judged difficulty due to study complications related to a psychiatric disorder or psychological symptoms&lt;/li&gt;&lt;li&gt;Judged unsuitable patient for study participation by the investigator for any other reason&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Suturing time in the uterine wall defect</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Blood loss</Description></Measure><Measure><Description>Amount of drainage</Description></Measure><Measure><Description>Duration of drain placement</Description></Measure><Measure><Description>Length of hospital stay</Description></Measure><Measure><Description>Adverse events (intraoperative and postoperative)</Description></Measure><Measure><Description>Degree of adhesion formation by second-look</Description></Measure><Measure><Description>Number of sutures used</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this randomized, comparative study was to confirm the superiority of a test treatment group using V-Loc180 to a current standard of care group using a multifilament suture Polysorb in patients undergoing laparoscopic myomectomy [&lt;ulink linkType="Reference" linkID="1416276"&gt;1416276&lt;/ulink&gt;]. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be treated with Polysorb or  V-Loc180 [&lt;ulink linkType="Reference" linkID="1416276"&gt;1416276&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Uterine fibroids</Disease><PatientSegments><PatientSegment><PatientSegment id="11544">Subjects with Uterine Fibroids</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="11552">Subjects with History of/Scheduled for Therapy</PatientSegment><SubSegments><SubSegment id="11555">Subjects with history of/scheduled for surgical/procedural therapy</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">JPRN-UMIN000007591</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><SecondaryEndpoints><SecondaryEndpoint disease="Uterine fibroids" id="23037"><Endpoint>Assessment of Fertility Outcomes</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Uterine fibroids" id="23039"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Uterine fibroids" id="23040">Assessment of post-operative blood loss</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Uterine fibroids" id="23041"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Uterine fibroids" id="20498"><Criterion>Subjects with Uterine Fibroids</Criterion></Inclusion><Inclusion disease="Uterine fibroids" id="20512"><Criterion>Subjects Without Uterine Fibroid Therapy</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Uterine fibroids" id="17667"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion></Exclusion><Exclusion disease="Uterine fibroids" id="17673"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion></Exclusion><Exclusion disease="Uterine fibroids" id="17675"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Uterine fibroids" id="17683"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Exclusion><Exclusion disease="Uterine fibroids" id="17689"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-05-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="139649"><TitleDisplay>An Investigation into the Effects of Sodium Nitrite on Cardiac Function in Patients Undergoing Cardiac Catheterization</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UKCRN 14103</Identifier></Identifiers><Indications><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>sodium nitrite</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1040912" type="Company"><TargetEntity id="4298156505" type="organizationId">British Heart Foundation</TargetEntity></SourceEntity><SourceEntity id="23507" type="Company"><TargetEntity id="4296365401" type="organizationId">King's College London</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="23507">King's College London</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1040912">British Heart Foundation</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>50</PatientCountEnrollment><DateEnd type="estimated">2015-04-30T00:00:00Z</DateEnd><DateChangeLast>2014-02-07T13:29:52Z</DateChangeLast><DateAdded>2013-06-13T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Kings College Hospital</Affiliation><Email>katherinemartin1@nhs.net ,</Email><Name>Katherine Martin</Name></Contact><Contact type="Public contact"><Name>Ajay Shah</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients undergoing cardiac catheterization for investigation of ischemic heart disease&lt;/li&gt;&lt;li&gt;Patients who do not have an adequate understanding of verbal or written English will still be given the opportunity to participate through a professional or informal translation service in their preferred language&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Patients who are unable to consent for themselves&lt;/li&gt;&lt;li&gt;Any patient with low blood pressure (&amp;lt; 90 mmHg systolic). Nitrite and nitrate very rarely lower the blood pressure further&lt;/li&gt;&lt;li&gt;Glucose-6-Phosphatase deficiency&lt;/li&gt;&lt;li&gt;Significant flow limiting coronary atherosclerosis&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To assess using a high fidelity catheter placed in the left ventricle and measuring the response to the infusion of nitrite at three doses or glyceryl nitrate (GTN) at one dose for comparison</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to assess using a high fidelity catheter placed in the left ventricle and measuring the response to the infusion of sodium nitrite at three doses or glyceryl nitrate (GTN) at one dose for comparison. The study aimed  to evaluate the response of the heart to nitrite [&lt;ulink linkType="Reference" linkID="1438500"&gt;1438500&lt;/ulink&gt;].  &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive infusion of sodium nitrite at three doses or glyceryl nitrate (GTN) at one dose [&lt;ulink linkType="Reference" linkID="1438500"&gt;1438500&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="UK"><Sites><Site><Contacts/></Site><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="207">Subjects Undergoing /Underwent Major Cardiac Intervention</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8419">Subjects with Visceral Pain</PatientSegment><SubSegments><SubSegment id="8420">Subjects with cardiac pain</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms><OtherEndpoints><OtherEndpoint disease="Coronary artery disease" id="2666"><Endpoint>Assessment of Procedure and Procedure Related Events</Endpoint></OtherEndpoint><OtherEndpoint disease="Pain" id="25894"><Endpoint>Assessment of Response Rates (RR)</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1170">Cardiac catheterization/coronary angiography</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22134"><Criterion>Subjects with Visceral Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22135">Subjects with chest pain of cardiac origin</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22189"><Criterion>Conditions Associated with Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22192">Subjects with cardiovascular disease/disorder associated pain</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1780"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20095"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Pain" id="20097">Subjects with pre-specified vital signs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Pain" id="20115"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-06-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="148573"><TitleDisplay>Predictors of Impaired Daytime Sleep and Wakefulness in Patients With Parkinson Disease Treated With Older (Ergot) Versus Newer (Nonergot) Dopamine Agonists</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="255">Parkinsons disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bromocriptine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pergolide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pramipexole</Name><Drug id="4151">pramipexole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ropinirole</Name><Drug id="4908">ropinirole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4151">pramipexole</Drug><IndicationsPioneer/><Companies><Company><Company id="20688">University of Toronto</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4908">ropinirole</Drug><IndicationsPioneer/><Companies><Company><Company id="20688">University of Toronto</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4908" type="Drug"><TargetEntity id="100359" type="siDrug">Ropinirole hydrochloride</TargetEntity></SourceEntity><SourceEntity id="4151" type="Drug"><TargetEntity id="130601" type="siDrug">Pramipexole hydrochloride</TargetEntity></SourceEntity><SourceEntity id="20688" type="Company"><TargetEntity id="4296883790" type="organizationId">University of Toronto</TargetEntity></SourceEntity><SourceEntity id="255" type="ciIndication"><TargetEntity id="G20" type="ICD10"/><TargetEntity id="10061536" type="MEDDRA"/><TargetEntity id="D010300" type="MeSH"/><TargetEntity id="-342157116" type="omicsDisease"/><TargetEntity id="127" type="siCondition"/></SourceEntity><SourceEntity id="149" type="Action"><TargetEntity id="131" type="Mechanism">Dopamine D2 Agonists</TargetEntity></SourceEntity><SourceEntity id="779" type="Action"><TargetEntity id="132" type="Mechanism">Dopamine D3 Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="20688">University of Toronto</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="149">Dopamine D2 receptor agonist</Action><Action id="779">Dopamine D3 receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2941">Antidepressant</Class><Class id="2947">Antiparkinsonian</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>80</PatientCountEnrollment><PatientCountEvaluable>80</PatientCountEvaluable><DateChangeLast>2014-01-30T11:13:32Z</DateChangeLast><DateAdded>2013-08-02T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Eighty nondemented, independent PD patients treated with dopamine agonists at the Toronto Western Hospital Sleep Research Unit, Toronto, Ontario&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Pathologic daytime sleep latency</Description></Measure><Measure><Description>Mean Multiple Sleep Latency Test score</Description></Measure><Measure><Description>Mean Maintenance of Wakefulness Test latency</Description></Measure><Measure><Description>Epworth Sleepiness Scale</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to perform a systematic evaluation of excessive daytime sleepiness using standard polysomnographic techniques [&lt;ulink linkType="Reference" linkID="1460228"&gt;1460228&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In January 2004, results were published. With respect to mean Multiple Sleep Latency Test scores (p = 0.90) or mean Maintenance of Wakefulness Test latencies (p = 0.29), patients treated with &lt;ulink linkType="Drug" linkID="4151"&gt;pramipexole dihydrochloride&lt;/ulink&gt; (n = 29), &lt;ulink linkType="Drug" linkID="4908"&gt;ropinirole&lt;/ulink&gt; (n = 28), or bromocriptine mesylate or pergolide mesylate (n = 23) did not differ. Pathologic daytime sleep latencies were observed in 18.8% of patients. High levodopa dosage equivalents was the main risk factor associated with pathologic daytime sleep latency. Subjective accounts of daytime sleep and wakefulness were not related to impaired daytime sleepiness or wakefulness (p = 0.72) [&lt;ulink linkType="Reference" linkID="1460228"&gt;1460228&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients treated with  &lt;ulink linkType="Drug" linkID="4151"&gt;pramipexole dihydrochloride&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="4908"&gt;ropinirole&lt;/ulink&gt;,  bromocriptine mesylate or pergolide mesylate were enrolled and observed [&lt;ulink linkType="Reference" linkID="1460228"&gt;1460228&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms><PatientSegmentByDisease><Disease>Parkinsons disease</Disease><PatientSegments><PatientSegment><PatientSegment id="7375">Subjects with History of Treatment</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries/><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Parkinsons disease" id="44293"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Parkinsons disease" id="10179">Assessment of sleep parameters</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Parkinsons disease" id="6112"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="6114">Subjects with history of dopamine agonist therapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Parkinsons disease" id="6168"><Criterion>Subjects with Idiopathic Parkinson's Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Parkinsons disease" id="7713"><Criterion>Subjects with Non-Motor Symptoms of Parkinson's Disease</Criterion><SubCriteria><SubCriterion disease="Parkinsons disease" id="7719">Subjects with dementia</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-08-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="158291"><TitleDisplay>Prospective Trial of Selective Ultrasound-Guided Obturator Nerve Blockade for Total Knee Replacement</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">ACTRN12607000640404</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>bupivacaine, AstraZeneca</Name><Drug id="48945">bupivacaine, AstraZeneca</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>morphine</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4271">ropivacaine</Drug><IndicationsPioneer/><Companies><Company><Company id="21104">St Vincents Hospital (Melbourne) Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="48945">bupivacaine, AstraZeneca</Drug><IndicationsPioneer/><Companies><Company><Company id="21104">St Vincents Hospital (Melbourne) Ltd</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4271" type="Drug"><TargetEntity id="129999" type="siDrug">Ropivacaine</TargetEntity><TargetEntity id="150269" type="siDrug">Ropivacaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="48945" type="Drug"><TargetEntity id="91311" type="siDrug">Bupivacaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="21104" type="Company"><TargetEntity id="4298146516" type="organizationId">St Vincent's Hospital (Melbourne) Ltd</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21104">St Vincents Hospital (Melbourne) Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="596">Injectable formulation</Technology><Technology id="654">Intrathecal formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="767">Rectal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><DateStart>2008-02-01T00:00:00Z</DateStart><DateChangeLast>2017-05-18T16:00:11Z</DateChangeLast><DateAdded>2013-10-30T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Department of Anaesthesia,St Vincents Hospital,Victoria Parade,Fitzroy, Victoria 3065, Australia</Affiliation><Email>timothy.lee@svhm.org.au</Email><Name>Timothy Lee</Name><Phone>92882211</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Undergoing unilateral total knee replacement&lt;/li&gt;&lt;li&gt;Communicative in English&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Without preexisting lower limb neurological deficits&lt;/li&gt;&lt;li&gt;Without opioid tolerance&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Cumulative morphine requirements</Description><Timeframe>6, 12 and 24 h post-surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Block performance time</Description><Timeframe>Measured during block placement, from time of needle insertion to time of needle removal</Timeframe></Measure><Measure><Description>Hip adductor strength</Description><Timeframe>Measured at 6 h post-surgery</Timeframe></Measure><Measure><Description>Cutaneous sensory deficit in obturator nerve distribution</Description><Timeframe>Measured at 6 h post-surgery</Timeframe></Measure><Measure><Description>Visual analogue pain scores</Description><Timeframe>6, 12 and 24 h post-surgery</Timeframe></Measure><Measure><Description>Patient satisfaction</Description><Timeframe>Measured at 24 h</Timeframe></Measure><Measure><Description>Complications</Description><Timeframe>Assessed at 10 days postoperatively</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of the study is  to determine its efficacy in providing analgesia following total knee joint replacement [&lt;ulink linkType="Reference" linkID="1489583"&gt;1489583&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would undergo selective ultrasound-guided obturator nerve blockade  preoperatively (using &lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; 37.5 to 75 mg), in addition to continuous femoral nerve blockade (&lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; 75 to 150 mg) and spinal anesthesia (isobaric &lt;ulink linkType="Drug" linkID="48945"&gt;bupivacaine&lt;/ulink&gt; 15 to 20 mg). Postoperative analgesia provided by femoral nerve local anaesthetic infusion (&lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; 16 to 24mg/hr), and morphine patient-controlled analgesia device (morphine 1 mg bolus at 5 min lockout) [&lt;ulink linkType="Reference" linkID="1489583"&gt;1489583&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Address3> 3065</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8386">Subjects with Acute Pain</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8424">Subjects with Post-Operative Pain</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1011">Australian New Zealand Clinical Trials Registry (ANZCTR)</Name><Identifiers><Identifier type="Secondary Organisational">ACTRN12607000640404</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25874">Based on Visual analog scale[VAS]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="25929"><Endpoint>Assessment of Procedural Analgesia/Anesthesia</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25931">Assessment of duration of block</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26000"><Endpoint>Assessment of Pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26007"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26053"><Endpoint>Assessment of Morbidity</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26055">Assessment of block-related complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35228">Assessment of patient satisfaction</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22087"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22088">Subjects with acute pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22142"><Criterion>Subjects with Peri-operative Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="22143">Subjects with post operative pain</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20112"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Pain" id="20114">Subjects co-morbid with CNS disorders/diseases</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Pain" id="20126">Subjects with hypersensitivity/contraindications to analgesics</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Non-Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2013-10-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="167008"><TitleDisplay>The Pharmacokinetics and Safety of Onartuzumab (MetMAb) in Chinese Patients With Locally Advanced or Metastatic Solid Tumors</TitleDisplay><TitleOfficial>A Phase I Study Of The Pharmacokinetics And Safety Of Onartuzumab In Chinese Patients With Locally Advanced Or Metastatic Solid Tumors</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02031731</Identifier><Identifier type="Organisational Study">YO28211</Identifier></Identifiers><Indications><Indication id="3713">Advanced solid tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>onartuzumab</Name><Drug id="46018">onartuzumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="46018">onartuzumab</Drug><IndicationsPioneer/><Companies><Company><Company id="19446">Roche Holding AG</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="46018" type="Drug"><TargetEntity id="449990" type="siDrug">Onartuzumab</TargetEntity></SourceEntity><SourceEntity id="19446" type="Company"><TargetEntity id="4295890594" type="organizationId">Roche Holding AG</TargetEntity></SourceEntity><SourceEntity id="675" type="Action"><TargetEntity id="1625" type="Mechanism">HGFR (MET; c-Met) Inhibitors</TargetEntity><TargetEntity id="2584" type="Mechanism">Hepatocyte Growth Factor (HGF) Antagonists</TargetEntity><TargetEntity id="2586" type="Mechanism">Anti-HGFR (Met)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>3</NumberOfSites><CompaniesSponsor><Company id="19446">Roche Holding AG</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="18518">MET gene modulator</Action><Action id="675">Hepatocyte growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="695">Metastasis inhibitor</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="537">Chimeric antibody</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2014-01-13T00:00:00Z</DateStart><DateEnd type="actual">2014-04-14T00:00:00Z</DateEnd><DateChangeLast>2017-03-27T12:50:29Z</DateChangeLast><DateAdded>2014-01-13T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hoffmann-La Roche</Affiliation><Name>Clinical Trials</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age&amp;gt;/= 18 years&lt;/li&gt;&lt;li&gt;Histologically confirmed locally advanced or metastatic solid tumor that does not respond to standard treatment or for which there is no further standard treatment&lt;/li&gt;&lt;li&gt;Eastern Cooperative Oncology Group (ECOG) performance status from 0 to 2&lt;/li&gt;&lt;li&gt;Use of effective contraception&lt;/li&gt;&lt;li&gt;Life expectancy&amp;gt; 3 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Brain metastasis or spinal cord compression that has not yet been definitively treated with surgery and/or radiation, and/or patients with brain metastasis that have been receiving corticosteroids&lt;/li&gt;&lt;li&gt;Previously diagnosed and treated central nervous system (CNS) metastasis or spinal cord compression that has not been clinically stable for at least 2 months&lt;/li&gt;&lt;li&gt;Treatment with anti-tumor therapy within 4 weeks before the start of study treatment, with the following exception: patients with metastatic prostate cancer on maintenance hormonal therapy, provided they meet all other eligibility criteria&lt;/li&gt;&lt;li&gt;Current, serious or uncontrolled, systemic illness&lt;/li&gt;&lt;li&gt;Recent stroke (within the past 6 months)&lt;/li&gt;&lt;li&gt;Active autoimmune disease that is not controlled by nonsteroidal anti-inflammatory drugs (NSAIDs)&lt;/li&gt;&lt;li&gt;History of cardiovascular conditions&lt;/li&gt;&lt;li&gt;Any other disease, gastrointestinal abnormality, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the patient at high risk from treatment complications&lt;/li&gt;&lt;li&gt;Receipt of any investigational agent, or participation in any other clinical study, within 4 weeks before the start of study treatment&lt;/li&gt;&lt;li&gt;Major surgery within 4 weeks before the start of study treatment, without complete recovery&lt;/li&gt;&lt;li&gt;Significant traumatic injury within 3 weeks before the start of study treatment (All wounds must be fully healed prior to day 1)&lt;/li&gt;&lt;li&gt;Uncontrolled excess calcium levels&lt;/li&gt;&lt;li&gt;Known human immunodeficiency virus (HIV) infection&lt;/li&gt;&lt;li&gt;Inadequate organ function&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of adverse events</Description><Timeframe>Up to one year</Timeframe></Measure><Measure><Description>Total exposure of MetMAb, as measured by area under the concentration-time curve (AUC)</Description><Timeframe>Up to one year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Incidence of anti-therapeutic antibodies against MetMAb</Description><Timeframe>Up to one year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase I study would examine the pharmacokinetics and safety of onartuzumab (&lt;ulink linkType="Drug" linkID="46018"&gt;MetMAb&lt;/ulink&gt;) in      Chinese patients with locally advanced or metastatic solid tumors.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would  be divided      into three cohorts, which will each be given a different dose of &lt;ulink linkType="Drug" linkID="46018"&gt;MetMAb&lt;/ulink&gt;. The cohorts would be      treated sequentially with 4, 15 or 30 mg/kg of &lt;ulink linkType="Drug" linkID="46018"&gt;MetMAb&lt;/ulink&gt; iv q3w. Patients would be treated for up to 16 cycles (21 days each) or one      year, whichever occurs first, in the absence of disease progression.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Beijing Cancer Hospital</Name><Address1>Beijing</Address1><Address3>100142</Address3><Contacts/></Site><Site><Name>Sun Yet-sen University Cancer Center</Name><Address1>Guangzhou</Address1><Address3>510060</Address3><Contacts/></Site><Site><Name>the First Hospital of Jilin University</Name><Address1>Changchun</Address1><Address3>130021</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7960">Subjects with Locally Advanced Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7961">Subjects with Advanced/Metastatic Solid Tumors</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7967">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02031731</Identifier></Identifiers></Registry><Registry><Name id="1039">Center for Drug Evaluation</Name><Identifiers><Identifier/></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15287"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15250"><Endpoint>Assessment of Antibodies</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13095"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13096"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13102"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13105">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13109"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13110">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Solid tumor" id="13111">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Solid tumor" id="13112">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13129"><Criterion>Subjects with Treatment Refractory Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10714"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10731"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10737">Patient with history of surgical interventions/procedure</SubCriterion><SubCriterion disease="Solid tumor" id="10738">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="26453"><Criterion>Subjects with Evidence of Metastasis</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10761">Subjects with brain/CNS metastasis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2014-04-14T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2014-01-08T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-01-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-11-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="193375"><TitleDisplay>Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children</TitleDisplay><TitleOfficial>Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in children-a Single Blinded Randomized Controlled Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00380497</Identifier><Identifier type="Organisational Study">1000008846</Identifier></Identifiers><Indications><Indication id="3010">Colonoscopy</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Golytely</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Pico-Salax</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="16994" type="Company"><TargetEntity id="4298148028" type="organizationId">Hospital for Sick Children</TargetEntity></SourceEntity><SourceEntity id="3010" type="ciIndication"><TargetEntity id="10010007" type="MEDDRA"/><TargetEntity id="D003113" type="MeSH"/><TargetEntity id="-132434084" type="omicsDisease"/><TargetEntity id="3335" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="16994">Hospital for Sick Children</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Borderline product</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>83</PatientCountEnrollment><DateStart>2006-09-30T00:00:00Z</DateStart><DateEnd type="actual">2007-09-30T00:00:00Z</DateEnd><DateChangeLast>2018-02-05T22:01:08Z</DateChangeLast><DateAdded>2014-06-05T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>The Hospital for Sick Children, Toronto Canada</Affiliation><Name>Simon Ling, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Children between 4 and 18 years of age&lt;/li&gt;&lt;li&gt;Undergoing full elective ambulatory colonoscopy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Evidence of bowel obstruction, prior partial or total colectomy and significant renal failure (GFR&amp;lt; 50 mls/min/1.73 m2)&lt;/li&gt;&lt;li&gt;Second dose of Pico-Salax will not be given to children with blood pressure&amp;lt; 10th percentile or pulse rate &amp;gt; 90th% of normal reference value for age, or in children with a clinical need for bolus iv fluids decided by the clinical fellow&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Patient's satisfaction from the regimen as assessed by a questionnaire completed by the child and parents</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cleanout effectiveness (measured by: rating of a blinded gastroenterologist, the need for enema supplement, procedure length and whether the planned destination was reached</Description></Measure><Measure><Description>Side effects (measured by: dehydration assessment, questionnaires completed by the nurse and the patient, and blood tests)</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial was to compare patient's satisfaction from Pico-Salax with the      standard of care, poly-ethylene glycol and electrolyte solution, for bowel cleanout before      colonoscopy in children, and to compare effectiveness.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive Pico-Salax  in two divided doses, each in one cup of water or  Golytely for colon cleanout. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Canada"><Sites><Site><Name>The Hospital for Sick Children</Name><Address1>Toronto</Address1><Address2>Ontario</Address2><Address3>M5G 1X8</Address3><CountrySubDivision>Ontario</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00380497</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2007-09-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2006-09-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-05T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="198687"><TitleDisplay>Neuromuscular Block in Laryngeal Mask Airway(LMA) Insertion</TitleDisplay><TitleOfficial>Effect of Neuromuscular Blockade on the Insertion of ProSeal Laryngeal Mask Airway and Postoperative Pharyngolaryngeal Discomfort</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01035021</Identifier><Identifier type="Organisational Study">LMA_M_RELAX</Identifier></Identifiers><Indications><Indication id="19">Anesthesia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ProSeal</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>propofol, AstraZeneca/Fresenius</Name><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug></Intervention><Intervention type="InterventionPrimary"><Name>remifentanil</Name><Drug id="4208">remifentanil</Drug></Intervention><Intervention type="InterventionPrimary"><Name>rocuronium</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4208">remifentanil</Drug><IndicationsPioneer/><Companies><Company><Company id="1003017">Seoul National University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44308">propofol, AstraZeneca/Fresenius</Drug><IndicationsPioneer/><Companies><Company><Company id="1003017">Seoul National University Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4208" type="Drug"><TargetEntity id="185000" type="siDrug">Remifentanil hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44308" type="Drug"><TargetEntity id="90057" type="siDrug">Propofol</TargetEntity></SourceEntity><SourceEntity id="1003017" type="Company"><TargetEntity id="5035524531" type="organizationId">Seoul National University Hospital</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1003017">Seoul National University Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2944">Hypnotic</Class><Class id="2946">Analgesic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="597">Injectable emulsion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>160</PatientCountEnrollment><PatientCountEvaluable>160</PatientCountEvaluable><DateStart>2009-06-30T00:00:00Z</DateStart><DateEnd type="actual">2010-04-30T00:00:00Z</DateEnd><DateChangeLast>2018-11-21T07:21:56Z</DateChangeLast><DateAdded>2014-06-25T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Seoul National University Bundang Hospital</Affiliation><Name>Hyoseok Na, Pf</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Age  18 to 70 years&lt;/li&gt;&lt;li&gt;American society of anesthesiologist status 1 to 2&lt;/li&gt;&lt;li&gt;Elective general anesthesia&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known or predicted difficult airway&lt;/li&gt;&lt;li&gt;Recent sore throat&lt;/li&gt;&lt;li&gt;Mouth opening&amp;lt; 2.5 cm&lt;/li&gt;&lt;li&gt;At risk of aspiration&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Success rate and insertion time</Description><Timeframe>When laryngeal mask airway was inserted</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Traumatic event</Description></Measure><Measure><Description>LMA ProSeal insertion condition (insertion time, successful insertion attempt number, fiberoptic bronchoscopic grade, and sealing pressure)</Description></Measure><Measure><Description>Complication after the removal of LMA - bleeding, sore throat</Description><Timeframe>1 h  after the LMA was removed</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2014, results were published. In both groups, anatomic fit, complications during emergence, and the severity of blood stain and postoperative sore throat were similar  [&lt;ulink linkType="Reference" linkID="1583298"&gt;1583298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2015, results were published. The incidence of traumatic events was significantly reduced in no NMBA group when compared to the NMBA group (16.3 versus 32.5%, p = 0.026) [&lt;ulink linkType="Reference" linkID="1691795"&gt;1691795&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to evaluate the success rate, insertion time and complication      depending on the use of neuromuscular blocking agent (NMBA) when inserting the laryngeal mask      airway (LMA).&lt;/para&gt;&lt;para&gt;The objective of this study was to compare the quantitative clinical performances of the streamlined liner of the pharynx airway (SLIPA) and the ProSeal laryngeal mask airway (LMA ProSeal) regarding intensity of gastric distension in patients undergoing laparoscopic cholecystectomy  [&lt;ulink linkType="Reference" linkID="1583298"&gt;1583298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Aim of the study was to compare the pharyngolaryngeal discomfort exerted by LMA ProSeal according to the neuromuscular block [&lt;ulink linkType="Reference" linkID="1691795"&gt;1691795&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2014, results were published.  No statistically prominent differences was reported between groups for each gastric size. The change of gastric size within the SLIPA group was not statistically prominent for both raters. Change within the LMA ProSeal group was prominent in rater 2 (p = 0.045) and marginally significant for rater 1 (p = 0.056) [&lt;ulink linkType="Reference" linkID="1583298"&gt;1583298&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2015, results were published. Both the groups (NMBA and no NMBA) showed similar LMA ProSeal insertion conditions (insertion time, successful insertion attempt number, fiberoptic bronchograde, and sealing pressure). Compared to using a neuromuscular blocking agent, LMA ProSeal was successfully inserted in non-paralyzed patients with less postoperative pharyngolaryngeal discomfort (30.0 versus 13.8%; p = 0.021) [&lt;ulink linkType="Reference" linkID="1691795"&gt;1691795&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would be randomized as follows:&lt;br/&gt;Arm 1: patients would receive &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4208"&gt;remifentanil&lt;/ulink&gt; and ProSeal laryngeal mask airway would be inserted by the standard technique.&lt;br/&gt;Arm 2: patients would receive &lt;ulink linkType="Drug" linkID="44308"&gt;propofol&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="4208"&gt;remifentanil&lt;/ulink&gt; and rocuronium (0.06 mg/kg) and ProSeal laryngeal mask airway would be inserted by the standard technique. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients undergo airway management with the SLIPA or LMA ProSeal  [&lt;ulink linkType="Reference" linkID="1583298"&gt;1583298&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Patients (n = 160) who were undergoing surgery for breast disease or inguinal hernia received anesthesia with propofol and remifentanil by target controlled infusion. Rocuronium 0.6 mg/kg (NMBA group) or normal saline (No-NMBA group) was administered after the patients lost consciousness, followed by insertion of LMA ProSeal [&lt;ulink linkType="Reference" linkID="1691795"&gt;1691795&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="453826">rocuronium</Intervention><Treatments><Treatment><Dose>0.06 milligram/kg</Dose><Route></Route></Treatment><Treatment><Dose>0.6 milligram/kg</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="South Korea"><Sites><Site><Name>Seoul National University Bundang Hospital</Name><Address1>Seongnam-si</Address1><Address2>Gyeonggi-do</Address2><Address3>463-707</Address3><CountrySubDivision>Gyeonggi-do</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01035021</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><PrimaryCompletionDate type="Actual">2010-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2009-12-17T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-06-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2014-08-20T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="204849"><TitleDisplay>Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration</TitleDisplay><TitleOfficial>Is CD35, CD21 and CD55 Associated With Exudative Age-related Macular Degeneration</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01174407</Identifier><Identifier type="Organisational Study">EK08010-VK</Identifier><Identifier type="Other">NTR1569</Identifier></Identifiers><Indications><Indication id="1226">Age related macular degeneration</Indication></Indications><BiomarkerNames><BiomarkerName id="3448" role="Disease marker" type="Genomic;Proteomic">Complement receptor type 2</BiomarkerName><BiomarkerName id="3731" role="Disease marker" type="Genomic">Complement decay-accelerating factor</BiomarkerName><BiomarkerName id="3753" role="Disease marker" type="Genomic;Proteomic">Complement receptor type 1</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1043257" type="Company"><TargetEntity id="5035564076" type="organizationId">Rudolf Foundation Clinic</TargetEntity></SourceEntity><SourceEntity id="1226" type="ciIndication"><TargetEntity id="4830" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1043257">Rudolf Foundation Clinic</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Case Control</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2008-09-30T00:00:00Z</DateStart><DateEnd type="estimated">2010-08-31T00:00:00Z</DateEnd><DateChangeLast>2018-06-07T07:06:04Z</DateChangeLast><DateAdded>2014-07-25T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>paulina.haas@wienkav.at</Email><Name>MD. Paulina Haas</Name></Contact><Contact type="Scientific contact"><Email>paulina.haas@wienkav.at</Email><Name>MD. Paulina Haas</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Man and women over 18 years old&lt;/li&gt;&lt;li&gt;Filled out informed consent&lt;/li&gt;&lt;li&gt;Diagnosis of non-exudative/ exudative age related macular degeneneration&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Inherited retinal diseases&lt;/li&gt;&lt;li&gt;Other acquired retinal/ macular&lt;/li&gt;&lt;li&gt;Missing informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Determine a possible implication of CD21, CD35 and CD55 in the pathogenesis of age-related macular degeneration</Description><Timeframe>1 day</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Eexpression rates of on AMD-patients and a healthy control group</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study is to determine a possible implication of CD21, CD35 and CD55 in      the pathogenesis of age-related macular degeneration. The aim is to asses a difference in      expression rates of these factors on AMD-patients and a healthy control group.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be assessed for CD35, CD21 and CD55 by  drawing the blood (10 ml/once).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Austria"><Sites><Site><Name>Rudolf Foundation Clinic</Name><Address1>Vienna</Address1><Address3>1030</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Age related macular degeneration</Disease><PatientSegments><PatientSegment><PatientSegment id="9074">Subjects with Dry Age-related Macular Degeneration(AMD)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9078">Subjects with Wet Age-related Macular Degeneration(AMD)</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01174407</Identifier></Identifiers></Registry><Registry><Name id="1015">Netherlands Trial Registry (NTR)</Name><Identifiers><Identifier>NTR1569</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Age related macular degeneration" id="16117"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Age related macular degeneration" id="13803"><Criterion>Subjects with Dry Age-related Macular Degeneration(AMD)</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Age related macular degeneration" id="13959"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2009-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2008-11-19T00:00:00Z</DateFirstReceived><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-07-25T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="206482"><TitleDisplay>Quantification of Liver Iron Overload and Steatosis Using Magnetic Resonance Imaging</TitleDisplay><TitleOfficial>Quantification of Liver Iron Overload and Steatosis Using a New Magnetic Resonance Imaging Multiecho Gradient-echo Sequence</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT00401336</Identifier><Identifier type="Organisational Study">DGS 2006/0197</Identifier><Identifier type="Secondary Organisational">PHRC/04-08</Identifier><Identifier type="Secondary Organisational">CIC0203/044</Identifier><Identifier type="Trial Acronym">SURFER</Identifier></Identifiers><Indications><Indication id="154">Hepatitis</Indication><Indication id="3294">Metabolic syndrome X</Indication></Indications><BiomarkerNames><BiomarkerName id="1239" role="Disease marker" type="Biochemical">Iron</BiomarkerName><BiomarkerName id="19940" role="Disease marker" type="Structural (imaging)">Hepatic fat</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Magnetic resonance imaging multiecho gradient-echo sequence</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1039408" type="Company"><TargetEntity id="5035559621" type="organizationId">Rennes University Hospital</TargetEntity></SourceEntity><SourceEntity id="1043352" type="Company"><TargetEntity id="5035561472" type="organizationId">Ministere Du Travail</TargetEntity></SourceEntity><SourceEntity id="154" type="ciIndication"><TargetEntity id="10019717" type="MEDDRA"/><TargetEntity id="D006505" type="MeSH"/><TargetEntity id="-1968993298" type="omicsDisease"/><TargetEntity id="424" type="siCondition"/></SourceEntity><SourceEntity id="3294" type="ciIndication"><TargetEntity id="E88.81" type="ICD10"/><TargetEntity id="10052066" type="MEDDRA"/><TargetEntity id="D024821" type="MeSH"/><TargetEntity id="-65628361" type="omicsDisease"/><TargetEntity id="512" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>10</NumberOfSites><CompaniesSponsor><Company id="1039408">Rennes University Hospital</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1043352">Ministry of Health, France</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Diagnosis</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>250</PatientCountEnrollment><DateStart>2006-11-30T00:00:00Z</DateStart><DateEnd type="actual">2013-03-01T00:00:00Z</DateEnd><DateChangeLast>2014-08-04T16:01:23Z</DateChangeLast><DateAdded>2014-08-04T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Rennes University Hospital</Affiliation><Email>ericbellissant@chu-rennesfr</Email><Name>Eric Bellissant, MD, PhD</Name><Phone>33-2-9928-9200</Phone></Contact><Contact type="Scientific contact"><Affiliation>Rennes University Hospital</Affiliation><Name>Yves Gandon, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Hopital Donostia-San Sebastian San Sebastian Spain</Affiliation><Email>jmalustiza@osatek.es</Email><Name>Jose Alustiza</Name><Phone>00 34 943007075</Phone></Contact><Contact type="Scientific contact"><Affiliation>CHU Angers; Angers; 49033; France</Affiliation><Email>ChAube@chu-angersfr</Email><Name>Christophe Aube</Name><Phone>33-1-4135-4279</Phone></Contact><Contact type="Scientific contact"><Affiliation>Hopital Saint Eloi; Montpellier; 34000; France</Affiliation><Name>Pierre Baldet</Name></Contact><Contact type="Scientific contact"><Affiliation>Hopital Tenon; Paris; 75970; France</Affiliation><Email>franckboudghene@tnnaphpfr</Email><Name>Franck Boudghene</Name><Phone>33-1-5601-7269</Phone></Contact><Contact type="Scientific contact"><Affiliation>CHU Angers; Angers; 49033; France</Affiliation><Name>Jerome Boursier</Name></Contact><Contact type="Scientific contact"><Affiliation>Hopital du Brabois; Vandoeuvre les Nancy; 54511; France</Affiliation><Name>Jean-Pierre Bronowicki</Name></Contact><Contact type="Scientific contact"><Affiliation>CHU Angers; Angers; 49033; France</Affiliation><Name>Paul Cales</Name></Contact><Contact type="Scientific contact"><Affiliation>Hopital Tenon; Paris; 75970; France</Affiliation><Name>Patrice Callard</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adults &gt; 18 years&lt;/li&gt;&lt;li&gt;Planned liver biopsy (or liver biopsy within 2 months before inclusion) for one of these indications: suspicion of liver iron overload, metabolic syndrome, hepatitis B or C, alcohol abuse. No change in diet, transfusions or iron depletion must have occur between the liver biopsy and the MRI&lt;/li&gt;&lt;li&gt;Having given a written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Non cooperating patient&lt;/li&gt;&lt;li&gt;Patient with dyspnea&lt;/li&gt;&lt;li&gt;Patient with contra-indication to MR imaging (pace-maker, heart valve)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Liver to muscle signal intensity ratio and T2* calculation versus liver iron concentration</Description><Timeframe>During examination</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Correlation between biochemical and MRI quantification of liver iron</Description><Timeframe>During examination</Timeframe></Measure><Measure><Description>Correlation between participating centers</Description><Timeframe>During examination</Timeframe></Measure><Measure><Description>Difference between in-phase and out-phase T2* calculation versus liver fat concentration</Description><Timeframe>During examination</Timeframe></Measure><Measure><Description>Influence of the antenna for the multiecho gradient-echo sequence</Description><Timeframe>During examination</Timeframe></Measure><Measure><Description>Reproducibility of the multiecho gradient-echo sequence</Description><Timeframe>During examination</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of      the study was to use a simplified magnetic resonance imaging (MRI) technique to quantify      simultaneously iron and fat contents in the liver and to compare the results to the      quantification obtained biochemically.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who need a liver biopsy would be proposed to be enrolled in the study. A magnetic      resonance (MR) study would be performed using breath-hold gradient echo sequences with a      single echo and a new multiple-echo gradient-echo sequence. Liver and muscle MR signal would be quantitatively determined and compared to biochemical assessment of liver iron      concentration and steatosis quantification.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Hopital Donostia-San Sebastian</Name><Address1>San Sebastian</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Name>CHU Angers</Name><Address1>Angers</Address1><Address3>49033</Address3><Contacts/></Site><Site><Name>Hôpital Beaujon</Name><Address1>Clichy</Address1><Address3>92118</Address3><Contacts/></Site><Site><Name>Hôpital Edouard Herriot</Name><Address1>Lyon</Address1><Address3>69003</Address3><Contacts/></Site><Site><Name>Hôpital Huriez</Name><Address1>Lille</Address1><Address3>59037</Address3><Contacts/></Site><Site><Name>Hôpital Saint Eloi</Name><Address1>Montpellier</Address1><Address3>34000</Address3><Contacts/></Site><Site><Name>Hôpital Tenon</Name><Address1>Paris</Address1><Address3>75970</Address3><Contacts/></Site><Site><Name>Hôpital de Pontchaillou</Name><Address1>Rennes</Address1><Address3>35033</Address3><Contacts/></Site><Site><Name>Hôpital de la Timone</Name><Address1>Marseille</Address1><Address3>13385</Address3><Contacts/></Site><Site><Name>Hôpital du Brabois</Name><Address1>Vandoeuvre les Nancy</Address1><Address3>54511</Address3><Contacts/></Site><Site><Name>Hopital Beaujon</Name><Address1>Clichy</Address1><Address3> 92118</Address3><Contacts/></Site><Site><Name>Hopital Edouard Herriot</Name><Address1>Lyon</Address1><Address3> 69003</Address3><Contacts/></Site><Site><Name>Hopital Huriez</Name><Address1>Lille</Address1><Address3> 59037</Address3><Contacts/></Site><Site><Name>Hopital Saint Eloi</Name><Address1>Montpellier</Address1><Address3> 34000</Address3><Contacts/></Site><Site><Name>Hopital Tenon</Name><Address1>Paris</Address1><Address3> 75970</Address3><Contacts/></Site><Site><Name>Hopital de Pontchaillou</Name><Address1>Rennes</Address1><Address3> 35033</Address3><Contacts/></Site><Site><Name>Hopital de la Timone</Name><Address1>Marseille</Address1><Address3> 13 385</Address3><Contacts/></Site><Site><Name>Hopital du Brabois</Name><Address1>Vandoeuvre Les Nancy</Address1><Address3> 54511</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatitis C virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="461">Subjects with Chronic Hepatitis C Infection</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Hepatitis B virus infection</Disease><PatientSegments><PatientSegment><PatientSegment id="19014">Subjects with Hepatitis B Infection</PatientSegment><SubSegments><SubSegment id="10099">Subjects with Chronic Hepatitis B Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00401336</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatitis B virus infection" id="18322"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Metabolic syndrome X" id="21035"><Endpoint>Assessment of Liver Functions</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hepatitis B virus infection" id="18307"><Endpoint>Hematological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21035"><Endpoint>Assessment of Liver Functions</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Metabolic syndrome X" id="21061"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Metabolic syndrome X" id="21064">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint><SubEndpoint disease="Metabolic syndrome X" id="21066">Assessment by echocardiography</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin resistance" id="23377"><Endpoint>Assessment of Liver Functions</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23378">Assessment of hepatic fat content</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insulin resistance" id="23384"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Insulin resistance" id="23388">Assessment by Magnetic Resonance Imaging (MRI)</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatitis C virus infection" id="1751"><Criterion>Subjects with Chronic Hepatitis C Infection</Criterion></Inclusion><Inclusion disease="Hepatitis C virus infection" id="1778"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Hepatitis C virus infection" id="1779">Subjects co-morbid with alcoholism</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatitis B virus infection" id="16775"><Criterion>Subjects with Chronic Hepatitis B Infection</Criterion></Inclusion><Inclusion disease="Metabolic syndrome X" id="19348"><Criterion>Subjects with Metabolic Syndrome</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="20215"><Criterion>Insulin Resistance in Other Metabolic Diseases Subjects</Criterion></Inclusion><Inclusion disease="Insulin resistance" id="20217"><Criterion>Hepatitis C Subjects with Insulin Resistance</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatitis C virus infection" id="2666"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Hepatitis B virus infection" id="14270"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion></Exclusion><Exclusion disease="Metabolic syndrome X" id="15492"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Insulin resistance" id="18043"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-03-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2014-08-04T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="228821"><TitleDisplay>Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecological Surgery</TitleDisplay><TitleOfficial>UW14030: Epidural Anesthesia as Part of an Enhanced Recovery Pathway in Gynecological Surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02423876</Identifier><Identifier type="Organisational Study">UW14030</Identifier><Identifier type="Secondary Organisational">NCI-2015-00395</Identifier><Identifier type="Secondary Organisational">P30CA014520</Identifier></Identifiers><Indications><Indication id="20">Pain</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="274" role="Therapeutic effect marker" type="Genomic;Proteomic">Tumor necrosis factor</BiomarkerName><BiomarkerName id="812" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-2</BiomarkerName><BiomarkerName id="2534" role="Therapeutic effect marker" type="Biochemical">Hydrocortisone</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>epidural placement</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>hydromorphone</Name></Intervention><Intervention type="InterventionPrimary"><Name>ropivacaine</Name><Drug id="4271">ropivacaine</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>enhanced recovery pathway</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4271">ropivacaine</Drug><IndicationsPioneer/><Companies><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="DOL1000742">University of Wisconsin-Madison</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4271" type="Drug"><TargetEntity id="129999" type="siDrug">Ropivacaine</TargetEntity><TargetEntity id="150269" type="siDrug">Ropivacaine hydrochloride</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="DOL1000742" type="Company"><TargetEntity id="5000726299" type="organizationId">University of Wisconsin-Madison</TargetEntity></SourceEntity><SourceEntity id="20" type="ciIndication"><TargetEntity id="10033371" type="MEDDRA"/><TargetEntity id="D010146" type="MeSH"/><TargetEntity id="-1585850437" type="omicsDisease"/><TargetEntity id="1" type="siCondition"/></SourceEntity><SourceEntity id="498" type="Action"><TargetEntity id="358" type="Mechanism">Sodium Channel Blockers</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="DOL1000742">University of Wisconsin-Madison</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="498">Sodium channel inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1669">Local anesthetic</Class><Class id="2946">Analgesic</Class></Class><Technologies><Technology id="654">Intrathecal formulation</Technology><Technology id="767">Rectal formulation</Technology><Technology id="622">Rectal formulation local</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>110</PatientCountEnrollment><DateStart>2015-03-17T00:00:00Z</DateStart><DateEnd type="estimated">2020-07-31T00:00:00Z</DateEnd><DateChangeLast>2019-06-07T04:36:53Z</DateChangeLast><DateAdded>2015-05-13T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>cancerconnect@uwcarbone.wisc.edu</Email><Name>Cancer Connect</Name><Phone>(800) 622-8922</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of Wisconsin, Madison</Affiliation><Name>Lisa Barroilhet</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;:&lt;ul&gt;&lt;li&gt;Patients undergoing gynecological surgery via midline vertical laparotomy at University of Wisconsin Hospital and Clinics (UWHC)&lt;/li&gt;&lt;li&gt;Patients must be English speaking&lt;/li&gt;&lt;li&gt;Patients must have the ability to understand visual and verbal pain scales&lt;/li&gt;&lt;li&gt;Patients must be eligible for epidural placement&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;:&lt;ul&gt;&lt;li&gt;Known allergy to local anesthetics&lt;/li&gt;&lt;li&gt;Known history of chronic pain disorders and/or chronic opioid use defined as&amp;gt; 10 mg po morphine or equivalent used daily for at least 30 days prior to enrollment&lt;/li&gt;&lt;li&gt;Patient is a prisoner or incarcerated&lt;/li&gt;&lt;li&gt;Significant liver disease that would inhibit prescription of opioids&lt;/li&gt;&lt;li&gt;Significant kidney disease that would inhibit administration of gabapentin&lt;/li&gt;&lt;li&gt;Patient has a history of opioid dependence requiring rehabilitation or the use of opioid antagonists&lt;/li&gt;&lt;li&gt;Patient is pregnant&lt;/li&gt;&lt;li&gt;Patients with a planned exploration with biopsies (no organs removed) will be excluded from the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Relative pain scores, as measured by the pain NRS: relative pain scores between the epidural and non-epidural group will be analyzed by calculating a two-sided 95% confidence interval on the difference in mean scores between the two groups and concluding non-inferiority if this lies entirely below two points (mean non-epidural pain score proven, within a 95% confidence limit, to be at most two points worse than mean pain score in the epidural group)</Description><Timeframe>Up to 24 h post-surgery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Average daily pain score as measured by pain NRS scores: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Up to 2 days following surgery</Timeframe></Measure><Measure><Description>Change in stress and inflammation serum markers as measured by interleukin IL-2, IL-6, tumor necrosis factor, C-reactive protein, and salivary cortisol levels: Will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Baseline to up to day 1 post-surgery</Timeframe></Measure><Measure><Description>Epidural discontinuation rates prior to planned removal (in epidural group only): will be tabulated and presented for each group (where applicable)</Description><Timeframe>Up to post-operative day 1</Timeframe></Measure><Measure><Description>Length of hospital stay: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>From admission to time of discharge order placement, assessed up to 4 weeks post-surgery</Timeframe></Measure><Measure><Description>Length of time until return of bowel function: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>From completion of surgery to passage of flatusassessed up to 4 weeks post-surgery</Timeframe></Measure><Measure><Description>Number of recorded episodes of emesis: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Up to 4 weeks post-surgery</Timeframe></Measure><Measure><Description>Patient satisfaction scores, as measured by the HCAHPS, NRS, and Brief Pain Inventory: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>At 4 weeks post-operative visit</Timeframe></Measure><Measure><Description>Post-operative antiemetic use: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Up to 4 weeks post-surgery</Timeframe></Measure><Measure><Description>Post-operative complications (UTIs, thromboembolic events, pneumonia, blood transfusion, myocardial infarction, falls): will be tabulated and presented for each group (where applicable)</Description><Timeframe>Up to day 1 post-surgery</Timeframe></Measure><Measure><Description>Readmission rate: will be compared using two-sided 95% confidence intervals for their mean differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Up to 4 weeks post-surgery</Timeframe></Measure><Measure><Description>Total opioid use measured in oral morphine equivalents: will be compared using two-sided 95% confidence intervals for their mesn differences. Superiority tests at the two-sided .05 level will be conducted by determining whether these confidence intervals overlap</Description><Timeframe>Up to first 2 days post-surgery</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objectives of randomized clinical trial are:&lt;/para&gt;&lt;para&gt;Primary objectives: &lt;br/&gt;Mean postoperative pain score for the first 24 h post-operatively, (measured by the      Numeric Rating Scale [NRS], which rates pain on a 1 to 10 scale, collected routinely on the      post-operative floor) will be compared between the epidural and no epidural groups.&lt;/para&gt;&lt;para&gt;Secondary objectives are:&lt;br/&gt;Total opioid use measured in oral morphine equivalents for the first two days      post-surgery.&lt;br/&gt;Length of hospital stay (measured in hours from admission to time of discharge order      placement).&lt;br/&gt;Post-operative antiemetic use and number of recorded episodes of emesis.&lt;br/&gt;Return of      bowel function (measured in hours from completion of surgery to passage of flatus).&lt;br/&gt;Subject satisfaction at the 4 week post-operative visit (as measured by two pain      satisfaction questions taken from the Hospital Consumer Assessment of Healthcare Providers      and Systems [HCAHPS] survey).&lt;br/&gt;Post-operative complications (urinary tract infections [UTIs], thromboembolic events,      pneumonia, blood transfusion, myocardial infarction, falls).&lt;br/&gt;Readmission rate.&lt;br/&gt;Epidural discontinuation rates prior to planned removal (in      epidural group only).&lt;br/&gt;Stress and inflammation serum and saliva markers at baseline and the first day after      surgery, as well as at their post-operative visit.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will be randomized to one of two treatment arms.&lt;br/&gt;Arm I: patients undergo epidural placement in the first day surgery pre-operative area or      similar areas suitable for insertion of epidural catheters. In the postoperative anesthesia      care unit, patients may receive medication via the epidural on an as needed basis, as      determined by the anesthesia team. Dosing and rate of standardized medication will be      managed by the anesthesia team until the epidural is removed. Patients complete the ERP      comprising increased activity, dietary restrictions, fluid balance, as well as antinausea,      antiinflammatory and pain medications at specific times. Patients will have access to      additional pain medications as needed to control their pain.&lt;br/&gt;Standard epidural medications and dosage are as follows:&lt;br/&gt;A 0.1% &lt;ulink linkType="Drug" linkID="4271"&gt;ropivacaine&lt;/ulink&gt; + 10 microg/ml hydromorphone at 6 ml/h continuous rate.&lt;br/&gt;A 3 ml/h RN bolus, to be used as needed based on pain ratings.&lt;br/&gt;A 3 ml/30 min patient bolus, which is available on patient demand.&lt;/para&gt;&lt;para&gt;Arm II: patients complete the ERP comprising increased activity, dietary restrictions, fluid      balance, as well as anti-nausea, anti-inflammatory and pain medications at specific times.      Patients will have access to additional pain medications as needed to control their pain.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Wisconsin Carbone Cancer Center</Name><Address1>Madison</Address1><Address2>Wisconsin</Address2><Address3>53792</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>cancerconnect@uwcarbone.wisc.edu</Email><Name>Cancer M. Connect</Name><Phone>800-622-8922</Phone></Contact><Contact type="Facility investigator"><Name>Lisa M. Barroilhet</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pain</Disease><PatientSegments><PatientSegment><PatientSegment id="8425">Subjects in need of Procedural Analgesia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02423876</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35054">Assessment by Numerical Analog Scale (NRS/NAS)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Pain" id="25873"><Endpoint>Assessment of Intensity of Pain</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="25875">Based on Numerical Rating Scale [NRS]</SubEndpoint><SubEndpoint disease="Pain" id="25877">Based on Brief Pain Inventory[BPI]</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26014"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26024">Assessment of Inflammatory/Immunological Markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26029"><Endpoint>Assessment of hospitalization</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26032"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26054">Assessment of postoperative complications</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="26038"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="26044">Assessment of analgesic use/rescue medication</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pain" id="34784"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Pain" id="35054">Assessment by Numerical Analog Scale (NRS/NAS)</SubEndpoint><SubEndpoint disease="Pain" id="35228">Assessment of patient satisfaction</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pain" id="22141"><Criterion>Subjects in Need of Procedural Analgesia</Criterion></Inclusion><Inclusion disease="Pain" id="22148"><Criterion>Subjects Based on Pain Scale Ratings</Criterion><SubCriteria><SubCriterion disease="Pain" id="22154">Based on Verbal Rating Scale [VRS]</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22252"><Criterion>Subjects with History of/Scheduled for Therapy for other Indication</Criterion><SubCriteria><SubCriterion disease="Pain" id="22256">Subjects with history/scheduled for surgery for other indication</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="22262"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="22269">Subjects able to communicate in the language specified in the protocol</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pain" id="34827"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Pain" id="22264">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pain" id="20014"><Criterion>Subjects Based on Duration of Pain</Criterion><SubCriteria><SubCriterion disease="Pain" id="20017">Subjects with chronic pain</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20117"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Pain" id="20131"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Pain" id="20132">Subjects with history/scheduled to receive opioids</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="20182"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Pain" id="20186">Protocol specified exclusion criteria for women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pain" id="24893"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Pain" id="26044"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Pain" id="20116">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-06-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-04-14T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-05-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-01-21T00:00:00Z</Date><Reason id="310">Protocol &amp; Results section updates</Reason></Change></ChangeHistory></Trial><Trial id="231217"><TitleDisplay>Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC</TitleDisplay><TitleOfficial>A Phase II Study of Sipuleucel-T With or Without Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02463799</Identifier><Identifier type="Organisational Study">J1522</Identifier><Identifier type="Other">IRB00056435</Identifier></Identifiers><Indications><Indication id="1829">Bone metastases</Indication><Indication id="2399">Adenocarcinoma</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="38" role="Therapeutic effect marker" type="Genomic;Proteomic">Prostate-specific antigen</BiomarkerName><BiomarkerName id="2412" role="Therapeutic effect marker" type="Proteomic">Immunoglobulin M</BiomarkerName><BiomarkerName id="3451" role="Therapeutic effect marker" type="Genomic;Proteomic">Immunoglobulin G</BiomarkerName><BiomarkerName id="28899" role="Therapeutic effect marker" type="Genomic;Proteomic">Alkaline phosphatase</BiomarkerName><BiomarkerName id="46506" role="Therapeutic effect marker" type="Cellular">T-Lymphocytes</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>radium Ra 223 dichloride</Name><Drug id="40115">radium Ra 223 dichloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>sipuleucel-T</Name><Drug id="17735">sipuleucel-T</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>sipuleucel-T</Name><Drug id="17735">sipuleucel-T</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="17735">sipuleucel-T</Drug><IndicationsPioneer><Indication id="1829">Bone metastases</Indication></IndicationsPioneer><Companies><Company><Company id="1042135">Sidney Kimmel Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="13709">Dendreon Corp</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="14455">Bayer AG</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="40115">radium Ra 223 dichloride</Drug><IndicationsPioneer/><Companies><Company><Company id="1042135">Sidney Kimmel Comprehensive Cancer Center</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="13709">Dendreon Corp</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="14455">Bayer AG</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="17735" type="Drug"><TargetEntity id="259673" type="siDrug">Sipuleucel-T</TargetEntity></SourceEntity><SourceEntity id="40115" type="Drug"><TargetEntity id="321351" type="siDrug">Radium Ra 223 dichloride</TargetEntity></SourceEntity><SourceEntity id="1042135" type="Company"><TargetEntity id="5036229123" type="organizationId">Sidney Kimmel Comprehensive Cancer Center</TargetEntity></SourceEntity><SourceEntity id="13709" type="Company"><TargetEntity id="4295915801" type="organizationId">Dendreon Corp</TargetEntity></SourceEntity><SourceEntity id="14455" type="Company"><TargetEntity id="4295869217" type="organizationId">Bayer AG</TargetEntity></SourceEntity><SourceEntity id="1829" type="ciIndication"><TargetEntity id="10027452" type="MEDDRA"/></SourceEntity><SourceEntity id="2399" type="ciIndication"><TargetEntity id="10001141" type="MEDDRA"/><TargetEntity id="D000230" type="MeSH"/><TargetEntity id="-1620546969" type="omicsDisease"/><TargetEntity id="656" type="siCondition"/></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>5</NumberOfSites><CompaniesSponsor><Company id="1042135">Sidney Kimmel Comprehensive Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator><Company id="13709">Dendreon Corp</Company><Company id="14455">Bayer AG</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="9773">Prostatic acid phosphatase modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="12379">Therapeutic vaccine</Class><Class id="1545">Anticancer</Class><Class id="4790">Genetically engineered autologous cell therapy</Class><Class id="527">Bone synthesis inhibitor</Class><Class id="5721">Radiotherapeutic</Class></Class><Technologies><Technology id="67">Antigen</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="570">Cell therapy</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="724">Radiolabeling</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology><Technology id="1653">Tumor antigen</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Vaccine</Category><Category>Cell therapy</Category><Category>Gene therapy</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>36</PatientCountEnrollment><DateStart>2016-02-22T00:00:00Z</DateStart><DateEnd type="estimated">2020-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-05T02:12:09Z</DateChangeLast><DateAdded>2015-06-28T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Duke University</Affiliation><Email>andrew.armstrong@duke.edu</Email><Name>Andrew Armstrong, MD</Name><Phone>919-668-4667</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tulane Cancer Center</Affiliation><Email>osartor@tulane.edu</Email><Name>Oliver Sartor, MD</Name><Phone>504-988-7869</Phone></Contact><Contact type="Scientific contact"><Affiliation>Johns Hopkins University</Affiliation><Email>eantona1@jhmi.edu</Email><Name>Emmanuel Antonarakis, MD</Name><Phone>443-287-0553</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Written informed consent provided prior to initiation of study procedures&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Histologically documented adenocarcinoma prostate cancer confirmed by a pathology report from prostate biopsy or a radical prostatectomy specimen. If prostatic tumor is of mixed histology,&amp;gt; 50% of the tumor must be adenocarcinoma&lt;/li&gt;&lt;li&gt;Bone metastasis as manifested by one or more lesions on a bone scan performed within 2 months of screening&lt;/li&gt;&lt;li&gt;Castrate-resistant prostate cancer, in the setting of castrate levels of testosterone (&amp;lt;/= 50 ng/dl), defined as current or historical evidence of disease progression concomitant with surgical castration or androgen deprivation therapy (ADT), as demonstrated by two consecutive rises in PSA or new lesions on bone scan:&lt;ul&gt;&lt;li&gt;PSA progression will be defined as two rising PSA values compared to a reference value, measured at least 7 days apart and the second value is &gt;/= 2 ng/ml. It must be documented within 2 months of screening&lt;/li&gt;&lt;li&gt;Appearance of one or more new areas of abnormal uptake on bone scan when compared to imaging studies acquired during castration therapy or against the precastration studies if there was no response. Increased uptake of pre-existing lesions on bone scan does not constitute progression. It must be documented within 4 months of screening&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Serum PSA &gt;/= 2.0 ng/ml&lt;/li&gt;&lt;li&gt;Screening ECOG perf status&amp;lt;/= 1&lt;/li&gt;&lt;li&gt;Asymptomatic or minimally symptomatic disease (no narcotic analgesic; other analgesics use is allowed)&lt;/li&gt;&lt;li&gt;Prior abiraterone and enzalutamide are permitted, but not required&lt;/li&gt;&lt;li&gt;Concurrent osteoclast-inhibitory therapies (zoledronic acid, denosumab) are permitted if patients have been on a stable dose for at least 1 month&lt;/li&gt;&lt;li&gt;Adequate screening hematological, renal, and liver function as evidenced by laboratory test results within the following ranges&amp;lt;/= 28 days prior to registration:&lt;ul&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1.5 x 10(9)/l&lt;/li&gt;&lt;li&gt;Platelet count &gt;/= 100 x 10(9)/l&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/= 10.0 g/dl&lt;/li&gt;&lt;li&gt;Total bilirubin level&amp;lt;/= 1.5 x institutional upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)&amp;lt;/= 2.5 x ULN&lt;/li&gt;&lt;li&gt;Creatinine&amp;lt;/= 1.5 x ULN&lt;/li&gt;&lt;li&gt;Albumin&amp;gt; 25 g/l&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;The presence of known lung or liver metastasis &gt; 1.0 cm in the long axis diameter&lt;/li&gt;&lt;li&gt;The presence of lymphadenopathy &gt; 3 cm in the short-axis diameter&lt;/li&gt;&lt;li&gt;The presence of known brain metastasis&lt;/li&gt;&lt;li&gt;Spinal cord compression, imminent long bone fracture, or any other condition that, in the opinion of the investigator, is likely to require radiation therapy and/or steroids for pain control during the active phase&lt;/li&gt;&lt;li&gt;Previous treatment with chemotherapy for mCRPC (adjuvant chemotherapy is permitted), or chemotherapy for any reason within two years prior to registration&lt;/li&gt;&lt;li&gt;Intention to receive chemotherapy within 6 months after enrollment in protocol therapy&lt;/li&gt;&lt;li&gt;History of radiation therapy, either via external beam or brachytherapy within 28 days prior to registration&lt;/li&gt;&lt;li&gt;Systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastasis within previous 24 weeks&lt;/li&gt;&lt;li&gt;Prior history of other cancers (except non-melanoma skin cancers or low-grade low-stage urothelial cancers)&lt;/li&gt;&lt;li&gt;Use of prednisone or equivalent systemic corticosteroid within 2 weeks of treatment. Use of inhaled, intranasal, intra-articular, and topical steroids is allowed. Oral or intravenous steroids to prevent or treat intravenous contrast reactions are allowed&lt;/li&gt;&lt;li&gt;Use of opioid analgesics for cancer-related pain&lt;/li&gt;&lt;li&gt;Use of experimental drug within 4 weeks of treatment&lt;/li&gt;&lt;li&gt;Uncontrolled medical conditions including diabetes, heart failure, COPD, ulcerative colitis, or Crohn's disease&lt;/li&gt;&lt;li&gt;Uncontrolled fecal incontinence&lt;/li&gt;&lt;li&gt;Any medical intervention, any other condition, or any other circumstance which, in the opinion of the investigator, could compromise adherence with study requirements or otherwise compromise the study's objectives&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Immune responses to treatment with sipuleucel-T (with or without radium-223) measured by peripheral PA2024 T-cell proliferation using a 3H-thymidine incorporation assay at 6 weeks after first sipuleucel-T infusion in each arm reported as stimulation index (SI)</Description><Timeframe>10 weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To evaluate PA2024 and PAP-antigen specific antibody (IgM/IgG) response to sipuleucel-T over time</Description><Timeframe>Up to 58 weeks</Timeframe></Measure><Measure><Description>To evaluate peripheral antigen (PAP)-specific T-cell activation to sipuleucel-T over time using IFNgamma ELIPSOT</Description><Timeframe>Up to 58 weeks</Timeframe></Measure><Measure><Description>To evaluate peripheral antigen PA2024 -specific T-cell proliferation over time using 3H-thymidine incorporation assay</Description><Timeframe>Up to 58 weeks</Timeframe></Measure><Measure><Description>To evaluate sipuleucel-T induced antigen spread (epitope spread) phenomena: detecting IgG reponses to prespecified off-target Ag using multiplex Ab assay, exploration of new off-target Ag by detecting IgG responses using protein microarray</Description><Timeframe>Up to 18 weeks</Timeframe></Measure><Measure><Description>To evaluate the sipuleucel-T product immune parameters</Description><Timeframe>Up to 58 weeks</Timeframe></Measure><Measure><Description>To evaluate time to alkaline phosphatase (ALP) progression</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To evaluate time to first chemotherapy use</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To evaluate time to first skeletal related event (SRE)</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To evaluate time to pain progression and first cancer-related opioid use</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To evaluate time to prostate-specific antigen (PSA) progression based on PCWG2</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To evaluate time to radiographical or clinical progression (RECIST/PCWG2)</Description><Timeframe>Up to two years</Timeframe></Measure><Measure><Description>To investigate safety of combined use of radium-223 and sipuleucel-T (composite measure of both arms): incidence and severity of adverse events and laboratory abnormalities, graded according to CTCAE version 4.0</Description><Timeframe>Up to two years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This clinical trial was to study the effect of &lt;ulink linkType="Drug" linkID="40115"&gt;radium-223&lt;/ulink&gt; (Xofigo, BAY88-8223) when added to &lt;ulink linkType="Drug" linkID="17735"&gt;sipuleucel-T&lt;/ulink&gt; (Provenge) for treating      castrate-resistant prostate cancer that has spread to the bone. This study would test  whether radium-223 added to sipuleucel-T increases the immune response and anti-tumor effect against prostate cancer.&lt;/para&gt;&lt;para&gt;The primary objective of this study was to determine whether radium-223 in combination with sipuleucel-T enhances immune response to sipuleucel-T measured by peripeheral PA2024-specific T-cell proliferation compared with sipuleucel-T alone.&lt;/para&gt;&lt;para&gt;Immune objectives were:&lt;br/&gt;To evaluate Ag-specific T-cell proliferation and activation.&lt;br/&gt;To evaluate Ag-specific antibody response to sipuleucel-T.&lt;br/&gt;To evaluate Ag (epitope) spread phenomena.&lt;/para&gt;&lt;para&gt;Clinical objectives were:&lt;br/&gt;To investigate safety of radium-23 and sipuleucel-T combination.&lt;br/&gt;To evaluate time to PSA progression.&lt;br/&gt;To evaluate time to radiographical or clinical progression.&lt;br/&gt;To evaluate time to first skeletal related event (SRE) [&lt;ulink linkType="Reference" linkID="1666001"&gt;1666001&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Eligible patients would  be registered and randomly      assigned in a 1 : 1 ratio to &lt;br/&gt;Arm 1: patients would  receive radium-223 with three infusions of sipuleucel-T starting after second radium-223.&lt;br/&gt;Arm 2: patients would receive three infusions of sipuleucel-T alone. &lt;/para&gt;&lt;para&gt;Patients in both arms (sipuleucel-T and radium) would undergo a standard 1.5 to 2.0 blood      volume leukapheresis, followed approximately 3 days later by an iv infusion of sipuleucel-T, every 2 weeks, at weeks 6, 8, and 10.      This process would occur a total of three times at approximately 2-week intervals. Patients in      arm 1 would receive a total of six infusions of radium-223 iv injections at a dose of 50 kBq/kg (1.35 microcurie)/kg body weight per standard of care, q4w, at weeks 0, 4, 8, 12, 16, and 20.&lt;/para&gt;&lt;para&gt;All patients would be allowed to receive the best supportive care which includes secondary      hormonal manipulation as required. No chemotherapy, external-beam radiation, or other      radionuclides would be allowed while on active treatment but would be permitted after completion of      active treatment. Glucocorticoid-containing treatments shall be minimized to less than the      equivalent dose of prednisone 10 mg daily if feasible for the 3 months following sipuleucel-T      therapy. All patients would continue medical or surgical castration during treatment. Immune response blood test would be performed at baseline, weeks 6, 10, 14, 26, 39 and 52 after first    sipuleucel-T  infusion and immune response would be monitored at 4th radium-223 infusion. Project accural rate was three patients/month. Expected duration of study was two years [&lt;ulink linkType="Reference" linkID="1666001"&gt;1666001&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Cedars-Sinai Medical Center</Name><Address1>Los Angeles</Address1><Address2>California</Address2><Address3>90048</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>Duke University</Name><Address1>Durham</Address1><Address2>North Carolina</Address2><Address3>27710</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Name>Johns Hopkins Hospital</Name><Address1>Baltimore</Address1><Address2>Maryland</Address2><Address3>21231</Address3><CountrySubDivision code="MD">Maryland</CountrySubDivision><Contacts/></Site><Site><Name>Sibley Memorial Hospital</Name><Address1>Washington</Address1><Address2>District of Columbia</Address2><Address3>20016</Address3><CountrySubDivision code="DC">District of Columbia</CountrySubDivision><Contacts/></Site><Site><Name>Tulane Cancer Center</Name><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70112</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Prostate tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3564">Subjects with Advanced/Metastatic Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3583">Subjects with Castrate Resistant Prostate Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3586">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="9106">Subjects with Rising PSA levels</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="12018">Subjects with adenocarcinoma of prostate</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02463799</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Prostate tumor" id="9129"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="9130">Assessment of cellular response</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Prostate tumor" id="7088"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7090">Assessment of clinical progression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7112"><Endpoint>Assessment of pain</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7129"><Endpoint>Assessment of Prostate Specific Antigen(PSA) Dependent Variables</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7138">Assessment of time to PSA  progression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7158"><Endpoint>Assessment of Markers of Tumor Growth and Progression</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7164">Assessment of cell proliferation markers</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7166"><Endpoint>Assessment of Markers of Bone/Cartilage/Collagen Turnover</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7167">Assessment of serum/bone alkaline phosphatase</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7179"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7189"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7190">Assessment of adverse events/serious adverse events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="7207"><Endpoint>Assessment of Skeletal Related Events</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="7209">Time to development of skeletal related events (SRE)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="9129"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="9130">Assessment of cellular response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Prostate tumor" id="26571"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Prostate tumor" id="31928">Assessment by CTCAE grading system</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Prostate tumor" id="3704"><Criterion>Subjects with Progressive Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3705">Subjects with rising PSA levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3710"><Criterion>Subjects with Asymptomatic Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3711"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3714"><Criterion>Subjects with Histologically/Cytologically Confirmed Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3715">Subjects with adenocarcinoma of prostate</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3716"><Criterion>Subjects with Prostate Specific Laboratory Values</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3717">Subjects with castrate level of testosterone</SubCriterion><SubCriterion disease="Prostate tumor" id="3719">Subjects with specified PSA levels</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3724"><Criterion>Subjects with acceptable hematological value</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3737"><Criterion>Subjects with Protocol Specified Performance Status </Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3745"><Criterion>Subjects on Prior/Concurrent Therapy for Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3746">Subjects on prior/concurrent hormone therapy</SubCriterion><SubCriterion disease="Prostate tumor" id="3750">Subjects on prior/concurrent biologics/immunotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="3755"><Criterion>Subjects with Castrate Resistant Prostate Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="3771"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="7091"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Prostate tumor" id="33310"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3726">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Prostate tumor" id="34007"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="3727">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Prostate tumor" id="4845"><Criterion>Subjects with Advanced/Metastatic Prostate Cancer</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4847">Subjects with brain metastasis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4864"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4876"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4894"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4909"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Prostate tumor" id="4918"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4899">Subjects with Auto-immune/Inflammatory diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4965"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4967">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Prostate tumor" id="4968">Subjects on prior/concurrent radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="4975"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="4976">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="5004"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5013">Subjects Exposed to Study Drug/device/procedure</SubCriterion><SubCriterion disease="Prostate tumor" id="5015">Subjects unsuitable to participate as per investigator</SubCriterion><SubCriterion disease="Prostate tumor" id="14249">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Prostate tumor" id="27938"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Prostate tumor" id="5010">Subjects unable to comply with study requirements</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-11-30T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2019-02-07T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>35.55 Months</EnrollmentPeriod><EnrollmentRate>1.01 Patients/Month</EnrollmentRate><DateFirstReceived>2015-05-21T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-06-28T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2015-12-29T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-02-14T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="234561"><TitleDisplay>Study of a Single Primary Dose Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) in Healthy Subjects</TitleDisplay><TitleOfficial>Immunogenicity and Safety of a Single Primary Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) Given to Healthy Subjects in Vietnam</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02492165</Identifier><Identifier type="Secondary Organisational">U1111-1143-8142</Identifier><Identifier type="Organisational Study">JEC13</Identifier><Identifier type="Other">2015-JEC13-BR</Identifier><Identifier type="Other">NCT02821221</Identifier></Identifiers><Indications><Indication id="1283">Japanese encephalitis virus infection</Indication></Indications><BiomarkerNames><BiomarkerName id="44216" role="Toxic effect marker" type="Physiological">Body temperature</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ChimeriVax-JE</Name><Drug id="15255">ChimeriVax-JE</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15255">ChimeriVax-JE</Drug><IndicationsPioneer/><Companies><Company><Company id="1063086">National Institute of Hygiene and Epidemiology, Vietnam</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="22127">Sanofi Pasteur</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15255" type="Drug"><TargetEntity id="292954" type="siDrug">ChimeriVax-JE</TargetEntity></SourceEntity><SourceEntity id="1063086" type="Company"><TargetEntity id="5036351865" type="organizationId">National Institute of Hygiene and Epidemiology Vietnam</TargetEntity></SourceEntity><SourceEntity id="22127" type="Company"><TargetEntity id="5000043854" type="organizationId">Sanofi Pasteur SA</TargetEntity></SourceEntity><SourceEntity id="1283" type="ciIndication"><TargetEntity id="A83.0" type="ICD10"/><TargetEntity id="10014596" type="MEDDRA"/><TargetEntity id="D004672" type="MeSH"/><TargetEntity id="79139" type="ORPHANET"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="22127">Sanofi Pasteur</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1063086">National Institute of Hygiene and Epidemiology, Vietnam</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="12364">Live attenuated viral vaccine</Class><Class id="12378">Prophylactic vaccine</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="62">Virus recombinant</Technology></Technologies><TermsPatientSelection><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Infants (6-23 months)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Asian Ancestry</Term><Term>Japanese Ancestry</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Vaccine</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>250</PatientCountEnrollment><PatientCountEvaluable>250</PatientCountEvaluable><DateStart>2015-06-30T00:00:00Z</DateStart><DateEnd type="actual">2016-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-07-30T13:21:50Z</DateChangeLast><DateAdded>2015-08-01T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Sanofi Pasteur SA</Affiliation><Name>Medical Director</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 9 months through 60 years on the day of inclusion&lt;/li&gt;&lt;li&gt;For adults: informed consent form has been signed and dated by the subject. For minors: informed consent form has been signed and dated by the parent or legally acceptable representative. In addition, in accordance with the Institution Ethics Committee/Institution Review Board requirements and as appropriate for the age of the subject, the subject may be required to sign and date the informed consent form if aged 12 to 17 years or assent form if aged 8 to 11 years&lt;/li&gt;&lt;li&gt;Subject and parents/legally acceptable representatives are able to attend all scheduled visits and comply with all study procedures&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Subject is pregnant, or lactating, or of childbearing potential (to be considered of non-childbearing potential, a female must be pre-menarche, or post-menopausal for at least one year, or surgically sterile, or using an effective method of contraception or abstinence from &gt;/= 4 weeks prior to vaccination until at least 4 weeks after vaccination)&lt;/li&gt;&lt;li&gt;Participation at the time of study enrollment (or in the 4 weeks preceding the study vaccination) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or a medical procedure&lt;/li&gt;&lt;li&gt;Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned receipt of any vaccine in the 4 weeks following the study vaccination, except for inactivated influenza vaccination, which may be received &gt;/= 2 weeks before the study vaccine&lt;/li&gt;&lt;li&gt;Previous vaccination against flavivirus disease, including Japanese Encephalitis(JE), dengue, and yellow fever&lt;/li&gt;&lt;li&gt;Receipt of immune globulins, blood, or blood-derived products in the past 3 months that might interfere with the assessment of the immune response&lt;/li&gt;&lt;li&gt;Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy (for more than 2 consecutive weeks within the 4 weeks preceding vaccination)&lt;/li&gt;&lt;li&gt;History of flavivirus infection (confirmed either clinically, serologically, or virologically)&lt;/li&gt;&lt;li&gt;History of central nervous system disorder or disease, including seizures&lt;/li&gt;&lt;li&gt;Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the study or to a vaccine containing any of the same substances&lt;/li&gt;&lt;li&gt;Known thrombocytopenia, contraindicating vaccination&lt;/li&gt;&lt;li&gt;Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating vaccination&lt;/li&gt;&lt;li&gt;Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily&lt;/li&gt;&lt;li&gt;Current alcohol abuse or drug addiction&lt;/li&gt;&lt;li&gt;Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion&lt;/li&gt;&lt;li&gt;Febrile illness (temperature &gt;/= 38 degC) or moderate or severe acute illness/infection on the day of vaccination, according to Investigator judgment. A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided&lt;/li&gt;&lt;li&gt;Receipt of any chronic anti-viral in the 2 months preceding the study vaccination or planned receipt of any anti-viral in the 4 weeks following the study vaccination. Short-term antiviral drugs for flu or herpes can be administered provided there is a wash-out period of 1 week before the administration of the vaccine&lt;/li&gt;&lt;li&gt;Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Number of participants with solicited injection site reactions and systemic events following a single primary dose of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV): solicited injection-site: &lt;/= 23 months age: tenderness, erythema, and swelling: for &gt;/= 2 years age: pain, erythema, and swelling. solicited systemic reactions: &lt;/= 23 months age, fever (temperature) vomiting, crying abnormal, drowsiness, appetite loss, Irritability, for &gt;/= 2 years age, fever (temperature) headache, malaise, and myalgia. Grade 3: tenderness, cries when injected limb is moved; pain, incapacitating, unable to perform usual activities or significant; prevents daily activity (&gt;/= 12 years); erythema and swelling (&lt;/= 23 months to 11 years), &gt;/= 50 mm or &gt; 100 mm (&gt;/= 12 years). Grade 3 fever, &gt; 39.5 degC (&lt;/= 23 months) or &gt;/= 39.0 degC (&gt;/= 2 years); vomiting, &gt;/= 6 episodes per 24 hours; crying abnormal, &gt; 3 hours; drowsiness, sleeping most of the time; appetite loss</Description><Timeframe>Day 0 up to day 14 post-vaccination</Timeframe></Measure><Measure><Description>Percentage of participants With Japanese encephalitis seroprotection following a single primary dose of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV) (time frame: day 0 [pre-vaccination] and day 28 post-vaccination): neutralizing antibodies were measured using a Japanese encephalitis chimeric virus (JE CV) 50% plaque reduction neutralization test (PRNT50). seroprotection was defined as antibody titer levels &gt;/= 10 (1/dil)</Description><Timeframe>Day 0 (pre-vaccination) and Day 28 post-vaccination</Timeframe></Measure><Measure><Description>Percentage of participants with Japanese encephalitis seroconversion following a single primary dose of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV) (time frame: day 0 [pre-vaccination] and day 28 post-vaccination): neutralizing antibodies were measured using a Japanese encephalitis chimeric virus (JE CV) 50% plaque reduction neutralization test (PRNT50). Seroconversion was defined as participants with a pre-vaccination titer &lt; 10 (1/dil) and post-vaccination titer &gt;/= 10 (1/dil) or participants with pre vaccination titer &gt;/= 10 (1/dil) and a &gt;/= 4-fold increase from pre- to post-vaccination</Description><Timeframe>Day 0 (pre-vaccination) and Day 28 post-vaccination</Timeframe></Measure><Measure><Description>Summary of Geometric Mean Titers (GMTs) of Japanese encephalitis antibodies following a single primary dose of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV): neutralizing antibodies were measured using a Japanese encephalitis chimeric virus (JE CV) 50% plaque reduction neutralization test (PRNT50)</Description><Timeframe>Day 0 (pre-vaccination) and Day 28 post-vaccination</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Immunogenicity</Description><Timeframe>At baseline and 28 days after vaccination</Timeframe></Measure><Measure><Description>Safety and reactogenecity: solicited and unsolicited adverse events</Description><Timeframe>From day 0 to day 28 (plus five days)</Timeframe></Measure><Measure><Description>Serious adverse events (SAEs)</Description><Timeframe>From day 0 to day 14</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In April 2017, results were presented. IMOJEV was observed to be well tolerated. None of the subjects reported an immediate adverse event (AE). A total of four grade 3 solicited systemic reactions were observed with the maximum duration of 3 days. Grade 1 diarrhea considered related to vaccination was reported in one patient. During the study, two serious AEs were reported but nothing was related to vaccination [&lt;ulink linkType="Reference" linkID="1942855"&gt;1942855&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2018, results were published. During the study there were no safety concerns [&lt;ulink linkType="Reference" linkID="2036318"&gt;2036318&lt;/ulink&gt;].&lt;br/&gt;&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to describe the immunogenicity and safety of &lt;ulink linkType="Drug" linkID="15255"&gt;IMOJEV&lt;/ulink&gt; (live attenuated Japanese encephalitis chimeric virus vaccine) in adult      and pediatric populations in Vietnam and serve a bridging study to compare immunogenicity,      reactogenicity, and safety data obtained with IMOJEV in the Vietnamese population with data      from other Asian pediatric populations.&lt;/para&gt;&lt;para&gt;Primary objective of the study was to describe the safety profile of a single-dose of IMOJEV. Secondary objective of the study was to evaluate the immune response to JE 28 days after the administration of a single-dose           of IMOJEV in healthy Vietnamese subjects aged from 9 months to 60 years.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2017, results were presented. At baseline, the proportion of subjects with seroprotective antibody titers increased with increasing age (20% of subjects from 9 months to 4 years of age, 41.7% of subjects from 5 to 11 years of age, 67.8% of subjects from 12 to 17 years of age and 83.3% of subjects from 18 to 60 years of age). Similarly, there was an increase in geometric mean titers at baseline with increasing age (from 9.08 [1/dil] in subjects from 9 months to 4 years of age up to 474 [1/dil] in subjects from 18 to 60 years of age). From 9 months to 4 years of age group, all subjects expect three were seroprotected following vaccination [&lt;ulink linkType="Reference" linkID="1942855"&gt;1942855&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2018, results were published. After 28 days of vaccination, seroconversion (titer &gt;/= 10 [1/dil] in subjects Japanese Encephalitis (JE) seronegative [titer &amp;lt; 10] at baseline [per protocol analysis], or a 4-fold rise from a baseline titer &gt;/= 10) and seroprotection (titer &gt;/= 10 [1/dil]) rates in protocol analysis were both 98.5%, and in full analysis set were 82.4 and 98.8%, respectively. In all age groups (subjects aged 9 months to 4 years, 5 to 11 years, 12 to 17 years and 18 to 60 years from day 0 to day 28), geometric mean titers (GMTs) ratios (day 28/day 0) were increased and found to be 55.3, 348, 296 and 194, respectively [&lt;ulink linkType="Reference" linkID="2036318"&gt;2036318&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Study subjects would be enrolled by age group (9 months through 4 years; or 5 through 11 years; or 12 through 17 years; or  18 through 60 years) and would each receive one sc injection of      IMOJEV 0.5 ml on day 0 given as primary vaccination. They would be assessed for immunogenicity and      safety, post-vaccination.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Subjects (n = 250) received one sc injection of IMOJEV on day 0 as primary vaccination [&lt;ulink linkType="Reference" linkID="1942855"&gt;1942855&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="2036318"&gt;2036318&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>ChimeriVax-JE</Name><Drug id="15255">ChimeriVax-JE</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="537486">ChimeriVax-JE</Intervention><Treatments><Treatment><Dose>0.5 mililitre</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Vietnam"><Sites><Site><Name>Preventive Medicine Centre of Hoa Binh Province</Name><Address1>Hoa Binh</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Japanese Encephalitis Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="15290">Others</PatientSegment><SubSegments><SubSegment id="10654">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02492165</Identifier><Identifier>NCT02821221</Identifier></Identifiers></Registry><Registry><Name id="1004">WHO ICTRP</Name><Identifiers><Identifier type="Secondary Organisational">U1111-1143-8142</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Japanese Encephalitis Vaccine" id="15331"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Japanese Encephalitis Vaccine" id="15332">Assessment of adverse events/serious adverse events</SubEndpoint><SubEndpoint disease="Japanese Encephalitis Vaccine" id="15333">Reactogenicity(local/systemic reactions)</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Japanese Encephalitis Vaccine" id="15326"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Japanese Encephalitis Vaccine" id="15327">Assessment of anti-JE antibodies</SubEndpoint><SubEndpoint disease="Japanese Encephalitis Vaccine" id="15328">Assessment of seropositivity/seroconversion rate</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Japanese Encephalitis Vaccine" id="14678"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Japanese Encephalitis Vaccine" id="34736"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Japanese Encephalitis Vaccine" id="14667">Healthy Subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Japanese Encephalitis Vaccine" id="12076"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="12081"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="12086"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="12089"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Japanese Encephalitis Vaccine" id="12090">Subjects with prior history of/scheduled to receive immunoglobulins/blood products for other indication</SubCriterion><SubCriterion disease="Japanese Encephalitis Vaccine" id="12091">Subjects with history of/scheduled to receive immunosuppressants for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="12092"><Criterion>Subjects with Contraindications to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="12093"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Japanese Encephalitis Vaccine" id="26533"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Japanese Encephalitis Vaccine" id="12087">Subjects with Prior Japanese Encephalitis Vaccination</SubCriterion><SubCriterion disease="Japanese Encephalitis Vaccine" id="12088">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2016-03-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2016-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.06 Months</EnrollmentPeriod><EnrollmentRate>35.41 Patients/Month</EnrollmentRate><DateFirstReceived>2015-07-05T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-08-01T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2016-04-20T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2016-07-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2017-09-19T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-09-19T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change></ChangeHistory></Trial><Trial id="238927"><TitleDisplay>Prophylactic Antibiotics Before RFA for HCC</TitleDisplay><TitleOfficial>Prophylactic Administration of Antibiotics Before Radiofrequency Ablation for Hepatocellular Carcinoma: A Randomized Trial</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02534961</Identifier><Identifier type="Organisational Study">2015-01-003B</Identifier></Identifiers><Indications><Indication id="746">Infectious disease</Indication></Indications><BiomarkerNames><BiomarkerName id="46" role="Therapeutic effect marker" type="Genomic;Proteomic">C-reactive protein</BiomarkerName><BiomarkerName id="125" role="Therapeutic effect marker" type="Cellular">Leukocyte count</BiomarkerName><BiomarkerName id="213" role="Therapeutic effect marker" type="Biochemical">Creatinine</BiomarkerName><BiomarkerName id="1211" role="Therapeutic effect marker" type="Genomic;Proteomic">Alanine transaminase</BiomarkerName><BiomarkerName id="2358" role="Therapeutic effect marker" type="Biochemical">Urea nitrogen</BiomarkerName><BiomarkerName id="2527" role="Therapeutic effect marker" type="Genomic;Proteomic">Aspartate aminotransferase</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>cefazolin</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="30729" type="Company"><TargetEntity id="5035524473" type="organizationId">Taipei Veterans General Hospital</TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="30729">Taipei Veterans General Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>600</PatientCountEnrollment><DateStart>2015-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-08-10T14:30:16Z</DateChangeLast><DateAdded>2015-09-15T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>cwsu2@vghtpe.gov.tw</Email><Extension>3352</Extension><Name>Chien-Wei Su, MD &amp; PhD</Name><Phone>886228712121</Phone></Contact><Contact type="Scientific contact"><Affiliation>Taipei Veterans General Hospital, Taiwan</Affiliation><Name>Chien-Wei Su, MD &amp; PhD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with HCC and underwent RFA&lt;/li&gt;&lt;li&gt;With tumor size&amp;lt; 5 cm without extra-hepatic metastasis:&lt;ul&gt;&lt;li&gt;The number of tumor was three or less&lt;/li&gt;&lt;li&gt;Child Pugh classification of liver function are grade A or B&lt;/li&gt;&lt;li&gt;Absence of other major diseases that might complicate RFA&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Age is younger than 20 years or older than 80 years&lt;/li&gt;&lt;li&gt;Patients have a terminal illness of any major organ system, like heart failure, uremia, chronic obstructive pulmonary disease, or non-hepatic malignancy&lt;/li&gt;&lt;li&gt;Patients have received antibiotics within the last 2 weeks. Patients will be subsequently excluded when initial bacteriological sampling turned out positive (occult infection)&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Infection after radiofrequency ablation: body temperature will be measured every 6 h for 72 h; acetaminophen at 500 mg will be used when patients complain of pain or have a high grade fever over 39°C after the procedure. The numbers of peripheral blood leukocytes, as well as levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), creatinine, C-reactive protein (CRP) and infection signs as above descriptions will be determined before, and at 24 hour, 3 to 7 day and 4 week after ablation therapy</Description><Timeframe>Within 4 weeks after radiofrequency ablation</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This randomized prospective study aims to investigate whether prophylactic administration of      antibiotics has an influence on inflammatory markers, liver function test results, or the      incidence of post-procedural infection in patients with hepatocellular carcinoma (HCC)      undergoing radiofrequency ablation (RFA).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In the study, patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing &gt;/= 120 kg) within 60 min before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established.&lt;br/&gt;Patients:&lt;br/&gt;This cohort study will prospectively enroll HCC patients undergoing RFA in Taipei           Veterans General Hospital and Taipei Medical University Hospital.&lt;br/&gt;The diagnosis of HCC is established by histology or on the basis of the findings of           typical radiologic features in a four-phase multidetector computed tomography (CT)scan or           dynamic contrast-enhanced magnetic resonance imaging (MRI).&lt;br/&gt;Inclusion criteria: tumor size &amp;lt; 5 cm without extra-hepatic metastasis; the           number of tumor was three or less; Child Pugh classification of liver function are grade A           or B; and the absence of other major diseases that might complicate RFA.&lt;br/&gt;Patients will be excluded from the study if they meet the following criteria. First,           the patient's age is younger than 20 years or older than 80 years. Second, the patients           have a terminal illness of any major organ system, like heart failure, uremia, chronic           obstructive pulmonary disease, or non-hepatic malignancy. Third, the patients have           received antibiotics within the last 2 weeks. Patients will be subsequently excluded           when initial bacteriological sampling turned out positive (occult infection).&lt;br/&gt;After disinfection of the skin surface and induction of local anesthesia with 1%           lidocaine, RFA will be performed with real-time ultrasonography guidance, and the RF           electrode will be advanced into the tumor. RFA device will be used the Cool-Tip           Radiofrequency System (Radionics, Burlington, MA). With the Cool-Tip device, treatment           will be performed with a single (2 or 3 cm active tip) needle electrode. Each tumor           has 1 to 4 ablations per session, depending on the tumor size. If the tumor is adjacent to           hollow viscera and can not be displaced with a safe margin of at least 2 cm by           positioning the patient in an oblique or lateral position, 5% dextrose will be           intraperitoneally instilled around the liver to displace the hollow viscera.&lt;br/&gt;After RFA, all patients will undergo immediate follow-up ultrasonography to evaluate           the possibility of bleeding or fluid accumulation. Dynamic CT scan or MRI will be done           one month after all of the tumors ablated by RFA. When these will be confirmed residual           tumors by showing contrast enhancement during the arterial phase and wash out in venous           phase, a second session of RFA will be conducted. If viable tumors persist after two           sessions of RFA therapy, treatment will be considered a failure. If no viable tumor is           detected, the patient will be regularly followed-up with abdominal sonography every 3           months.&lt;br/&gt;Tumor recurrence is suspected if there is elevated serum AFP level or new lesion           detected by surveillance ultrasonography. These would be confirmed by dynamic CT or           MRI. Local recurrence is defined as tumor recurrence at the same segment of a previous           tumor site, while intra-hepatic distant recurrence is diagnosed when a new lesion           occurs in a different segment of a previously treated tumor.&lt;/para&gt;&lt;para&gt;Randomization:&lt;br/&gt;Patients who fulfilled the inclusion criteria will be immediately randomized      to the two treatment groups by using consecutively numbered envelopes that contained the      treatment assignments, which were generated by a computer-allocated random digit number, in      a 1:1 ratio. Patients in the prophylactic group will receive antibiotic treatment right      after randomization with intravenous cefazolin 2 g (3 g for patients weighing &gt;/= 120 kg)      within 60 min before ablation therapy. Patients in the on-demand group will receive      antibiotic therapy only when infection will be suspected or established. Antibiotics will be      changed according to the antibiotic sensitivity test of cultured microorganisms.&lt;/para&gt;&lt;para&gt;Infection Assessment:&lt;br/&gt;All patients will be closely monitored with special emphasis on the      detection of bacterial infection through the hospitalization period. A careful physical      examination, complete white blood cell count, chest radiography, urine sediment, urine      culture, ascitic fluid neutrophil count and culture (if available), and blood culture will      be routinely performed before randomization. Physical examination will be performed at least      once per day during hospitalization. If a new infection is suspected, the same procedures to      assess infection would be performed at admission. New infections are suspected when there is      fever (&amp;gt; 38°C), hypothermia (&amp;lt; 36°C), unexpected hemodynamic instability, tachypnea, new onset      of chest symptoms, dysuria, abdominal pain, distention, as well as alteration of mental      state. A central venous catheter or urinary catheter would be inserted only when clinically      indicated.&lt;/para&gt;&lt;para&gt;Clinical Assessment and Follow-up:&lt;br/&gt;Body temperature will be measured every 6 h for 72      h; acetaminophen at 500 mg will be used when patients complain of pain or have a high      grade fever over 39°C after the procedure. The numbers of peripheral blood leukocytes, as      well as levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST),      blood urea nitrogen (BUN), creatinine, C-reactive protein (CRP) and infection signs as above      descriptions will be determined before, and at 24 h, 3 to 7 day and 4 week after ablation      therapy. Dynamic CT scan or MRI will be done one month after all of the tumors ablated by      RFA in order to estimate the effectiveness of RFA or HCC, and whether liver abscess,      cholangitis, cholangitis and peritonitis will be present. If a new infection is suspected      within one month after RFA, Dynamic CT scan or MRI will be done immediately. Post-procedure      infection is defined on the Guideline for Prevention of Surgical Site Infection, 1999,      Centers for Disease Control and Prevention (CDC).&lt;/para&gt;&lt;para&gt;Safety Assessment and Adverse Events:&lt;br/&gt;Adverse events will be recorded by the investigators      during hospitalization or at the 4-week out-patient follow-up visit.&lt;/para&gt;&lt;para&gt;Statistical Analysis:&lt;br/&gt;Pearson chi-square analysis or Fisher's exact test will be used to      compare categorical variables, while the Mann-Whitney U-test would be used to compare      continuous variables.&lt;br/&gt;Variables with statistical significance (p &amp;lt; 0.05) or proximate to it (p &amp;lt; 0.1) by univariate      analysis underwent multivariate analysis using a Cox's forward stepwise logistic regression      model. A two-tailed p value &amp;lt; 0.05 is considered statistically significant. All statistical      analyses will be performed using the Statistical Package for Social Sciences (SPSS 19.0 for      Windows, SPSS. Inc., Chicago, IL, USA).&lt;br/&gt;The infection rate of patients with HCC after RFA, without special emphasis on antibiotics      treatment, is 1.5 to 3%. Estimates of sample size are based on a infection rate assumed to be      1% for the prophylactic antibiotics group and 5% for the on-demand antibiotics group. The      type I (alpha) error and type II (beta) error are set to 0.05 and 0.2, respectively. The      sample size needed is estimated to be at least 282 patients per group. Taking into account      an expected dropout or missing data rate of 5%, the sample size needed is estimated to be at      least 594 patients. Consequently, we plan to enroll a total of 600 patients in this study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Taiwan"><Sites><Site><Name>Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital</Name><Address1>Taipei</Address1><Address3>112</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>cwsu2@vghtpe.gov.tw</Email><Extension>3352</Extension><Name>Chien-Wei Su, MD &amp; PhD</Name><Phone>886228712121</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hepatobiliary system tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="18937">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16345">Subjects with hepatocellular carcinoma</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02534961</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12090"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12094">Assessment of C reactive protein (CRP)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Hepatobiliary system tumor" id="12096"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Hepatobiliary system tumor" id="45933"><Endpoint>Anthropometric Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Hepatobiliary system tumor" id="12130">Assessment of anthropometric changes</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hepatobiliary system tumor" id="7832"><Criterion>Liver Cancer Subjects with Specific Child-Pugh Score</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="13159">Subjects with Child-Pugh class A liver function</SubCriterion><SubCriterion disease="Hepatobiliary system tumor" id="13160">Subjects with Child-Pugh class B liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="7872"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="7878">Subjects with history of surgery/procedure for hepato-biliary cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Hepatobiliary system tumor" id="34259"><Criterion>Subjects with specific disease</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="32046">Subjects with hepatocellular carcinoma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hepatobiliary system tumor" id="9411"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9412"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9422"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9426">Subjects with abnormal pulmonary functions</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="9447"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Hepatobiliary system tumor" id="26350"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Hepatobiliary system tumor" id="9425">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2015-08-25T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-09-15T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="242722"><TitleDisplay>A Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis</TitleDisplay><TitleOfficial>A Randomized Comparison of Transcatheter Heart Valves in High Risk Patients With Severe Aortic Stenosis: Medtronic CoreValve Versus Edwards SAPIEN XT (The CHOICE Trial)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT01645202</Identifier><Identifier type="Organisational Study">SK 107 -- 012/12 (II)</Identifier><Identifier type="Trial Acronym">CHOICE</Identifier></Identifiers><Indications><Indication id="2383">Aortic stenosis</Indication></Indications><BiomarkerNames><BiomarkerName id="12639" role="Therapeutic effect marker" type="Structural (imaging)">Aortic valve</BiomarkerName><BiomarkerName id="21963" role="Therapeutic effect marker" type="Physiological">Peak Aortic valve velocity</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Edwards Sapien XT valve</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Medtronic CoreValve</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Transcatheter Aortic Valve Implantation (TAVI)</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>balloon-expandable transcatheter heart valve</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>self-expandable transcatheter heart valve</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1077463" type="Company"><TargetEntity id="4297156989" type="organizationId">Segerberger Kliniken GmbH</TargetEntity></SourceEntity><SourceEntity id="2383" type="ciIndication"><TargetEntity id="10002906" type="MEDDRA"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1077463">Herz-Kreislauf-Zentrum Segeberger Kliniken GmbH</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>241</PatientCountEnrollment><PatientCountEvaluable>241</PatientCountEvaluable><DateStart>2012-03-31T00:00:00Z</DateStart><DateEnd type="actual">2018-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-03-04T11:12:18Z</DateChangeLast><DateAdded>2015-10-22T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Herzzentrum, Segeberger Kliniken, Bad Segeberg, Germany</Affiliation><Name>Gert Richardt, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Herzzentrum, Segeberger Kliniken, Bad Segeberg, Germany</Affiliation><Name>Mohamed Abdel-Wahab, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Severe aortic valve stenosis defined as aortic valve area (AVA)&amp;lt;/=  1cm2 or 0.6 cm2/m2&lt;/li&gt;&lt;li&gt;Presence of clinical symptoms defined as New York Heart Association (NYHA) functional class &gt;/=  2&lt;/li&gt;&lt;li&gt;Age&amp;gt; 75 years and/or Logistic EuroSCORE &gt;/=  20% and/or STS risk score &gt;/=  10% and/or contraindication to conventional surgical aortic valve replacement (porcelain aorta, previous chest radiation, chest deformation)&lt;/li&gt;&lt;li&gt;Native aortic valve annulus measuring 20 to 25 mm&lt;/li&gt;&lt;li&gt;Patients must be suitable for a transfemoral vascular access&lt;/li&gt;&lt;li&gt;The patient signing a written informed consent prior to intervention&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Life expectancy&amp;lt; 12 months due to co-morbid conditions&lt;/li&gt;&lt;li&gt;Native aortic valve annulus&amp;lt; 20  and &amp;gt; 25 mm (this could be amended if further valve sizes for the transfemoral approach become available for both prostheses during the study period)&lt;/li&gt;&lt;li&gt;Pre-existing aortic bioprosthesis&lt;/li&gt;&lt;li&gt;Cardiogenic shock or hemodynamic instability&lt;/li&gt;&lt;li&gt;History of, or active endocarditis&lt;/li&gt;&lt;li&gt;Contraindications for a transfemoral access&lt;/li&gt;&lt;li&gt;Active peptic ulcer or upper gastro-intestinal bleeding within the prior 3 months&lt;/li&gt;&lt;li&gt;Hypersensitivity or contraindication to aspirin, heparin or clopidogrel&lt;/li&gt;&lt;li&gt;Active infection requiring antibiotic treatment&lt;/li&gt;&lt;li&gt;An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 3 months post-enrolment&lt;/li&gt;&lt;li&gt;Patients actively participating in another drug or device investigational study and have not yet completed the primary endpoint follow-up period&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>'Device success' as recently defined by the Valve Academic Research Consortium: device success is a 'technical' composite endpoint including successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system, correct position of the device in the proper anatomical location, intended performance of the prosthetic heart valve (aortic valve area &gt; 1.2 cm2 and mean aortic valve gradient &lt; 20 mmHg or peak velocity &lt; 3 m/s, without moderate or severe prosthetic valve AR) and only one valve implanted in the proper anatomical location</Description><Timeframe>Immediately after the procedure</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>VARC-defined combined efficacy endpoint: a composite endpoint defined by VARC as: all cause mortality between 30 days and one year, failure of current therapy for aortic stenosis, requiring hospitalization for symptoms of valve-related or cardiac decompensation and prosthetic heart valve dysfunction (aortic valve area &lt; 1.2 cm2 and mean aortic valve gradient &gt; 20 mmHg or peak velocity &gt; 3 m/s or moderate or severe prosthetic valve AR)</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>VARC-defined combined safety endpoint: combined endpoint defined by VARC as: all cause mortality, major stroke, life threatening (or disabling) bleeding, acute kidney injury-Stage 3 (including renal replacement therapy), periprocedural myocardial infarction, major vascular complications and repeat procedure for valve-related dysfunction (surgical or interventional therapy)</Description><Timeframe>30 days</Timeframe></Measure><Measure><Description>Cardiovascular mortality as defined by VARC</Description><Timeframe>At 1, 6 and 12 months</Timeframe></Measure><Measure><Description>Major adverse cardiovascular and cerebrovascular events (MACCE): myocardial infarction, cardiac or vascular surgery and stroke</Description><Timeframe>At 30 days, 6 and 12 months</Timeframe></Measure><Measure><Description>Rehospitalization for heart failure</Description><Timeframe>At 12 months</Timeframe></Measure><Measure><Description>Quality of life (assessed with the Euro5Qual-questionnaire)</Description><Timeframe>At 12 months</Timeframe></Measure><Measure><Description>NYHA-class improvement</Description><Timeframe>At 30 days, 6 and 12 months</Timeframe></Measure><Measure><Description>Vascular complication as defined by VARC</Description><Timeframe>At 30 days</Timeframe></Measure><Measure><Description>Post-procedural pacemaker implantation</Description><Timeframe>At 1 month</Timeframe></Measure><Measure><Description>Major or minor bleeding: as defined be VARC</Description><Timeframe>At 30 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In August 2015 results were published. In the balloon and self-expandable groups, the rates of death of any cause at one year (17.4 versus 12.8% respectively;  p = 0.37) and of cardiovascular causes (12.4 versus 9.4% respectively; p = 0.54) were not statistically  different. Also the frequencies of all strokes (9.1 versus 3.4%; p = 0.11) and repeat hospitalization for heart failure (7.4 versus 12.8%;  p = 0.19) did not statistically  differ between balloon and self-expandable groups respectively. In the self-expandable group more than mild paravalvular regurgitation was more frequent (1.1 versus 12.1% respectively in balloon and self-expandable groups; p = 0.005) [&lt;ulink linkType="Reference" linkID="1702868"&gt;1702868&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, controlled, multicenter study was to compare  the acute hemodynamic performance of the      Edwards Sapien XT and the Medtronic CoreValve transcatheter heart valves in high risk      patients with severe symptomatic aortic stenosis.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In August 2015 results were published.  Results showed an elevated transvalvular gradients during follow-up  in four patients in the balloon-expandable group (3.4 versus  0% respectively in balloon and self-expandable groups; p = 0.12),  which  were further resolved with anticoagulant therapy, indicating  a thrombotic etiology   [&lt;ulink linkType="Reference" linkID="1702868"&gt;1702868&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;  Patients would be randomized to receive Transcatheter Aortic Valve Implantation (TAVI) with either Edwards Sapien XT valve or Medtronic CoreValve.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients      were randomized to receive transfemoral transcatheter aortic valve replacement with either balloon and self-expandable transcatheter heart valves [&lt;ulink linkType="Reference" linkID="1702868"&gt;1702868&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>balloon-expandable transcatheter heart valve</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="55">Cardiac failure</Indication><CountPatientsAffectedPercentage>7.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="57">Cardiovascular disease</Indication><CountPatientsAffectedPercentage>12.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="65">Stroke</Indication><CountPatientsAffectedPercentage>9.1</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>self-expandable transcatheter heart valve</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="55">Cardiac failure</Indication><CountPatientsAffectedPercentage>12.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="57">Cardiovascular disease</Indication><CountPatientsAffectedPercentage>9.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="65">Stroke</Indication><CountPatientsAffectedPercentage>3.4</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Segeberger Kliniken GmbH / Herzzentrum</Name><Address1>Bad Segeberg</Address1><Address2>Schleswig-Holstein</Address2><Address3>23795</Address3><CountrySubDivision>Schleswig-Holstein</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="61">Subjects with Symptomatic Disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="151">Subjects at risk of developing disease</PatientSegment><SubSegments><SubSegment id="81">Subjects with valvular heart disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="13416">Subjects with NYHA Functional Class	</PatientSegment><SubSegments><SubSegment id="76">Mild /NYHA Functional Class II Heart Failure Subjects</SubSegment><SubSegment id="77">Moderate/NYHA Functional Class III Heart Failure Subjects</SubSegment><SubSegment id="78">Severe/NYHA Functional Class IV Heart Failure Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Renal failure</Disease><PatientSegments><PatientSegment><PatientSegment id="8107">Subjects with Prerenal Causes for Acute Renal Failure(ARF)</PatientSegment><SubSegments><SubSegment id="8109">Subjects with cardiopulmonary disease</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01645202</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="2178"><Endpoint>Assessment of Device Related Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="2195">Performance of the device</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Renal failure" id="22991"><Endpoint>Assessment of Survival</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="973"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="974">Assessment of all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="1259"><Endpoint>Assessment of Renal Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="6790"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="561">Assessment of major adverse cardiac events (MACEs)</SubEndpoint><SubEndpoint disease="Cardiac failure" id="690">Assessment of fatal/non-fatal myocardial infarction</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Cardiac failure" id="6794"><Endpoint>Assessment of Non Cardiovascular  Events</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="558">Assessment of cerebrovascular adverse events (Stroke/TIA)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Renal failure" id="22985"><Endpoint>Assessment of Renal Replacement Therapy(RRT)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Renal failure" id="22999"><Endpoint>Assessment of Other Treatment Responses</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Renal failure" id="23006"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Renal failure" id="23008"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="258"><Criterion>Subjects with Congestive Heart Failure (CHF)</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="912"><Criterion>Subjects co-morbid with cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="327">Subjects co-morbid with valvular heart disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Renal failure" id="20154"><Criterion>Subjects with Prerenal Causes for Acute Renal Failure(ARF)</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="20155">Subjects with cardiopulmonary disease</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Renal failure" id="20186"><Criterion>Subjects with History/Scheduled for Renal Replacement Therapy</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="20187">Subjects with history/scheduled for filtration/dialysis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="31870"><Criterion>Inclusion of Subjects Based on NYHA Class</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="275">Subjects with heart failure, NYHA class II</SubCriterion><SubCriterion disease="Cardiac failure" id="276">Subjects with heart failure, NYHA class III</SubCriterion><SubCriterion disease="Cardiac failure" id="277">Subjects with heart failure, NYHA class IV</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="469"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="474">Subjects co-morbid with cardiogenic shock</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="481"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="485">Subjects with implanted/scheduled to receive pacemakers/device</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="525"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="526">Subjects with history of/scheduled to receive antibiotics for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="543"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="546">Subjects with hypersensitivity/contraindications to anticoagulant drugs</SubCriterion><SubCriterion disease="Cardiac failure" id="1391">Hypersensitivity/contraindications to antiplatelet drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="623"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="628">Acute/chronic bleeding or bleeding diathesis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="635"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="476">Subjects co-morbid with endocarditis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Renal failure" id="17906"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Renal failure" id="17918"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Renal failure" id="17933"><Criterion>Subjects with Hypersensitivity/Contraindication to Device/Procedures</Criterion><SubCriteria><SubCriterion disease="Renal failure" id="17934">Subjects with contraindication to drugs or its excipients</SubCriterion><SubCriterion disease="Renal failure" id="17936">Subjects with contraindications to procedures</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Renal failure" id="17947"><Criterion>Subjects with History Other Surgery</Criterion></Exclusion><Exclusion disease="Renal failure" id="17950"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2013-12-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2014-02-28T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>23.03 Months</EnrollmentPeriod><EnrollmentRate>10.46 Patients/Month</EnrollmentRate><DateFirstReceived>2012-06-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2015-10-22T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2019-03-04T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="24538"><TitleDisplay>Efficacy and Tolerability Study of Topical Cyclosporin in a Psoriasis Plaque Test</TitleDisplay><TitleOfficial>A Phase I, Single-Center, Randomized, Vehicle-Controlled Study, Double-Blind for the Study Preparations and Observer-Blind for the Comparators to Determine the Antipsoriatic Efficacy and Tolerability of Topical Formulations With Cyclosporin in a Psoriasis Plaque Test</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Other">EudraCT: 2006-001186-42</Identifier><Identifier type="Other">260114BS</Identifier><Identifier type="Other">ASF 1075-203</Identifier><Identifier type="Organisational Study">ISD001-CI-07</Identifier><Identifier type="NCT">NCT00578370</Identifier><Identifier type="Secondary Organisational">2007-002947-26</Identifier></Identifiers><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>ciclosporin (topical, psoriasis), Advancell/ISDIN</Name><Drug id="60285">ciclosporin (topical, psoriasis), Advancell/ISDIN</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>betamethasone</Name><Drug id="44281">betamethasone</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>calcipotriol</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="60285">ciclosporin (topical, psoriasis), Advancell/ISDIN</Drug><IndicationsPioneer><Indication id="281">Psoriasis</Indication></IndicationsPioneer><Companies><Company><Company id="1021534">ISDIN SA</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1021534" type="Company"><TargetEntity id="4297396701" type="organizationId">Isdin SA</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity><SourceEntity id="4010" type="Action"><TargetEntity id="1500" type="Mechanism">Calcineurin (PP-2B) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1021534">ISDIN SA</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="4010">Calcineurin inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15183">Topical antipsoriatic product</Class><Class id="396">Immunosuppressant</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="611">Dermatological formulation</Technology><Technology id="775">Dermatological gel formulation</Technology><Technology id="612">Emulsion dermatological</Technology><Technology id="1667">Nanoparticle formulation dermatological</Technology><Technology id="80">Peptide</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="90">Steroid</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>25</PatientCountEnrollment><PatientCountEvaluable>25</PatientCountEvaluable><DateStart>2007-11-30T00:00:00Z</DateStart><DateEnd type="actual">2008-04-30T00:00:00Z</DateEnd><DateChangeLast>2014-02-11T11:25:24Z</DateChangeLast><DateAdded>2008-08-27T09:50:08Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Bioskin GmbH</Affiliation><Name>Johannes Gassmueller</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Subjects with chronic plaque type psoriasis&lt;/li&gt;&lt;li&gt;Sexually active females of childbearing potential should either be surgically sterile        (hysterectomy or tubal ligation), or should use a highly effective medically accepted        contraceptive regimen&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Local treatment with antipsoriatics (except for salicylic acid in vaseline) in the 4 weeks        preceding and during the study (corticosteroids 8 weeks)&lt;/li&gt;&lt;li&gt;Systemic treatment with antipsoriatics or therapy with PUVA, selected ultraviolet photo        therapy in the 3 months preceding and during the study&lt;/li&gt;&lt;li&gt;Treatment with systemic or locally acting medications which might counter or influence the        study aim&lt;/li&gt;&lt;li&gt;Previous therapy with methotrexate over many years&lt;/li&gt;&lt;li&gt;Therapy with nephrotoxic medication&lt;/li&gt;&lt;li&gt;Therapy with digoxin, colchicin and statins&lt;/li&gt;&lt;li&gt;Medications which might influence the potassium metabolism&lt;/li&gt;&lt;li&gt;Subjects with known dysfunction of the calcium metabolism&lt;/li&gt;&lt;li&gt;Subjects with increased uric acid or potassium serum levels&lt;/li&gt;&lt;li&gt;Erythrodermic psoriasis, psoriasis punctata and pustular psoriasis or extended chronic        stationary forms of psoriasis&lt;/li&gt;&lt;li&gt;Subjects with acute virus infection&lt;/li&gt;&lt;li&gt;Subjects with acne, anogenital pruritus, rosacea, perioral dermatitis, specific skin        problems (skin tuberculosis, luetic skin diseases), vaccination reactions, skin infections        caused by bacteria or viruses        &lt;/li&gt;&lt;li&gt;Symptoms of a clinically significant illness that may influence the outcome of the study in        the 4 weeks before and during the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Psoriatic infiltrate measured by sonography</Description><Timeframe>26 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Skin condition measured by scoring</Description><Timeframe>26 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In March 2009, results were published. Overall, the &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporin&lt;/ulink&gt;-containing formulations were well tolerated. A 12 non-serious adverse events in this study that were considered to be unlikely or not related to the study medication were observed [&lt;ulink linkType="Reference" linkID="1523635"&gt;1523635&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was the demonstration of antipsoriatic efficacy and tolerability of      topical cutaneous &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporin&lt;/ulink&gt; in subjects with psoriasis vulgaris.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;The results demonstrated that the topical &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporine&lt;/ulink&gt; was effective [&lt;ulink linkType="Reference" linkID="909362"&gt;909362&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2009, results were published. A continuous decrease in infiltrate thickness was observed  with the &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporin&lt;/ulink&gt; 1.5 % formulation which led to over the study period measured in mm, as well as by AUC. With &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporin&lt;/ulink&gt; 1.5 % the reduction of the infiltrate  was significantly lower (p &amp;lt; 0.0001) when compared with the   active-free vehicle (primary objective). The mean infiltrate thickness was reduced by 25.22% at the last study day (day 26), comparable to mean reduction noted for the Daivonex solution (&lt;ulink linkType="Drug" linkID="12242"&gt;calcipotriol&lt;/ulink&gt; 0.005 %) (-27.55 %). There was no relevant changes in the mean infiltrate thickness for the &lt;ulink linkType="Drug" linkID="60285"&gt;cyclosporin&lt;/ulink&gt; 0.5 % formulation and the active ingredient-free vehicle (0.36 and 0.72 %, respectively) [&lt;ulink linkType="Reference" linkID="1523635"&gt;1523635&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In the present study, the topical cutaneous ciclosporin formulation for topical treatment of      psoriasis would be tested in low-dose for efficacy and tolerability. Two concentrations of the      ciclosporin formulation (0.5% and 1.5%), the corresponding vehicle, a marketed corticoid      preparation and a marketed topical Vitamin-D-analog would be tested simultaneously in the same      patient. Five test fields located at the torso and at the extremities would be examined per      subject, and would be treated non-occlusively on 22 study days over a period study of 26      days.      Experimental measurements (sonography) and clinical assessments would be performed at baseline      and on some study days.&lt;/para&gt;&lt;para&gt;The study would consist of five arms:&lt;br/&gt;Arm 1:  &lt;ulink linkType="Drug" linkID="60285"&gt;Cyclosporin&lt;/ulink&gt; 0.5% (Formulation 01B) cutaneous emulsion 200 microl qd (26 days).&lt;br/&gt;Arm 2:  &lt;ulink linkType="Drug" linkID="60285"&gt;Cyclosporin&lt;/ulink&gt; 1.5% (Formulation 02B) cutaneous emulsion 200 microl qd (26 days).&lt;br/&gt;Arm 3: 0.1% &lt;ulink linkType="Drug" linkID="44281"&gt;betamethasone&lt;/ulink&gt; solution 200 microl qd (26 days).&lt;br/&gt;Arm 4:    0.005% &lt;ulink linkType="Drug" linkID="12242"&gt;calcipotriol&lt;/ulink&gt; solution 200 microl qd (26 days).&lt;br/&gt;Arm 5: Formulation 00B cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200 microl qd (26 days).&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;In the present study the topical cutaneous ciclosporin formulation for topical treatment of      psoriasis will be tested in low-dose for efficacy and tolerability. Two concentrations of the      ciclosporin formulation (0.5% and 1.5%), the corresponding vehicle, a marketed corticoid      preparation and a marketed topical Vitamin-D-analog will be tested simultaneously in the same      patient. Five test fields located at the torso and at the extremities will be examined per      subject, and will be treated non-occlusively on 22 study days over a period study of 26      days.      Experimental measurements (sonography) and clinical assessments will be performed at baseline      and on some study days.&lt;/para&gt;&lt;para&gt;The study consists of five arms:&lt;br/&gt;Arm 1:  &lt;ulink linkType="Drug" linkID="60285"&gt;Cyclosporin&lt;/ulink&gt; 0.5% (Formulation 01B) cutaneous emulsion 200 microl qd (26 days).&lt;br/&gt;Arm 2:  &lt;ulink linkType="Drug" linkID="60285"&gt;Cyclosporin&lt;/ulink&gt; 1.5% (Formulation 02B) cutaneous emulsion 200 microl qd (26 days).&lt;br/&gt;Arm 3: 0.1% &lt;ulink linkType="Drug" linkID="44281"&gt;betamethasone&lt;/ulink&gt; solution 200 microl qd (26 days).&lt;br/&gt;Arm 4:    0.005% &lt;ulink linkType="Drug" linkID="12242"&gt;calcipotriol&lt;/ulink&gt; solution 200 microl qd (26 days).&lt;br/&gt;Arm 5: Formulation 00B cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200 microl qd (26 days) [&lt;ulink linkType="Reference" linkID="1523635"&gt;1523635&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Bioskin</Name><Address1>Hamburg</Address1><Address3>20095</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Psoriasis</Disease><PatientSegments><PatientSegment><PatientSegment id="3434">Subjects with Plaque Psoriasis/Psoriasis Vulgaris</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00578370</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2007-002947-26</Identifier><Identifier>EudraCT: 2006-001186-42</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Psoriasis" id="6551"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Psoriasis" id="6552">Ultrasound (US) findings</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6597"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Psoriasis" id="6599"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Psoriasis" id="6492"><Endpoint>Disease Severity Assessment by Other Scales</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Psoriasis" id="6540"><Endpoint>Changes in Characteristics of Skin/Lesion</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Psoriasis" id="3285"><Criterion>Subjects with Plaque Psoriasis/Psoriasis Vulgaris</Criterion></Inclusion><Inclusion disease="Psoriasis" id="3298"><Criterion>Subjects with Specific Disease Activity</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="3300">Subjects with chronic psoriasis</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Psoriasis" id="4509"><Criterion>Subjects with Other Specific Forms of Psoriasis</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4525"><Criterion>Subjects co-morbid with dermatological disease/disorder</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4532"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4548">Subjects co-morbid with electrolyte imbalance</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4538"><Criterion>Subjects co-morbid with endocrine/metabolic diseases/disorders</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4555"><Criterion>Subjects with History of Tuberculosis</Criterion></Exclusion><Exclusion disease="Psoriasis" id="4556"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4557">Subjects with history of / current bacterial infections</SubCriterion><SubCriterion disease="Psoriasis" id="4558">Subjects co-morbid with viral infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4564"><Criterion>Subjects with History of/Scheduled for Psoriasis Treatment</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4565">Subjects with history of/scheduled for systemic therapy</SubCriterion><SubCriterion disease="Psoriasis" id="4572">Subjects with history of/scheduled for phototherapy/photochemotherapy</SubCriterion><SubCriterion disease="Psoriasis" id="4573">Subjects with history of/scheduled for topical therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="4574"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4580">Subjects with history/scheduled to receive cardiovascular drugs for other indication</SubCriterion><SubCriterion disease="Psoriasis" id="4581">Subjects with history of lipid modifying agents</SubCriterion><SubCriterion disease="Psoriasis" id="4582">Subjects with history of anti-arthritis therapies</SubCriterion><SubCriterion disease="Psoriasis" id="4584">Subjects with history of drugs with nephrotoxicity</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Psoriasis" id="25154"><Criterion>Subjects with specific disease subtype</Criterion><SubCriteria><SubCriterion disease="Psoriasis" id="4510">Subjects with Erythrodermic Psoriasis</SubCriterion><SubCriterion disease="Psoriasis" id="4511">Subjects with Guttate Psoriasis</SubCriterion><SubCriterion disease="Psoriasis" id="4512">Subjects with Pustular Psoriasis</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate>2008-04-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-08-27T09:50:08Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="259250"><TitleDisplay>Benefits of human breast milk bank</TitleDisplay><TitleOfficial>Impact of human breast milk bank on the mortality and morbidity pattern in a NICU of a tertiary care hospital</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">CTRI/2016/04/006855</Identifier></Identifiers><Indications><Indication id="455">Premature labor</Indication></Indications><BiomarkerNames><BiomarkerName id="12058" role="Therapeutic effect marker" type="Anthropomorphic">Total body mass</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>fortified pasteurized donor human milk</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>unfortified pasteurized donor human milk</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1065866" type="Company"><TargetEntity id="5037142041" type="organizationId">Jawaharlal Institute of Postgraduate Medical Education Research</TargetEntity></SourceEntity><SourceEntity id="455" type="ciIndication"><TargetEntity id="O60" type="ICD10"/><TargetEntity id="10036600" type="MEDDRA"/><TargetEntity id="D007752" type="MeSH"/><TargetEntity id="-699701292" type="omicsDisease"/><TargetEntity id="567" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1065866">Jawaharlal Institute of Postgraduate Medical Education Research</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Newborn Infants (up to 5 months)</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>230</PatientCountEnrollment><DateStart>2016-05-02T00:00:00Z</DateStart><DateChangeLast>2016-05-05T09:53:05Z</DateChangeLast><DateAdded>2016-04-29T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Email>adhisivam1975@yahoo.co.uk</Email><Name>Adhisivam</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;PDHM will be prescribed on priority for intramural and extramural neonates admitted in JIPMER:&lt;ul&gt;&lt;li&gt;Preterm and sick babies&lt;/li&gt;&lt;li&gt;Babies of mothers with postpartum illnesses&lt;/li&gt;&lt;li&gt;Babies whose mothers have lactation failure, till their mothers' milk output improves&lt;/li&gt;&lt;li&gt;Only neonates of adult mothers will be included&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Others:&lt;ul&gt;&lt;li&gt;Abandoned neonates&lt;/li&gt;&lt;li&gt;Temporary interruption of breastfeeding&lt;/li&gt;&lt;li&gt;Babies whose mother died in the immediate postpartum period&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Neonates who are not inpatients&lt;/li&gt;&lt;li&gt;Neonates admitted in other hospitals  &lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Incidence of Necrotizing enterocolitis (NEC)</Description><Timeframe>0 to 28 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Severity of NEC, incidence of sepsis, mortality, duration of hospital stay, number of days to full enteral feeds and weight gain</Description><Timeframe>0 to 28 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective is to compare the effect of fortified pasteurized donor human milk (PDHM) versus unfortified PDHM on the incidence of NEC and immediate outcome among preterm neonates.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A HBMB will be set up in NICU, JIPMER as per Indian Academy of pediatrics (IAP) guidelines. All efforts to promote exclusive breastfeeding will continue and mothers will be encouraged to feed their infants their own milk. PDHM will be prescribed on priority for preterm and sick babies, babies of mothers with postpartum illnesses, and whose mothers have lactation failure, till their mothers' milk output improves. Abandoned neonates, temporary interruption of breastfeeding and babies whose mother died in the immediate postpartum period will also receive PDHM. The donor population will include healthy lactating mothers with healthy babies, who are voluntarily willing to give their extra breast milk for other babies without compromising the nutritional needs of their own baby. The donors can also include mothers attending well baby clinics, mothers whose babies are in neonatal intensive care units, those who have lost their babies but are willing to donate their milk, or lactating working staff in the hospital, and motivated mothers from the community. A donor with one or more of the following will not be eligible to donate milk: use of illegal drugs, tobacco products or alcohol, positive blood test for HIV, Hepatitis B or C or syphilis, use of radioactive drugs, acute illness in the mother, mastitis or fungal infection of the nipple or areola. A careful history, examination and scrutiny of medical records will be done for potential donors. In addition, it will be ensured that all these mothers are serologically negative for HIV, VDRL and Hepatitis B in the last 3 months.&lt;br/&gt;After counselling, checking suitability for donation and written informed consent, the donor will be sent to the breast milk collection area where breast milk will be collected under supervision of trained staff nurse with hygienic precautions by breastmilk pump. Raw breast milk will be refrigerated immediately. Breast milk from multiple donors will be pooled to ease processing and storage. Donor milk will be pasteurized at the recommended temperature of 62.5degC for a period of 30 min (Pretoria Holder pasteurization method).  Microbiological screening of donor milk will be done as soon as possible after pasteurization. The PDHM will be kept in dedicated freezer. Frozen PDHM would be thawed before administering to the neonate. After obtaining informed consent from the parents, neonates satisfying the inclusion criteria will be randomized prior to starting enteral feeds into two groups using computer generated random numbers kept in opaque sealed envelopes. Infants will be assessed for eligibility and randomization within 24 h of life. Aseptic precautions will be taken during fortification with PDHM and for fortification, a commercial human milk fortifier[Lactodex HMF, Raptakos Brett, Composition of HMF (per 2 g sachet to be mixed in 50 ml EBM) protein – 0.2 g, fat – 0.1 g, carbohydrate – 1.2 g, vitamin A –730 iu, vitamin D – 250 iu, calcium – 50 mg, phosphate – 25 mg, sodium – 1.75 mfortified g and energey – 6.5 kcal] will be used. Feeds will be started and advanced according to standard NICU protocol. Nutritional supplements (Vitamin D, Calcium, Iron and Vitamin E) will be added in standard doses once full enteral feeding will be achieved (100 ml/kg/day). Neonates will be fed with orogastric/ nasogastric tube or paladai. Non Nutritive Sucking and Kangaroo mother care will be encouraged. Neonates in both the groups will receive their mothers' own milk once it is available. Feeds will be advanced as per standard NICU protocol. Neonates will be monitored for clinical features of NEC and sepsis including vomiting, abdominal distention, abdominal wall erythema, tenderness and bleeding manifestations. Neonates in both groups will be managed as per standard NICU protocol. The demographic parameters and risk factors for NEC will be evaluated. The primary outcome will be the incidence of NEC. The secondary outcomes will include severity of NEC, incidence of sepsis, mortality, duration of hospital stay, number of days to full enteral feeds and weight gain. Neonates will be followed up for 28 days or discharge whichever will be earlier.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="India"><Sites><Site><Name>Jawaharlal Institute of Postgraduate Medical Education and Research JIPMER</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gynecological disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="17543">Women  giving birth/Obstetrics</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1012">Clinical Trials Registry India (CTRI)</Name><Identifiers><Identifier>CTRI/2016/04/006855</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other gynecological disorder" id="43656"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other gynecological disorder" id="43005"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other gynecological disorder" id="43656"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gynecological disorder" id="33094"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gynecological disorder" id="24303"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="268451"><TitleDisplay>Tranexamic Acid and Blood Clots in Knee Surgery</TitleDisplay><TitleOfficial>Does the Intra-operative Administration of Tranexamic Acid (TXA) Increase the Incidence of Deep Venous Thrombosis in Total Knee Arthroplasty?</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02867163</Identifier><Identifier type="Organisational Study">TXA IN TKR</Identifier></Identifiers><Indications><Indication id="574">Deep vein thrombosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>tranexamic acid</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20639" type="Company"><TargetEntity id="4296778364" type="organizationId">University of New Mexico</TargetEntity></SourceEntity><SourceEntity id="574" type="ciIndication"><TargetEntity id="10051055" type="MEDDRA"/><TargetEntity id="321" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20639">University of New Mexico</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2017-01-31T00:00:00Z</DateStart><DateEnd type="estimated">2017-12-31T00:00:00Z</DateEnd><DateChangeLast>2017-01-12T06:18:20Z</DateChangeLast><DateAdded>2016-08-23T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>timpetersen@salud.unm.edu</Email><Name>Tim Petersen, PhD</Name><Phone>5052721762</Phone></Contact><Contact type="Scientific contact"><Affiliation>University of New Mexico</Affiliation><Name>David Siegel, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult patients scheduled for total knee arthroplasty at Sandoval Regional Medical Center with an intra-operative dose of tranexamic acid&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Previous deep vein thrombosis or pulmonary embolism episode&lt;/li&gt;&lt;li&gt;Known coronary artery disease or peripheral vascular disease&lt;/li&gt;&lt;li&gt;Previously diagnosed hypercoagulable states (eg, Leiden factor V, antiphospholipid antibody, protein C or S deficiency)&lt;/li&gt;&lt;li&gt;Pregnancy&lt;/li&gt;&lt;li&gt;Creatinine clearance&amp;lt; 30 ml/min&lt;/li&gt;&lt;li&gt;Non-fluency in english&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Deep vein thrombosis: incidence of deep vein thrombosis diagnosed by ultrasound scan on post-operative day 1</Description><Timeframe>Day 1</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this observational trial is to estimate the incidence of deep vein thrombosis (DVT) in      total knee replacement patients who received an intra-operative dose of tranexamic acid.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This study will consist of 30 patients &amp;gt; 18 years of age scheduled for      total knee arthroplasty at Sandoval Regional Medical Center with administered intra-operative      tranexamic acid, intravenous or local administration, in any dosage, who do not meet the exclusion criteria. The patients will be examined on      post-operative day 1. Lower-extremity ultrasound will be used to screen for deep vein      thrombosis (DVT). Incidence data for DVT will then be compared with the historical incidence      rate at the institution for total knee arthroplasty without the use of tranexamic acid,      which is approximately 12%. Patients found on screening to have deep vein thrombosis will be      referred for appropriate care.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Sandoval Regional Medical Center</Name><Address1>Rio Rancho</Address1><Address2>New Mexico</Address2><Address3>87144</Address3><CountrySubDivision code="NM">New Mexico</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>dsiegel@salud.unm.edu</Email><Name>David Siegel, MD</Name><Phone>505-272-2610</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Thrombosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7323">Subjects with Venous Thrombosis</PatientSegment><SubSegments><SubSegment id="7396">Subjects with deep vein thrombosis</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7331">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7340">Subjects with orthopedic conditions/disorders</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7350">Subjects with History of/Undergoing Procedures/Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other musculoskeletal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17553">Subjects Undergoing Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02867163</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10252"><Endpoint>Assessment of Deep Vein Thrombosis(DVT)/DVT Related Events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thrombosis" id="45419"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="5942"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="6192">Subjects with deep vein thrombosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="6000"><Criterion>Subjects with History/Scheduled for Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="6012">Subjects scheduled for orthopedic procedures/surgery</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other musculoskeletal disease" id="32681"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7573"><Criterion>Subjects with Thrombosis Related Complications</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7575">Subjects with pulmonary embolism as a complication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7590">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7584"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7596"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7602">Subjects with abnormal renal function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7668"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7670">Protocol specific criteria for exclusion of females</SubCriterion><SubCriterion disease="Thrombosis" id="7681">Subjects with language barriers</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24172"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24173"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion><Exclusion disease="Other musculoskeletal disease" id="24962"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Other musculoskeletal disease" id="24090">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2017-12-31T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-08-23T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-01-12T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="268942"><TitleDisplay>A retrospective study to evaluate safety and preliminary efficacy of nimotuzumab combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="1768">Nasopharyngeal carcinoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>chemoradiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>nimotuzumab</Name><Drug id="15860">nimotuzumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="15860">nimotuzumab</Drug><IndicationsPioneer/><Companies><Company><Company id="1039740">National Natural Science Foundation of China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1104446">National Health and Family Planning Commission, P R China</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="15860" type="Drug"><TargetEntity id="280998" type="siDrug">Nimotuzumab</TargetEntity></SourceEntity><SourceEntity id="1039740" type="Company"><TargetEntity id="5035563904" type="organizationId">National Natural Science Foundation of China</TargetEntity></SourceEntity><SourceEntity id="1104446" type="Company"><TargetEntity id="5037854125" type="organizationId">National Health and Family Planning Commission of People's Republic of China</TargetEntity></SourceEntity><SourceEntity id="1768" type="ciIndication"><TargetEntity id="10061306" type="MEDDRA"/><TargetEntity id="D009303" type="MeSH"/><TargetEntity id="150" type="ORPHANET"/><TargetEntity id="-1434303133" type="omicsDisease"/><TargetEntity id="2134" type="siCondition"/></SourceEntity><SourceEntity id="3755" type="Action"><TargetEntity id="2682" type="Mechanism">HER2 Vaccine</TargetEntity></SourceEntity><SourceEntity id="740" type="Action"><TargetEntity id="1071" type="Mechanism">EGFR (HER1; erbB1) Inhibitors</TargetEntity><TargetEntity id="1613" type="Mechanism">Anti-EGFR</TargetEntity><TargetEntity id="4344" type="Mechanism">EGFR (HER1; erbB1) (Mutant) Inhibitors</TargetEntity><TargetEntity id="4345" type="Mechanism">EGFR (Thr790Met Mutant) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1039740">National Natural Science Foundation of China</Company><Company id="1104446">National Health and Family Planning Commission, P R China</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3605">Epidermal growth factor receptor modulator</Action><Action id="3755">Erbb2 tyrosine kinase receptor modulator</Action><Action id="740">Epidermal growth factor receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="12379">Therapeutic vaccine</Class><Class id="1545">Anticancer</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Vaccine</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>42</PatientCountEnrollment><PatientCountEvaluable>42</PatientCountEvaluable><DateChangeLast>2019-01-28T06:28:36Z</DateChangeLast><DateAdded>2016-08-31T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with locally advanced nasopharyngeal carcinoma&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy: overall response rate (ORR), complete response, partial response, local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS)</Description></Measure><Measure><Description>Safety: adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In April 2016, results were published. The most common adverse events were mucositis (n = 19), hematological toxicity (n = 14). The grade 3 and 4 toxicity was observed in 6 and 3 patients, respectively. Skin rash was not observed    [&lt;ulink linkType="Reference" linkID="1790588"&gt;1790588&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to evaluate safety and preliminary efficacy of &lt;ulink linkType="Drug" linkID="15860"&gt;nimotuzumab&lt;/ulink&gt; combined with concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma patients [&lt;ulink linkType="Reference" linkID="1790588"&gt;1790588&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2016, results were published. Complete response and partial response were observed in 90.5 and 9.5%. Disease progression was not observed at early treatment response evaluation, and overall response rate was found to be 100%. At two years, recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were found to be 96.4, 93.1and 96.6% respectively    [&lt;ulink linkType="Reference" linkID="1790588"&gt;1790588&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who received nimotuzumab in combination with concurrent chemoradiotherapy were included and observed   [&lt;ulink linkType="Reference" linkID="1790588"&gt;1790588&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>nimotuzumab</Name><Drug id="15860">nimotuzumab</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="1263">Mucositis</Indication><CountPatientsTotal>42</CountPatientsTotal><CountPatientsAffected>19</CountPatientsAffected></AdverseEvent><AdverseEvent><Indication id="735">Toxicity</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-08-31T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-05-11T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change></ChangeHistory></Trial><Trial id="273909"><TitleDisplay>Dose-escalation Study of Oral Administration of S-055746 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome</TitleDisplay><TitleOfficial>Phase I, Dose-escalation Study of the Orally Administered Selective Bcl-2 Inhibitor S-055746 as Monotherapy for the Treatment of Patients With Acute Myeloid Leukemia (AML) or High or Very High Risk Myelodysplastic Syndrome (MDS)</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT02920541</Identifier><Identifier type="Secondary Organisational">2014-002559-24</Identifier><Identifier type="ISRCTN">ISRCTN73586707</Identifier><Identifier type="Organisational Study">CL1-055746-002</Identifier></Identifiers><Indications><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication></Indications><BiomarkerNames><BiomarkerName id="20" role="Therapeutic effect marker" type="Genomic;Proteomic">Apoptosis regulator Bcl-2</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>BCL-201</Name><Drug id="77270">BCL-201</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="77270">BCL-201</Drug><IndicationsPioneer><Indication id="1272">Myelodysplastic syndrome</Indication><Indication id="1731">Acute myelogenous leukemia</Indication></IndicationsPioneer><Companies><Company><Company id="1072647">Institut de Recherches Internationales Servier (France)</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company><Company><Company id="1125317">ADIR Association</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="19863">Servier</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1072647" type="Company"><TargetEntity id="5037839449" type="organizationId">Institut de Recherches Internationales Servier IRIS SARL</TargetEntity></SourceEntity><SourceEntity id="1125317" type="Company"><TargetEntity id="5051005321" type="organizationId">Aide Domicile Insuffisants Respiratoires</TargetEntity></SourceEntity><SourceEntity id="19863" type="Company"><TargetEntity id="4296695285" type="organizationId">Les Laboratoires Servier SAS</TargetEntity></SourceEntity><SourceEntity id="1272" type="ciIndication"><TargetEntity id="D46" type="ICD10"/><TargetEntity id="10028533" type="MEDDRA"/><TargetEntity id="D011289" type="MeSH"/><TargetEntity id="-376765165" type="omicsDisease"/><TargetEntity id="711" type="siCondition"/></SourceEntity><SourceEntity id="1731" type="ciIndication"><TargetEntity id="D015470" type="MeSH"/><TargetEntity id="519" type="ORPHANET"/><TargetEntity id="-1550871001" type="omicsDisease"/><TargetEntity id="686" type="siCondition"/></SourceEntity><SourceEntity id="16111" type="Action"><TargetEntity id="1812" type="Mechanism">Bcl-2 Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>6</NumberOfSites><CompaniesSponsor><Company id="1072647">Institut de Recherches Internationales Servier (France)</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1125317">ADIR Association</Company><Company id="19863">Servier</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="16111">Bcl-2 protein inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacodynamics</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>48</PatientCountEnrollment><PatientCountEvaluable>34</PatientCountEvaluable><DateStart>2015-01-31T00:00:00Z</DateStart><DateEnd type="actual">2018-05-24T00:00:00Z</DateEnd><DateChangeLast>2019-05-25T00:19:07Z</DateChangeLast><DateAdded>2016-10-24T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>The Alfred</Affiliation><Name>Andrew Wei</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Women or men aged  &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML excluding acute promyelocytic leukemia:&lt;ul&gt;&lt;li&gt;With relapsed or refractory disease or&lt;/li&gt;&lt;li&gt;Age&amp;gt;/=  65 years not previously treated for AML, who are not candidates for intensive chemotherapy or not candidates for standard chemotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with cytologically confirmed and documented MDS or non proliferative Chronic Myelomonocytic Leukemia (CMML) in relapse or refractory after previous treatment line including at least one hypomethylating agent therapy:&lt;ul&gt;&lt;li&gt;With high or very high risk MDS and without established alternative therapy&lt;/li&gt;&lt;li&gt;Transformed to AML and without established alternative therapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Ability to swallow oral tablet(s)&lt;/li&gt;&lt;li&gt;World Health Organization (WHO) performance status 0 to 2&lt;/li&gt;&lt;li&gt;-For MDS patients:&lt;ul&gt;&lt;li&gt;Platelets count &gt; 25 x 10(9)/l&lt;/li&gt;&lt;li&gt;Neutrophils &gt; 0.5 x 10(9)/l&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Circulating white blood cells&amp;lt;/= 30 x 10(9)/l and &amp;lt;/= 13 x 10(9)/l for non proliferative CMML &lt;/li&gt;&lt;li&gt;Adequate renal and hepatic functions&lt;/li&gt;&lt;li&gt;Negative serum pregnancy test within 7 days prior to the first day of study drug administration&lt;/li&gt;&lt;li&gt;Patients must use effective contraception&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Foreseeable poor compliance to the study procedures&lt;/li&gt;&lt;li&gt;Legally incapacitated person under guardianship or trusteeship&lt;/li&gt;&lt;li&gt;Pregnant or breast-feeding women&lt;/li&gt;&lt;li&gt;Participation in therapeutic interventional study involving investigational drug intake at the same time or within 2 weeks or at least five half-lives or patient already enrolled&lt;/li&gt;&lt;li&gt;Previous treatment with a BH3 mimetic&lt;/li&gt;&lt;li&gt;Patients who have not recovered to baseline or CTCAE&amp;lt;/= Grade 1 from toxicity due to all prior therapies received for the studied disease&lt;/li&gt;&lt;li&gt;Any previous anti-leukemic treatment for the studied disease within at least five half-lives or 2 weeks (hydroxycarbamide permitted)&lt;/li&gt;&lt;li&gt;Any radiotherapy within 4 weeks before first intake (except palliative radiotherapy at localized lesions)&lt;/li&gt;&lt;li&gt;Major surgery within 3 weeks before first intake of S-055746&lt;/li&gt;&lt;li&gt;Allogenic stem cell transplant within 6 months before the first intake of S-055746 and for patients who still need immunosuppressive treatment&lt;/li&gt;&lt;li&gt;Leukemic leptomeningeal or leukaemic central nervous system involvement&lt;/li&gt;&lt;li&gt;Concomitant uncontrolled infection, organ dysfunction or medical disease likely to interfere with evaluation of S-055746 safety or study outcome&lt;/li&gt;&lt;li&gt;Human immunodeficiency virus (HIV) infection, hepatitis B or active hepatitis C infection&lt;/li&gt;&lt;li&gt;Within 6 months prior to the first intake of S-055746, history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, and/or stenting, ischemic/hemorrhagic stroke, atrial fibrillation, digestive hemorrhagic risk, deep venous/arterial thromboembolic complication or bleeding diathesis&lt;/li&gt;&lt;li&gt;Decreased Left Ventricular Ejection Fraction (LVEF)&lt;/li&gt;&lt;li&gt;QTcF prolongation&lt;/li&gt;&lt;li&gt;Patients who are receiving QT prolonging drug&lt;/li&gt;&lt;li&gt;Coagulopathies with increased risk of bleeding complications&lt;/li&gt;&lt;li&gt;Other malignancy within two years prior to the first intake&lt;/li&gt;&lt;li&gt;Strong or moderate CYP3A4 inhibitors or inducers (treatment, food or drink products) within 7 days prior to the first intake&lt;/li&gt;&lt;li&gt;Treatment highly metabolized by the CYP3A4 or CYP2D6 and/or with a narrow therapeutic index, multi-enzymes and/or OATP and/or P-gp substrates or herbal products within 7 days prior to the first intake&lt;/li&gt;&lt;li&gt;Patients receiving proton pump inhibitor&lt;/li&gt;&lt;li&gt;Patients having received anticoagulant oral drugs, aspirin &gt; 325 mg/day and antiplatelets within 7 days prior to first S-055746 intake&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum Tolerated Dose (MTD): MTD is the highest drug dosage that is unlikely (&lt; 25% posterior probability) to cause DLT in &gt; 33% of the treated patients in the first cycle of S-055746 treatment</Description><Timeframe>During cycle 1 (21 days)</Timeframe></Measure><Measure><Description>Incidence of adverse events (AEs): characterized by severity and seriousness of AEs, laboratory abnormalities and other safety parameters such as electrocardiogram (ECG) changes</Description><Timeframe>From first dose until 30 days after the last dose intake</Timeframe></Measure><Measure><Description>Dose Limiting Toxicities in cycle 1</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Best response rate (BRR)</Description><Timeframe>Up to study completion (maximum of three years)</Timeframe></Measure><Measure><Description>Event free survival (EFS)</Description><Timeframe>From date of inclusion until the date of progression or date of death or discontinuation of treatment, whichever occurs first, assessed up to study completion (maximum of three years)</Timeframe></Measure><Measure><Description>Plasma concentration of S-055746</Description><Timeframe>Pre-dose on cycle 1 day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 to 12 h post-dose on C1D1, C1D8</Timeframe></Measure><Measure><Description>Progression free survival (PFS)</Description><Timeframe>From date of inclusion until the date of progression or date of death, whichever occurs first, assessed up to study completion (maximum of three years)</Timeframe></Measure><Measure><Description>The PK profile of S-055746: maximal concentration (Cmax)</Description><Timeframe>Pre-dose on cycle 1 day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 to 12 h post-dose on C1D1, C1D8</Timeframe></Measure><Measure><Description>The pharmacokinetic (PK) profile of S-055746: area Under the Curve (AUC)</Description><Timeframe>Pre-dose on cycle 1 day 1 (C1D1), C1D2, C1D3, C1D8, C1D9, C2D1 ; 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 to 12 h post-dose on C1D1, C1D8</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In June 2017, results were presented. Premature study discontinuation due to progressive disease, adverse event (AE), physician decision and patient decision/consent withdrawal was observed in 22, 5, 2 and 0 AML patients, respectively; and 0, 0, 2 and 1 MDS patients, respectively. Any grade AE, related AE, severe AE of &gt;/= grade 3, serious AE (SAE) and related SAE were reported by 34, 14, 31, 28 and 3 patients in overall treatment group, respectively. Severe AE like anemia, thrombocytopenia, febrile neutropenia and hypokalemia of grade 3 were reported by 11, 2, 8, 2 and 6 patients, respectively. Anemia, thrombocytopenia and neutropenia of grade 4 were reported by 1, 10 and 5 patients, respectively. Hematological AE were the most frequently reported grade &gt;/= 3 AEs. Diarrhea (9%), anemia (9%), thrombocytopenia (6%), muscle spasms (6%) and asthenia (6%) were the most frequently reported related AE. After 6 cycles of treatment (900 mg), a patient reported a grade 5 AE for cardiac failure (drug-related). Non-related fatal AEs like sepsis, hemorrhagic stroke, pneumonia and disease progression were reported by 7 patients. There were no DLTs, clinical or laboratory tumor lysis syndrome, and no safety signals concern (change in ECG, vital signs or biological data). Under fasted conditions, monotherapy S-55746 dose of up to 1300 mg was well tolerated [&lt;ulink linkType="Reference" linkID="1939371"&gt;1939371&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this study was to determine the safety profile and tolerability of &lt;ulink linkType="Drug" linkID="77270"&gt;S-055746&lt;/ulink&gt; in      patients with AML, and high or very high risk MDS, in terms of dose-limiting toxicities      (DLTs), maximum tolerated dose (MTD) and determine the recommended phase II dose (RP2D)      through safety profile (DLT, MTD), PK profile, PD profile and preliminary efficacy. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In June 2017, results were presented. MTD was not reached. Of 30 response evaluable patients, 50% of patients exhibited a decrease in bone marrow blast, which included 87% of patients who reached nadir within the first two cycles of treatment. In patients with AML, partial remission and complete remission with incomplete blood count recovery were achieved by 1 patient each. All 4 MDS patients exhibited stable disease for 1 to &amp;gt; 10 months. In another pharmacokinetic food interaction study, of 7 patients who received S-55746, the assessment was performed in 5 patients. In fasting and fed conditions, peak concentration was observed within approximately 2 and 5 h after S-55746 treatment, respectively. Following S-55746 treatment under fasting and fed conditions, patients demonstrated an apparently moderate elimination t1/2 with values of approximately 13 and 8 h, respectively. When compared to fasting conditions, treatment with S-55746 under fed conditions (treatment with drug after ingestion of moderate meal of 400 to 500 kcal with 150 kcal of fat) demonstrated approximately 6-fold higher values of Cmax and AUC [&lt;ulink linkType="Reference" linkID="1939371"&gt;1939371&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This trial would be a dose-escalation trial. A modified version of the Continual Reassessment Method (mCRM) would be used for dose allocation process. The first daily dose tested would be 100 mg, and then a panel of daily doses from 50 to 1000 mg could be tested according to the dose allocation process of the mCRM. Doses over 1000 mg and intermediate doses could be proposed depending on available results during the study. Patients would receive S-055746, per os administration, from 50 to 2000 mg qd during a 21-day cycle. Patients would receive 21-day cycles of treatment until a discontinuation criterion is met.&lt;br/&gt;Treatment duration for the patients would be until evidence of treatment failure, the occurrence of unacceptable toxicity, death, exercise of investigator discretion, withdrawal of consent or if clinically indicated after discussion between investigator and the sponsor on a case by case basis. Film-coated tablets containing 50 mg or 100 mg of S-055746. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received S-55746 (po tablets qd) in a 21 day treatment schedule until disease progression or unacceptable toxicity; and according to modified version of continual reassessment method for dose allocation process, patients could receive 50 to 2000 mg after giving informed consent. In fasting conditions, the S-55746 dose ranged from 100 to 1300 mg/day  [&lt;ulink linkType="Reference" linkID="1939371"&gt;1939371&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>BCL-201</Name><Drug id="77270">BCL-201</Drug><Dose unit="milligram dose">900.0</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="55">Cardiac failure</Indication><CountPatientsTotal>34</CountPatientsTotal><CountPatientsAffected>1</CountPatientsAffected></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>BCL-201</Name><Drug id="77270">BCL-201</Drug></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>9.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="114">Sepsis</Indication></AdverseEvent><AdverseEvent><Indication id="17">Anemia</Indication><CountPatientsAffectedPercentage>9.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="181">Hypokalemia</Indication></AdverseEvent><AdverseEvent><Indication id="1991">Neutropenia</Indication></AdverseEvent><AdverseEvent><Indication id="324">Thrombocytopenia</Indication><CountPatientsAffectedPercentage>6.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="358">Muscle spasm</Indication><CountPatientsAffectedPercentage>6.0</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="360">Pneumonia</Indication></AdverseEvent><AdverseEvent><Indication id="3677">Hemorrhagic stroke</Indication></AdverseEvent><AdverseEvent><Indication id="3795">Febrile neutropenia</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="638454">BCL-201</Intervention><Treatments><Treatment><Dose>50 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>100 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>1000 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>1300 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>2000 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Contacts/></Site><Site><Name>Department of Haematology</Name><Contacts/></Site><Site><Name>Royal Melbourne Hospital</Name><Contacts/></Site><Site><Name>Royal Melbourne Hospital</Name><Address1>Parkville</Address1><Contacts/></Site><Site><Name>The Alfred Hospital</Name><Address1>Melbourne</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Contacts/></Site><Site><Name>Hôpital Lyon-Sud</Name><Contacts/></Site><Site><Name>Hôpital Saint-Louis</Name><Contacts/></Site><Site><Name>Institut Paoli Calmettes</Name><Contacts/></Site><Site><Name>Centre Hospitalier Lyon Sud</Name><Address1>Pierre Bénite</Address1><Contacts/></Site><Site><Name>Hôpital Saint Louis</Name><Address1>Paris</Address1><Contacts/></Site><Site><Name>Institut Paoli Calmettes</Name><Address1>Marseille</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="3977">Subjects with Acute Myeloid Leukemia (AML)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3987">Subjects with Secondary Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3999">Subjects with Treatment Resistant Disease</PatientSegment><SubSegments><SubSegment id="4000">Subjects with chemotherapy resistant disease</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="4003">Subjects with Relapsed/Recurrent Leukemia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19052">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Myelodysplastic syndrome</Disease><PatientSegments><PatientSegment><PatientSegment id="8708">Subjects at Risk of Developing Myelodysplastic Syndrome</PatientSegment><SubSegments><SubSegment id="8728">Subjects with High Risk Myelodysplastic Syndrome</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8734">Subjects with Relapsed/Recurrent Myelodysplastic Syndrome</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="8735">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT02920541</Identifier></Identifiers></Registry><Registry><Name id="1001">European Clinical Trials Database (EudraCT)</Name><Identifiers><Identifier type="Secondary Organisational">2014-002559-24</Identifier></Identifiers></Registry><Registry><Name id="1002">International Standard Randomised Controlled Trial Number Register (ISRCTN)</Name><Identifiers><Identifier type="ISRCTN">ISRCTN73586707</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7987">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="7988"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8090">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8145"><Endpoint>Assessment of Vital Signs</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11882"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11916">Assessment of maximum tolerated dose (MTD)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11912"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11915">Assessment of dose limiting toxicity</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11914"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11929"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Myelodysplastic syndrome" id="11936"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Leukemia" id="7891"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7897"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7898">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7909">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7935"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="43187">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Leukemia" id="43188">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8071"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="8072">Assessment of gene expression profile/signature</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="8109"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11816"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11817"><Endpoint>Assessment of Survival</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11815">Assessment of event free survival (EFS)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11820"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11821">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11882"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11884"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint><SubEndpoints><SubEndpoint disease="Myelodysplastic syndrome" id="11944">Assessment of gene expression</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11899"><Endpoint>Assessment of Disease Progression</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Myelodysplastic syndrome" id="11924"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Leukemia" id="4977"><Criterion>Subjects with Secondary Leukemia</Criterion></Inclusion><Inclusion disease="Leukemia" id="4981"><Criterion>Subjects with Acute Myeloid Leukemia (AML)</Criterion></Inclusion><Inclusion disease="Leukemia" id="5063"><Criterion>Subjects Diagnosed by Specific Methods</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5065">Subjects with histo-pathologically confirmed leukemia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5077">Subjects with normal/adequate hematopoietic function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5085"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5086">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Leukemia" id="5087">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Leukemia" id="5088">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5164"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5165">Subjects with progressive/refractory leukemia to chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5173"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5206">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5195"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Leukemia" id="7092"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5102">Subjects with history of anti-cancer chemotherapy</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7612"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7613">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7614">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7615">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7629"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7630"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7631"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7632">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="7633">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7638"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7644">Protocol specified inclusion criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="7656"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Leukemia" id="22405"><Criterion>Treatment Naive Subjects</Criterion></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="33739"><Criterion>Subjects with risk of disease recurrence</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7598">Subjects with High Risk Myelodysplastic Syndrome</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="34033"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7634">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="34112"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7645">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34143"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5196">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Myelodysplastic syndrome" id="34418"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="7639">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34442"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5190">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Leukemia" id="6489"><Criterion>Subjects with Acute Myeloid Leukemia</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6504">Subjects with promyelocytic leukemia (M3)</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6527"><Criterion>Leukemia Subjects with Advanced Disease</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6530">Subjects with central nervous system involvement of leukemia</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6534"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Leukemia" id="6546"><Criterion>Subjects co-morbid with infections</Criterion></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="6700"><Criterion>Subjects with Specific Grade of Toxicity</Criterion></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6656">Subjects with history of surgery/procedure</SubCriterion><SubCriterion disease="Leukemia" id="6716">Subjects with history of participation in other trial/have received treatment with a drug that has not received regulatory approval</SubCriterion><SubCriterion disease="Leukemia" id="6719">Subjects with physical abnormality or laboratory abnormality which would make it inappropriate to participate in the study</SubCriterion><SubCriterion disease="Leukemia" id="6720">Subjects with previous exposure to study drug</SubCriterion><SubCriterion disease="Leukemia" id="6723">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="8709"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6645">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Leukemia" id="6659">Subjects with history of stem cell therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9160"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9161"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9162"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9163">Subjects co-morbid with HIV infection</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9164">Subjects co-morbid with hepatitis virus infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9171"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9176">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9188"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9193">Subjects with history of radiotherapy</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9194">Subjects with history of surgical interventions/procedure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9196"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9197"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="9200"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9203">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9208">Subjects with inadequate organ function</SubCriterion><SubCriterion disease="Myelodysplastic syndrome" id="9210">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="25591"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9205">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="26354"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9174">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="27879"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6718">Subjects unwilling or unable to comply with the protocol/study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Myelodysplastic syndrome" id="27897"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Myelodysplastic syndrome" id="9202">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-05-24T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>38.03 Months</EnrollmentPeriod><EnrollmentRate>1.26 Patients/Month</EnrollmentRate><DateFirstReceived>2016-08-23T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-10-24T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-09-08T00:00:00Z</Date><Reason id="303">Results Available</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="Added"><Date>2017-09-08T00:00:00Z</Date><Reason id="306">Adverse Event Added</Reason></Change><Change type="updated"><Date>2018-03-18T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-10-25T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2019-04-25T00:00:00Z</Date><Reason id="315">Eligibility Criteria updates</Reason></Change></ChangeHistory></Trial><Trial id="282560"><TitleDisplay>Changes in presepsin concentrations after colorectal surgery</TitleDisplay><TitleOfficial>Changes in presepsin concentrations after colorectal surgery</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000025313</Identifier></Identifiers><Indications><Indication id="746">Infectious disease</Indication></Indications><BiomarkerNames><BiomarkerName id="44619" role="Disease marker" type="Proteomic">Presepsin</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1003415" type="Company"><TargetEntity id="4296519547" type="organizationId">Hirosaki University</TargetEntity></SourceEntity><SourceEntity id="746" type="ciIndication"><TargetEntity id="10021789" type="MEDDRA"/><TargetEntity id="D007239" type="MeSH"/><TargetEntity id="-367065996" type="omicsDisease"/><TargetEntity id="799" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1003415">Hirosaki University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2016-12-17T00:00:00Z</DateStart><DateChangeLast>2017-01-17T11:40:03Z</DateChangeLast><DateAdded>2016-12-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Hirosaki University Hospital ; Department f Anesthesiology</Affiliation><Email>kishiko_sk1064@hirosaki-u.ac.jp</Email><Name>Kishiko Nakai</Name><Phone>0172-39-5113</Phone></Contact><Contact type="Scientific contact"><Affiliation>Hirosaki University Hospital ; Department of Anesthesiology</Affiliation><Email>kishiko_sk1064@hirosaki-u.ac.jp</Email><Name>Kishiko Nakai</Name><Phone>0172-39-5113</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult patients who undergo elective colorectal surgery&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Preoperative infectious diseases&lt;/li&gt;&lt;li&gt;End-stage kidney desease&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Comparison of presepsin concentrations in groups with infectious complications and without infections comlications</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to describe the kinetics of presepsin after colorectal surgery for the early detection of postoperative infection.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Adult patients who will undergo elective colorectal surgery will be included and observed in this trial.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other gastrointestinal disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18219">Subjects with specific disease</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="18739">Subjects Undergoing Surgery</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other infectious disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18263">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="17548">Subjects with surgical site infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000025313</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other infectious disease" id="43746"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other gastrointestinal disease" id="32953"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other infectious disease" id="33156"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gastrointestinal disease" id="35070"><Criterion>Subjects with specific disease</Criterion></Inclusion><Inclusion disease="Other infectious disease" id="35077"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gastrointestinal disease" id="24021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other infectious disease" id="24697"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2016-12-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="300847"><TitleDisplay>Evaluation of effect of pentoxifylline in burned patients</TitleDisplay><TitleOfficial>Evaluation of effect of pentoxifylline in reduction of systemic inflammatory response in burned patients above 40%</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">IRCT2017050133737N1</Identifier><Identifier type="Secondary Organisational">IR.TBZMED.REC.1396.71</Identifier></Identifiers><Indications><Indication id="188">Inflammatory disease</Indication><Indication id="52">Skin burns</Indication></Indications><BiomarkerNames><BiomarkerName id="176" role="Therapeutic effect marker" type="Genomic;Proteomic">Interleukin-6</BiomarkerName><BiomarkerName id="11622" role="Therapeutic effect marker" type="Genomic">Interleukin 1</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pentoxifylline</Name><Drug id="44306">pentoxifylline</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44306">pentoxifylline</Drug><IndicationsPioneer><Indication id="52">Skin burns</Indication></IndicationsPioneer><Companies><Company><Company id="25107">Tabriz University of Medical Sciences</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="44306" type="Drug"><TargetEntity id="143975" type="siDrug">Pentoxifylline</TargetEntity></SourceEntity><SourceEntity id="25107" type="Company"><TargetEntity id="5035529437" type="organizationId">Tabriz University of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="188" type="ciIndication"><TargetEntity id="10061218" type="MEDDRA"/><TargetEntity id="D007249" type="MeSH"/><TargetEntity id="-308860612" type="omicsDisease"/><TargetEntity id="1181" type="siCondition"/></SourceEntity><SourceEntity id="52" type="ciIndication"><TargetEntity id="D002056" type="MeSH"/><TargetEntity id="-672164191" type="omicsDisease"/><TargetEntity id="452" type="siCondition"/></SourceEntity><SourceEntity id="8052" type="Action"><TargetEntity id="466" type="Mechanism">Phosphodiesterase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25107">Tabriz University of Medical Sciences</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="8052">Phosphoric diester hydrolase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="312">Platelet aggregation inhibitor</Class></Class><Technologies><Technology id="641">Controlled release formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>80</PatientCountEnrollment><DateStart>2016-03-20T00:00:00Z</DateStart><DateChangeLast>2017-06-12T16:00:23Z</DateChangeLast><DateAdded>2017-06-10T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Tabriz university of medical sciences</Affiliation><Email>Amir.h.ladan@gmail.com</Email><Name>Amir hossein ladan</Name><Phone>0098416694441 0098914410641</Phone></Contact><Contact type="Scientific contact"><Affiliation>Tabriz University Of Medical Sciences</Affiliation><Email>Hemmat.maghsoodi@gmail.com</Email><Name>Hemmat Maghsoodi</Name><Phone>0098416694441 00989141156477</Phone></Contact><Contact type="Public contact"><Affiliation>Tabriz University of Medical Sciences</Affiliation><Email>Amir.H.Ladan@gmail.com</Email><Name>Amir Hossein Ladan</Name><Phone>00984136694441 0098144010641</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Burn above 40% of body surface&lt;/li&gt;&lt;li&gt;Admission in maximum of an h&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known comorbidities such as renal and heart faliure and respiratory disorders&lt;/li&gt;&lt;li&gt;Any other type of trauma&lt;/li&gt;&lt;li&gt;Disagree of patient or first degree relatives for participating in study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Serum levels of IL-1and IL-6: measuring serum levels</Description><Timeframe>At admission time and days 3, 5 and 7</Timeframe></Measure><Measure><Description>Days of admission to ICU: registered by days and h</Description><Timeframe>From admission to discharge</Timeframe></Measure><Measure><Description>Death or discharge: registered outcome</Description><Timeframe>From admission to discharge or death</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this trial is to evaluate the effect of &lt;ulink linkType="Drug" linkID="44306"&gt;pentoxifylline&lt;/ulink&gt; in reduction of systemic inflammatory response in burned patients above 40%.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This will be  a double-blinded, randomized, control trial with placebo control in single center in which 80 patients who will be refered with above 40% of burn which has been evaluated by a general surgeon according to body surface to Tabriz Sina Hospital's Emergency Department will be included if they reach ED within an hour and have no comorbidities such as renal and heart failure and respiratory disorders and any other trauma and after taking the informed consent, the patients will enter the study voluntarily by himself or first degree relatives. They will be divided randomly in two groups, in each group standard protocols of treatment begins and blood sampling for quantifying inflammatory mediators will perform. In one group tab pentoxifylline 400 mg will be given po every 8 h and the other group will be given placebo same shape and null substance. Then other blood samples will be catch in days 3, 5 and 7 for quantifying IL-1 and IL-6. Primary outcome will be  comparison the blood levels of inflammatory mediators in two groups. Secondary outcome will be length of ICU admission will be registered as days and hours and also the outcome of patient.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Iran"><Sites><Site><Name>Sina Hospital</Name><Address1>Tabriz</Address1><Address2>East Azerbayjan</Address2><CountrySubDivision>East Azerbayjan</CountrySubDivision><Contacts><Contact type="Facility contact"><Name>Hemmat Maghsoodi</Name></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other dermatological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="17864">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="16196">Subjects with Skin Burn</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1014">Iranian Registry of Clinical Trials (IRCT)</Name><Identifiers><Identifier type="Secondary Organisational">IRCT2017050133737N1</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other dermatological disease" id="42862"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other dermatological disease" id="43508"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other dermatological disease" id="32830"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other dermatological disease" id="33233"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other dermatological disease" id="23963"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24776">Subjects with cardiac diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other dermatological disease" id="26749"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other dermatological disease" id="24354">Subjects with noncompliance to study protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateEnrollmentEnd type="actual">2017-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>12.39 Months</EnrollmentPeriod><EnrollmentRate>6.46 Patients/Month</EnrollmentRate><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-06-10T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="303098"><TitleDisplay>Post-operative Discomfort After Dental General Anesthesia</TitleDisplay><TitleOfficial>Post-operative Discomfort and Emergence Delirium In Children Receiving Dental Treatment Under General Anesthesia: Comparison Of Nasal Tracheal Intubation and Laryngeal Mask Airway</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03197753</Identifier><Identifier type="Organisational Study">2017/011</Identifier></Identifiers><Indications><Indication id="2978">General anesthesia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>laryngeal mask airway insertion</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>remifentanil</Name><Drug id="4208">remifentanil</Drug></Intervention><Intervention type="InterventionPrimary"><Name>rocuronium</Name></Intervention><Intervention type="InterventionPrimary"><Name>sevoflurane</Name><Drug id="5356">sevoflurane</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>nasotracheal tube insertion</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="4208">remifentanil</Drug><IndicationsPioneer/><Companies><Company><Company id="1055398">Adnan Menderes University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="5356">sevoflurane</Drug><IndicationsPioneer/><Companies><Company><Company id="1055398">Adnan Menderes University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="4208" type="Drug"><TargetEntity id="185000" type="siDrug">Remifentanil hydrochloride</TargetEntity></SourceEntity><SourceEntity id="5356" type="Drug"><TargetEntity id="90235" type="siDrug">Sevoflurane</TargetEntity></SourceEntity><SourceEntity id="1055398" type="Company"><TargetEntity id="5035564587" type="organizationId">Adnan Menderes Universitesi</TargetEntity></SourceEntity><SourceEntity id="2978" type="ciIndication"><TargetEntity id="10018060" type="MEDDRA"/><TargetEntity id="D000768" type="MeSH"/></SourceEntity><SourceEntity id="293" type="Action"><TargetEntity id="271" type="Mechanism">mu-Opioid Agonists</TargetEntity><TargetEntity id="5725" type="Mechanism">mu-Opioid Positive Allosteric Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1055398">Adnan Menderes University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="293">Opioid receptor mu agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1668">General anesthetic</Class><Class id="2946">Analgesic</Class><Class id="59620">Unspecified drug target</Class></Class><Technologies><Technology id="616">Inhalant formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Children (6-12 yrs)</Term><Term>Preschool Children (2-5 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Single Blind</Term><Term>Prevention</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>70</PatientCountEnrollment><DateStart>2017-06-15T00:00:00Z</DateStart><DateEnd type="actual">2017-08-04T00:00:00Z</DateEnd><DateChangeLast>2018-10-15T22:32:16Z</DateChangeLast><DateAdded>2017-07-07T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Adnan Menderes University</Affiliation><Name>Sultan KELES, Dr.</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged 3 to 7 years&lt;/li&gt;&lt;li&gt;ASA I and II&lt;/li&gt;&lt;li&gt;Lack of chairside cooperation for dental treatment in clinical setting&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A history of of anticipated difficult entubation&lt;/li&gt;&lt;li&gt;Patient with pharyngeal pathology patients with known pulmonory or cardiovascular disease&lt;/li&gt;&lt;li&gt;When the expected dental procedure was &gt; 2 h&lt;/li&gt;&lt;li&gt;Mental retardation and those whose parents did not consent to their participation in the study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Post-operative discomfort: sore throat</Description><Timeframe>Post-operative 1 h</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this prospective, randomized, controlled clinical trial was to compare immediate      post-operative discomfort, emergence delirium and recovery time of the patients intubated      using either laryngeal mask airway or nasotracheal intubation.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;A total of 70 children aged 3 to 7 years would receive full mouth dental rehabilitation under      general anesthesia. Children would be randomly grouped into laryngeal mask airway (LMA) group      (n = 35) and nasotracheal intubation (NTI) groups (n = 35). In LMA group LMA would be inserted after      anesthesia induction using 8% &lt;ulink linkType="Drug" linkID="5356"&gt;sevoflurane&lt;/ulink&gt;. In NTI group rocuronium and &lt;ulink linkType="Drug" linkID="4208"&gt;remifentanil&lt;/ulink&gt; would be      given intravenously during 8% sevoflurane induction and the patients would be intubated by a      nasotracheal tube. After completion of the dental treatments patients would be transferred to      the post anesthesia care unit (PACU). Duration of dental operation, duration of anesthesia,      recovery time, post-operative discomfort, emergence delirium, pediatric dentist's access would be      recorded.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Turkey"><Sites><Site><Name>Sultan Keles</Name><Address1>Aydın</Address1><Address2>Efeler</Address2><Address3>09100</Address3><CountrySubDivision>Efeler</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other mouth disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16681">Others</PatientSegment><SubSegments><SubSegment id="18747">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03197753</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other mouth disease" id="43699"><Endpoint>Clinical Assessments</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other mouth disease" id="46435"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other mouth disease" id="46435"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Other mouth disease" id="46482"><Endpoint>Assessment of Therapy Related Outcomes</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other mouth disease" id="34642"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="33062">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other mouth disease" id="35331"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Other mouth disease" id="35327">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other mouth disease" id="24056"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="24305"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other mouth disease" id="25616"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2017-08-01T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-06-22T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-07-07T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2017-08-21T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="30545"><TitleDisplay>A phase I/II, placebo-controlled study to evaluate the efficacy of siplizumab in adult steroid-naive bone marrow transplant (BMT) or stem cell transplant (SCT) recipients</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="2990">Stem cell transplantation</Indication><Indication id="3101">Bone marrow transplant rejection</Indication><Indication id="616">Graft versus host disease</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>methylprednisolone</Name></Intervention><Intervention type="InterventionPrimary"><Name>siplizumab</Name><Drug id="14216">siplizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="14216">siplizumab</Drug><IndicationsPioneer><Indication id="2990">Stem cell transplantation</Indication><Indication id="3101">Bone marrow transplant rejection</Indication></IndicationsPioneer><Companies><Company><Company id="14847">BioTransplant Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="18008">MedImmune LLC</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="21279">Universite Catholique de Louvain</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="14216" type="Drug"><TargetEntity id="250466" type="siDrug">Siplizumab</TargetEntity></SourceEntity><SourceEntity id="14847" type="Company"><TargetEntity id="4295905730" type="organizationId">Biotransplant Inc</TargetEntity></SourceEntity><SourceEntity id="18008" type="Company"><TargetEntity id="4295907119" type="organizationId">Medimmune LLC</TargetEntity></SourceEntity><SourceEntity id="21279" type="Company"><TargetEntity id="5000691790" type="organizationId">Universite Catholique De Louvain</TargetEntity></SourceEntity><SourceEntity id="2990" type="ciIndication"><TargetEntity id="10063581" type="MEDDRA"/><TargetEntity id="D033581" type="MeSH"/><TargetEntity id="-1019569811" type="omicsDisease"/><TargetEntity id="1863" type="siCondition"/></SourceEntity><SourceEntity id="3101" type="ciIndication"><TargetEntity id="T86.01" type="ICD10"/><TargetEntity id="996.85" type="ICD9"/><TargetEntity id="10048396" type="MEDDRA"/></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"/><TargetEntity id="10018651" type="MEDDRA"/><TargetEntity id="D006086" type="MeSH"/><TargetEntity id="39812" type="ORPHANET"/><TargetEntity id="-1437372564" type="omicsDisease"/><TargetEntity id="1129" type="siCondition"/></SourceEntity><SourceEntity id="5019" type="Action"><TargetEntity id="1568" type="Mechanism">Anti-CD2</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1/Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="21279">Universite Catholique de Louvain</Company></CompaniesSponsor><CompaniesCollaborator><Company id="14847">BioTransplant Inc</Company><Company id="18008">MedImmune LLC</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="5019">Lymphocyte function antigen-3 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15184">Systemic antipsoriatic product</Class><Class id="1596">Immunomodulator</Class><Class id="2953">Anti-inflammatory</Class><Class id="5019">Lymphocyte function antigen-3 receptor antagonist</Class><Class id="55685">Anticancer monoclonal antibody</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>32</PatientCountEnrollment><DateStart>1998-12-14T00:00:00Z</DateStart><DateChangeLast>2008-10-20T10:54:10Z</DateChangeLast><DateAdded>2008-10-20T10:48:16Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Adult steroid-naive bone marrow transplant (BMT) or stem cell transplant (SCT) recipients&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was designed to evaluate the efficacy of &lt;ulink linkType="Drug" linkID="14216"&gt;siplizumab&lt;/ulink&gt; in   adult  steroid-naive bone marrow transplant (BMT) or stem cell transplant (SCT) recipients [&lt;ulink linkType="Reference" linkID="309251"&gt;309251&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive &lt;ulink linkType="Drug" linkID="14216"&gt;siplizumab&lt;/ulink&gt; combined with corticosteroids (methylprednisolone). All patients would receive the standard initial GvHD treatment with corticosteroids [&lt;ulink linkType="Reference" linkID="309251"&gt;309251&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-10-20T10:48:16Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="313705"><TitleDisplay>Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)</TitleDisplay><TitleOfficial>An Open-label, Single-Sequence, Crossover, Drug-drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03291288</Identifier><Identifier type="Organisational Study">PL3397-A-U126</Identifier></Identifiers><Indications><Indication id="199">Leukemia</Indication><Indication id="205">Melanoma</Indication><Indication id="3205">Gastrointestinal stromal tumor</Indication><Indication id="3531">Pigmented villonodular synovitis</Indication></Indications><BiomarkerNames><BiomarkerName id="74" role="Disease marker" type="Genomic;Proteomic">Mast/stem cell growth factor receptor</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>pexidartinib</Name><Drug id="62957">pexidartinib</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>midazolam hydrochloride</Name><Drug id="44303">midazolam hydrochloride</Drug></Intervention><Intervention type="InterventionPrimary"><Name>pexidartinib</Name><Drug id="62957">pexidartinib</Drug></Intervention><Intervention type="InterventionPrimary"><Name>tolbutamide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44303">midazolam hydrochloride</Drug><IndicationsPioneer><Indication id="199">Leukemia</Indication><Indication id="205">Melanoma</Indication><Indication id="3531">Pigmented villonodular synovitis</Indication></IndicationsPioneer><Companies><Company><Company id="1020322">Daiichi Sankyo Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="62957">pexidartinib</Drug><IndicationsPioneer><Indication id="199">Leukemia</Indication><Indication id="205">Melanoma</Indication></IndicationsPioneer><Companies><Company><Company id="1020322">Daiichi Sankyo Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="62957">pexidartinib</Drug><IndicationsPioneer><Indication id="199">Leukemia</Indication><Indication id="205">Melanoma</Indication></IndicationsPioneer><Companies><Company><Company id="1020322">Daiichi Sankyo Inc</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="62957" type="Drug"><TargetEntity id="655649" type="siDrug">Pexidartinib hydrochloride</TargetEntity><TargetEntity id="655649" type="siDrug">Pexidartinib hydrochloride</TargetEntity></SourceEntity><SourceEntity id="44303" type="Drug"><TargetEntity id="91131" type="siDrug">Midazolam maleate</TargetEntity></SourceEntity><SourceEntity id="1020322" type="Company"><TargetEntity id="5036167611" type="organizationId">Daiichi Sankyo Inc</TargetEntity></SourceEntity><SourceEntity id="199" type="ciIndication"><TargetEntity id="10024288" type="MEDDRA"/><TargetEntity id="D007938" type="MeSH"/><TargetEntity id="-609576380" type="omicsDisease"/><TargetEntity id="683" type="siCondition"/></SourceEntity><SourceEntity id="205" type="ciIndication"><TargetEntity id="C43" type="ICD10"/><TargetEntity id="10025650" type="MEDDRA"/><TargetEntity id="D008545" type="MeSH"/><TargetEntity id="-361092282" type="omicsDisease"/><TargetEntity id="705" type="siCondition"/></SourceEntity><SourceEntity id="3205" type="ciIndication"><TargetEntity id="10051066" type="MEDDRA"/><TargetEntity id="D046152" type="MeSH"/><TargetEntity id="44890" type="ORPHANET"/><TargetEntity id="-1743085733" type="omicsDisease"/><TargetEntity id="668" type="siCondition"/></SourceEntity><SourceEntity id="3531" type="ciIndication"><TargetEntity id="D013586" type="MeSH"/><TargetEntity id="66627" type="ORPHANET"/><TargetEntity id="-1132862140" type="omicsDisease"/><TargetEntity id="1927" type="siCondition"/></SourceEntity><SourceEntity id="3154" type="Action"><TargetEntity id="2314" type="Mechanism">CSF1R (c-FMS) Inhibitors</TargetEntity><TargetEntity id="4836" type="Mechanism">Anti-Colony Stimulating Factor 1 Receptor (CSF1R)</TargetEntity><TargetEntity id="4956" type="Mechanism">Anti-M-CSF</TargetEntity></SourceEntity><SourceEntity id="3806" type="Action"><TargetEntity id="1628" type="Mechanism">Flt3 (FLK2/STK1) Inhibitors</TargetEntity><TargetEntity id="1910" type="Mechanism">Anti-CD135 (flt-3)</TargetEntity></SourceEntity><SourceEntity id="3808" type="Action"><TargetEntity id="1704" type="Mechanism">KIT (C-KIT) Inhibitors</TargetEntity><TargetEntity id="3405" type="Mechanism">Anti-c-KIT</TargetEntity><TargetEntity id="5665" type="Mechanism">KIT (C-KIT) (Asp816Val Mutant) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="81" type="Action"><TargetEntity id="191" type="Mechanism">GABA(A) BZ Site Receptor Agonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="3">No longer recruiting</RecruitmentStatus><NumberOfSites>11</NumberOfSites><CompaniesSponsor><Company id="1020322">Daiichi Sankyo Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="15591">SL cytokine ligand inhibitor</Action><Action id="3154">CSF-1 antagonist</Action><Action id="3806">Flt3 tyrosine kinase inhibitor</Action><Action id="3808">Kit tyrosine kinase inhibitor</Action><Action id="81">Benzodiazepine receptor agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="1615">Neuroprotectant</Class><Class id="1668">General anesthetic</Class><Class id="2942">Anxiolytic</Class><Class id="2953">Anti-inflammatory</Class><Class id="62255">Anticancer protein kinase inhibitor</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="586">Capsule formulation</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="596">Injectable formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="766">Parenteral formulation unspecified</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>30</PatientCountEnrollment><DateStart>2018-02-26T00:00:00Z</DateStart><DateEnd type="estimated">2020-04-28T00:00:00Z</DateEnd><DateChangeLast>2019-04-23T09:56:11Z</DateChangeLast><DateAdded>2017-09-26T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Daiichi Sankyo, Inc.</Affiliation><Name>Global Clinical Leader</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Is the age of majority in country of residence&lt;/li&gt;&lt;li&gt;Has a diagnosis of:&lt;ul&gt;&lt;li&gt;Tenosynovial giant cell tumor (TGCT), which is associated with severe morbidity or functional limitations and for whom surgery is not an option (prior pexidartinib is permitted for TGCT patients unless ineffective or not tolerated and there has been a washout period of at least 4 weeks)&lt;/li&gt;&lt;li&gt;KIT-mutant tumor, including melanoma or gastrointestinal stromal tumor (GIST), for which there is no standard systemic therapy&lt;/li&gt;&lt;li&gt;Other solid tumors (all comers) for which there is no standard systemic therapy and there is a rationale for use of pexidartinib at the Investigator's discretion&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;If a female of childbearing potential, had a negative serum pregnancy test within 14 days before enrollment, or within 72 h before enrollment where required&lt;/li&gt;&lt;li&gt;Is a non-sterile male or female willing to use of one of the protocol-defined highly effective contraception methods:&lt;ul&gt;&lt;li&gt;Intra-uterine device (nonhormonal or hormonal)&lt;/li&gt;&lt;li&gt;Sexual abstinence (only if this is in line with the patient's current lifestyle)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;Barrier methods (eg, condom, diaphragm) used in combination with hormonal methods associated with inhibition of ovulationIs a surgically sterile male or female, or is postmenopausal for at least 1 year, at least 50 years of age, with a follicle-stimulating hormone level &gt; 40 mIU/ml&lt;ul&gt;&lt;li&gt;Has adequate hematologic, hepatic, and renal function as defined by the protocol&lt;/li&gt;&lt;li&gt;Is able and willing to follow all study procedures&lt;/li&gt;&lt;li&gt;Has provided a signed informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Is pregnant or breastfeeding&lt;/li&gt;&lt;li&gt;Is unable to swallow oral medication&lt;/li&gt;&lt;li&gt;Is unable to follow study procedures&lt;/li&gt;&lt;li&gt;Is taking or has taken any medications or therapies outside of protocol-defined parameters&lt;/li&gt;&lt;li&gt;Has any disease or condition that, per protocol or in the opinion of the investigator, might affect:&lt;ul&gt;&lt;li&gt;Safety and well-being of the participant or offspring&lt;/li&gt;&lt;li&gt;Safety of study staff&lt;/li&gt;&lt;li&gt;Analysis of results&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Maximum concentration (Cmax) for midazolam: plasma samples for midazolam will be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (+/- 10 min up to 1 h, +/- 10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15)</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>Cmax for tolbutamide: plasma samples for tolbutamide will be collected at predose, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 24, and 48 h (+/- 10 min up to 1 h, +/- 10% thereafter) on Days 1 to 3, and also when co-administered with pexidartinib on Days 3 (to 5) and Days 13 (to 15)</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>Time to maximum concentration (Tmax) for midazolam</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>Tmax for tolbutamide</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>Area under the curve to the last observable concentration (AUClast) for midazolam</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>AUClast for tolbutamide</Description><Timeframe>Within 15 days</Timeframe></Measure><Measure><Description>Number of participants with an adverse event by the end of Part 2</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Overall response rate (ORR) by the end of Part 2: ORR is defined as the percentage of participants who achieve a confirmed complete response (CR) or partial response (PR) based on locally read tumor assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or other applicable assessment of treatment response based upon the applicable tumor</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Cmax for pexidartinib and its metabolites: plasma samples for pexidartinib and its metabolite will be collected at predose, 0.5, 1, 2, 2.5, 3, 4, 6, 8, and 10 (±1) h after the first dose on Day 3, and at steady state when co-administered with midazolam and tolbutamide on Day 13</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>Tmax for pexidartinib and its metabolite</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>AUClast for pexidartinib and its metabolite</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>Cmax for midazolam metabolite</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>Tmax for midazolam metabolite</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>AUClast for midazolam metabolite</Description><Timeframe>Within 13 days</Timeframe></Measure><Measure><Description>Metabolite to parent ratio (MPR) for midazolam</Description><Timeframe>Within 13 days</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study has two parts:&lt;br/&gt;Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9 substrates using midazolam (&lt;ulink linkType="Drug" linkID="44303"&gt;Versed&lt;/ulink&gt;) and tolbutamide.&lt;br/&gt;Part 2 will test the efficacy and safety of pexidartinib (&lt;ulink linkType="Drug" linkID="62957"&gt;PLX-3397&lt;/ulink&gt;) treatment in various tumor types.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Participants will be divided into four arms:&lt;br/&gt;Arm 1: Part 1 - reference treatment. On Day 1 all participants will receive a single po dose each of midazolam (2 mg) and tolbutamide (500 mg), followed by blood draws for pharmacokinetic (PK) analysis.&lt;br/&gt;Arm 2: on Day 3 all participants will receive a single po dose each of midazolam (2 mg) and tolbutamide (500 mg) with morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis.&lt;br/&gt;Arm 3: all participants will receive only the 400 mg pm dose of pexidartinib on Day 3 and continue bid dosing of pexidartinib (400 mg for the am dose, and 400 mg for the pm dose) until Day 13. On Day 13, all participants will receive a single oral dose of midazolam (2 mg) and tolbutamide (500 mg) with the morning dose of pexidartinib (400 mg) followed by blood draws for PK analysis.&lt;br/&gt;Arm 4: On Day 13, all participants will receive a pm dose of 400 mg pexidartinib only. All participants will continue to receive pexidartinib bid dosing in 28-day cycles at the 400 mg/day dose for up to one year. The dose of pexidartinib may be further modified within that year, depending upon tolerance as defined in the protocol.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Netherlands"><Sites><Site><Name>Leids Universitair Medisch Centrum</Name><Address1>Leiden</Address1><Address3>2333 ZA</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="New Zealand"><Sites><Site><Name>Christchurch Hospital NZ</Name><Address1>Christchurch</Address1><Address3>8011</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Taiwan"><Sites><Site><Name>National Taiwan University Hospital</Name><Address1>Taipei</Address1><Address3>10002</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Name>Dana-Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02215</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>HonorHealth</Name><Address1>Scottsdale</Address1><Address2>Arizona</Address2><Address3>85258</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>Karmanos Cancer Center</Name><Address1>Detroit</Address1><Address2>Michigan</Address2><Address3>48201</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Name>Mary Crowley Cancer Research</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75230</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Northwell Health</Name><Address1>Lake Success</Address1><Address2>New York</Address2><Address3>10042</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Stanford University</Name><Address1>Palo Alto</Address1><Address2>California</Address2><Address3>94304</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Name>University of Arizona</Name><Address1>Tucson</Address1><Address2>Arizona</Address2><Address3>85719</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Name>University of Kansas Cancer Center</Name><Address1>Westwood</Address1><Address2>Kansas</Address2><Address3>66205</Address3><CountrySubDivision code="KS">Kansas</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Melanoma</Disease><PatientSegments><PatientSegment><PatientSegment id="12862">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1549197586" id="14817">KIT_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Leukemia</Disease><PatientSegments><PatientSegment><PatientSegment id="12847">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1549197586" id="16024">KIT_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="12849">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1549197586" id="14816">KIT_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Gastrointestinal stromal tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8492">Subjects with KIT-mutant or CD117-positive GIST</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12865">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1549197586" id="14819">KIT_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Testis tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9295">Subjects with Testicular Germ Cell Tumor (TGCT)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="12871">Subjects with gene variants</PatientSegment><SubSegments><SubSegment genevariantId="-1549197586" id="19736">KIT_HUMAN_Mutation</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03291288</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Melanoma" id="7025"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Melanoma" id="7027"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Melanoma" id="7037"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="43187">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Leukemia" id="43188">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8077"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Leukemia" id="8078"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Gastrointestinal stromal tumor" id="12446"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Gastrointestinal stromal tumor" id="12458"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Gastrointestinal stromal tumor" id="12460"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13286"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13288"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Testis tumor" id="13304"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15285"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15287"><Endpoint>Assessment of adverse events</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Melanoma" id="6945"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Melanoma" id="6940">Assessment of overall/objective response rate</SubEndpoint><SubEndpoint disease="Melanoma" id="6943">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Melanoma" id="6944">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Melanoma" id="6966"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Melanoma" id="6972">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Melanoma" id="7037"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7906"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="7907">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Leukemia" id="7908">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Leukemia" id="7909">Assessment of Overall/Objective Response Rate (ORR)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Leukemia" id="7981"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Leukemia" id="43187">Assessment of maximum concentration of drug (Cmax)</SubEndpoint><SubEndpoint disease="Leukemia" id="43188">Area under concentration curve (AUC)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Gastrointestinal stromal tumor" id="12408"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Gastrointestinal stromal tumor" id="12409">Assessment of objective/overall response rate (ORR)</SubEndpoint><SubEndpoint disease="Gastrointestinal stromal tumor" id="12410">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Gastrointestinal stromal tumor" id="12411">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Gastrointestinal stromal tumor" id="12421"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Gastrointestinal stromal tumor" id="12446"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Testis tumor" id="13242"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Testis tumor" id="13243">Assessment of objective response rate (ORR)</SubEndpoint><SubEndpoint disease="Testis tumor" id="13245">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Testis tumor" id="13246">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Testis tumor" id="13283"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Testis tumor" id="13304"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15211"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15212">Assessment of objective response rate (ORR)</SubEndpoint><SubEndpoint disease="Solid tumor" id="15214">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Solid tumor" id="15215">Assessment of Complete Response</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15276"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="26827">Assessment by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15312"><Endpoint>Assessment of Pharmacokinetic/Pharmacodynamic Parameters</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Melanoma" id="4160"><Criterion>Subjects with Diagnosis of Melanoma</Criterion></Inclusion><Inclusion disease="Melanoma" id="4182"><Criterion>Subjects with Specified Biomarkers of Melanoma</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4186">Subjects with KIT mutation</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="4190"><Criterion>Subjects with Normal/Acceptable Hepatic Function</Criterion></Inclusion><Inclusion disease="Melanoma" id="4231"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4240">Protocol specified criteria for females</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5071"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5073">Subjects with normal/adequate liver function</SubCriterion><SubCriterion disease="Leukemia" id="5077">Subjects with normal/adequate hematopoietic function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="5187"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5206">Protocol specified inclusion criteria for females</SubCriterion><SubCriterion disease="Leukemia" id="5413">Subjects with study specific protocol requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="8455"><Criterion>Subjects with KIT-mutant or CD117-positive GIST</Criterion></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="8500"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8501">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Gastrointestinal stromal tumor" id="8502">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="8507"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8516">Protocol specified inclusion criteria for females</SubCriterion><SubCriterion disease="Gastrointestinal stromal tumor" id="8519">Subjects with ability to administer the medications as required</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="8886"><Criterion>Subjects with Testicular Germ Cell Tumor (TGCT)</Criterion></Inclusion><Inclusion disease="Testis tumor" id="8936"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8937">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Testis tumor" id="8938">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="8943"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8954">Subjects with ability to administer the medications as required</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13130"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13131">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Solid tumor" id="13132">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="13137"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13143">Protocol specified inclusion criteria for females</SubCriterion><SubCriterion disease="Solid tumor" id="13146">Subjects with ability to administer the medications as required</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="33399"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4198">Subjects with normal/acceptable hematological functions</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="33955"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4191">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="34010"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8503">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34013"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5074">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="34027"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8939">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34030"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13133">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="34073"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8517">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="34108"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8951">Non Pregnant/Non lactating women</SubCriterion><SubCriterion disease="Testis tumor" id="8952">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34117"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13144">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34143"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5196">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="34146"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4242">Men with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="34363"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8511">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="34415"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8946">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34423"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13138">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34442"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5190">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="34445"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4233">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Gastrointestinal stromal tumor" id="34816"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="8513">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Testis tumor" id="34887"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="8948">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34896"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13140">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Leukemia" id="34918"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="5189">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Melanoma" id="34924"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="4234">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Melanoma" id="5547"><Criterion>Subjects with History of/Scheduled for Other Treatments</Criterion></Exclusion><Exclusion disease="Melanoma" id="5565"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="5568">Subjects not suitable to take part in study according to investigator’s opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="6554"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Leukemia" id="6660"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Leukemia" id="6706"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6725">Subjects not suitable to take part in study according to investigator's opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastrointestinal stromal tumor" id="10021"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Gastrointestinal stromal tumor" id="10056"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Gastrointestinal stromal tumor" id="10060"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="10066">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Gastrointestinal stromal tumor" id="10073">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Testis tumor" id="10457"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Testis tumor" id="10489"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Testis tumor" id="10493"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="10496">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="10704"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10746">Subjects with medical condition interfering with the study protocol</SubCriterion><SubCriterion disease="Solid tumor" id="10753">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Melanoma" id="20280"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Melanoma" id="24952"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="5577">Pregnancy/Lactation/Women of childbearing potential/Intend to become pregnant/Without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastrointestinal stromal tumor" id="25508"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="10067">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10747">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Testis tumor" id="25673"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="10497">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="25755"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="25404">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Testis tumor" id="25767"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="10503">Pregnant/lactating women</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastrointestinal stromal tumor" id="27832"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Gastrointestinal stromal tumor" id="10065">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Leukemia" id="27879"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Leukemia" id="6718">Subjects unwilling or unable to comply with the protocol/study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Melanoma" id="27889"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Melanoma" id="5567">Subjects unable to comply with study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Solid tumor" id="27960"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10745">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Testis tumor" id="27966"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Testis tumor" id="10495">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-09-26T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2018-10-11T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>7.55 Months</EnrollmentPeriod><EnrollmentRate>3.97 Patients/Month</EnrollmentRate><DateFirstReceived>2017-09-19T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-09-26T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-04-05T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change><Change type="updated"><Date>2018-10-17T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="315981"><TitleDisplay>An observational study of role of nail bed methotrexate injections in isolated nail psoriasis: conventional drug via an unconventional route</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="281">Psoriasis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1081079" type="Company"><TargetEntity id="5039188003" type="organizationId">University College of Medical Sciences</TargetEntity></SourceEntity><SourceEntity id="1085225" type="Company"><TargetEntity id="5040047633" type="organizationId">Guru Teg Bahadur Hospital</TargetEntity></SourceEntity><SourceEntity id="281" type="ciIndication"><TargetEntity id="L40" type="ICD10"/><TargetEntity id="10037153" type="MEDDRA"/><TargetEntity id="D011565" type="MeSH"/><TargetEntity id="-1735788310" type="omicsDisease"/><TargetEntity id="490" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1081079">University College of Medical Sciences</Company><Company id="1085225">Guru Teg Bahadur Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TrialCategories><Category>Small molecule</Category></TrialCategories><PatientCountEnrollment>4</PatientCountEnrollment><PatientCountEvaluable>4</PatientCountEvaluable><DateChangeLast>2017-10-16T22:01:17Z</DateChangeLast><DateAdded>2017-10-16T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with nail psoriasis&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In April 2017, results were published. Adverse effects like pain, injection site pigmentation and nail bed hemorrhage were observed [&lt;ulink linkType="Reference" linkID="1970924"&gt;1970924&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this study was to evaluate the safety and efficacy of nail bed methotrexate injections in isolated nail psoriasis [&lt;ulink linkType="Reference" linkID="1970924"&gt;1970924&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In April 2017, results were published. Mean baseline Nail Psoriasis Severity Index (NAPSI) was 4.77 (cumulative score 143; n = 30) which dropped successively at each visit to 2.43 (cumulative score 73; n = 30) at 15 weeks. Statistically significant decline in mean NAPSI from 4.87 to 2.17 was observed (p &amp;lt; 0.001; Friedman analysis) [&lt;ulink linkType="Reference" linkID="1970924"&gt;1970924&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients who were treated with injections of methotrexate(0.1 ml of a 25 mg/ml solution) into the nail bed at 3-weekly intervals were observed [&lt;ulink linkType="Reference" linkID="1970924"&gt;1970924&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>methotrexate</Name></Intervention><AdverseEvents><AdverseEvent><Indication id="20">Pain</Indication></AdverseEvent><AdverseEvent><Indication id="512">Pigment disorder</Indication></AdverseEvent><AdverseEvent><Indication id="552">Bleeding</Indication></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-10-16T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="322044"><TitleDisplay>Efficacy And Safety Of Xyloglucan In Acute Gastroenteritis In Children</TitleDisplay><TitleOfficial>Randomized, Double-Blind Clinical Trial To Evaluate Efficacy And Safety Of Xyloglucan In Acute Gastroenteritis In Children</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03357237</Identifier><Identifier type="Organisational Study">PEDXIL 01</Identifier></Identifiers><Indications><Indication id="102">Diarrhea</Indication><Indication id="2195">Gastroenteritis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>xyloglucan</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1092773" type="Company"><TargetEntity id="4298204317" type="organizationId">Hospital Universitario Puerta de Hierro Majadahonda</TargetEntity></SourceEntity><SourceEntity id="102" type="ciIndication"><TargetEntity id="10012735" type="MEDDRA"/><TargetEntity id="D003967" type="MeSH"/><TargetEntity id="-957779542" type="omicsDisease"/><TargetEntity id="380" type="siCondition"/></SourceEntity><SourceEntity id="2195" type="ciIndication"><TargetEntity id="10017888" type="MEDDRA"/><TargetEntity id="D005759" type="MeSH"/><TargetEntity id="-696158598" type="omicsDisease"/><TargetEntity id="905" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1092773">Hospital Puerta de Hierro Majadahonda</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Infants (6-23 months)</Term><Term>Newborn Infants (up to 5 months)</Term><Term>Preschool Children (2-5 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>120</PatientCountEnrollment><DateStart>2017-12-01T00:00:00Z</DateStart><DateEnd type="estimated">2018-07-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-13T16:34:25Z</DateChangeLast><DateAdded>2017-12-13T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>mariajo_p_G@hotmail.com</Email><Name>Maria Jose Garcia, MD</Name><Phone>34911 91 60 00</Phone></Contact><Contact type="Scientific contact"><Affiliation>Hospital Universitario Puerta de Hierro Majadahonda</Affiliation><Name>Enriqueta Roman, PHD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Clinical of acute gastroenteritis: change in the consistency of stools to 'loose' or liquid according to Bristol scale (6 or 7) or Amsterdam (infants) (A) and/or increase in the number of stools (&gt;/= 3/day) with a duration of&amp;lt; 72 h&lt;/li&gt;&lt;li&gt;Age &gt; 3 months and&amp;lt; 5 years&lt;/li&gt;&lt;li&gt;Written informed consent according to ICH/GCP and local legislation, obtained before any study procedure of parents or guardians&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Treatment with antibiotics, xyloglucan, gelatin tannate, racecadotril, smectite, probiotics or zinc (including oral rehydration solution containing zinc and / or probiotics) in the previous week&lt;/li&gt;&lt;li&gt;Exclusive breastfeeding&lt;/li&gt;&lt;li&gt;Chronic gastrointestinal disease (celiac disease, cystic fibrosis, inflammatory bowel disease, food allergy)&lt;/li&gt;&lt;li&gt;Immunodeficiencies&lt;/li&gt;&lt;li&gt;Malnutrition (weight / height / length&amp;lt; P3 according to WHO standards)&lt;/li&gt;&lt;li&gt;Severe dehydration&lt;/li&gt;&lt;li&gt;Impossibility of follow-up&lt;/li&gt;&lt;li&gt;Known hypersensitivity to gelatin or xyloglucan&lt;/li&gt;&lt;li&gt;Absence of informed consent&lt;/li&gt;&lt;li&gt;Caregivers/parents who can not understand or comply with all the instructions and requirements of the study&lt;/li&gt;&lt;li&gt;If in the opinion of the researcher there are findings in the physical examination, abnormalities in the results of the clinical analyzes or other medical, social or psychosocial factors that could negatively influence&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Time of resolution of diarrhea: number of days</Description><Timeframe>14 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A randomized, blinded study with a control group is proposed in this project to establish      solidly the efficacy and safety of xyloglucan in the treatment of acute gastroenteritis in children.&lt;/para&gt;&lt;para&gt;The main variable of evaluation will be the duration of diarrhea, defined as the time it      takes to normalize the consistency of stools (according to the Bristol or Amsterdam scale) or      their number.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consist of two groups:&lt;br/&gt;Group 1: patients will receive treatment regimen with oral rehydration solution and xyloglucan.&lt;br/&gt;Group 2: patients will receive treatment regimen with oral rehydration solution and placebo.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Hospital Puerta de Hierro</Name><Address1>Majadahonda</Address1><Address2>Madrid</Address2><Address3>28222</Address3><CountrySubDivision>Madrid</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Gastroenteritis</Disease><PatientSegments><PatientSegment><PatientSegment id="18813">Subjects with acute gastroenteritis</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03357237</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Gastroenteritis" id="46219"><Endpoint>Assessment of Gastrointestinal Symptoms</Endpoint></PrimaryEndpoint></PrimaryEndpoints><OtherEndpoints><OtherEndpoint disease="Gastroenteritis" id="43293"><Endpoint>Assessment of Safety and Tolerability</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Gastroenteritis" id="35122"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Gastroenteritis" id="35167"><Criterion>Subjects with Symptomatic Disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Gastroenteritis" id="24267"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Gastroenteritis" id="25027"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Gastroenteritis" id="25028">Subjects co-morbid with malnutrition</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Gastroenteritis" id="25506"><Criterion>Subjects with Protocol Specified Participation Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-01-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-11-24T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2017-12-13T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="330843"><TitleDisplay>Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage</TitleDisplay><TitleOfficial>Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage : a Retrospective Study</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03449420</Identifier><Identifier type="Organisational Study">ARMANDTROUSSEAU</Identifier></Identifiers><Indications><Indication id="552">Bleeding</Indication></Indications><BiomarkerNames><BiomarkerName id="177" role="Disease marker" type="Genomic;Proteomic">Fibrinogen</BiomarkerName><BiomarkerName id="1221" role="Disease marker" type="Physiological">Hematocrit</BiomarkerName><BiomarkerName id="2070" role="Disease marker" type="Physiological">Partial Thromboplastin Time</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1095973" type="Company"><TargetEntity id="5042384706" type="organizationId">Hopital Armand-Trousseau</TargetEntity></SourceEntity><SourceEntity id="552" type="ciIndication"><TargetEntity id="10055798" type="MEDDRA"/><TargetEntity id="D006470" type="MeSH"/><TargetEntity id="-1283225934" type="omicsDisease"/><TargetEntity id="327" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1095973">Hôpital Armand Trousseau</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Retrospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>100</PatientCountEnrollment><DateStart>2012-01-31T00:00:00Z</DateStart><DateEnd type="actual">2015-07-31T00:00:00Z</DateEnd><DateChangeLast>2018-03-05T11:00:37Z</DateChangeLast><DateAdded>2018-03-02T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Hôpital Armand Trousseau</Affiliation><Name>Agnes Rigouzzo, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Women presenting with a post partum hemorrhage&lt;/li&gt;&lt;li&gt;Needing sulprostone infusion&lt;/li&gt;&lt;li&gt;During third trimester of pregnancy&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Known coagulation disorders&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Calculated blood loss: calculated blood loss at 24 h after delivery (Sum of the volume of blood transfused and the volume of blood loss calculated by the decrease in hematocrit)</Description><Timeframe>During the 24 h after delivery</Timeframe></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to determine if thromboelastography parameters can be predictive of      severe post partum hemorrhage.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients presenting with a post partum hemorrhage would be included and observed in this study. A thromboelastography analysis will be realized at discretion of the anesthesiologist in charge. Kaolin and Functional Fibrinogen tests (TEG5000) will be performed on native blood sample.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>Hôpital Armand Trousseau</Name><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other hematological disease</Disease><PatientSegments><PatientSegment><PatientSegment id="18261">Subjects with specific disease</PatientSegment><SubSegments><SubSegment id="15990">Subjects with Hemorrhage</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Other gynecological disorder</Disease><PatientSegments><PatientSegment><PatientSegment id="16679">Others</PatientSegment><SubSegments><SubSegment id="19116">Pregnant subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="17543">Women  giving birth/Obstetrics</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03449420</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other hematological disease" id="43591"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other hematological disease" id="43959"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other hematological disease" id="33056"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other gynecological disorder" id="33094"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other hematological disease" id="35075"><Criterion>Subjects with specific disease</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other gynecological disorder" id="24055"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other hematological disease" id="27153"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2015-07-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2017-03-30T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-03-02T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="33093"><TitleDisplay>Study to Establish Bioequivalence of ReFacto AF (BDDrFVIII) With Advate (FLrFVIII) in Hemophilia A</TitleDisplay><TitleOfficial>A Randomized, Two-Way, Blinded, Crossover-Design Study to Establish the Bioequivalence of B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, Refacto AF) With a Full Length Recombinant Factor VIII Preparation (FLrFVIII, Advate), Followed by an Open-Label Trial of the Safety and Efficacy of ReFacto AF in Previously Treated Patients With Hemophilia A</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">3082B2-310</Identifier><Identifier type="NCT">NCT00141843</Identifier><Identifier type="Trial Acronym">Study 310</Identifier></Identifiers><Indications><Indication id="121">Factor VIII deficiency</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth</Name><Drug id="53695">recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>octocog alfa, Baxalta</Name><Drug id="31620">octocog alfa, Baxalta</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="53695">recombinant moroctocog alfa (plasma/albumin-free, hemophilia A), Wyeth</Drug><IndicationsPioneer/><Companies><Company><Company id="14112">Wyeth</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="14112" type="Company"><TargetEntity id="4295903346" type="organizationId">Wyeth LLC</TargetEntity></SourceEntity><SourceEntity id="121" type="ciIndication"><TargetEntity id="D66" type="ICD10"/><TargetEntity id="286.0" type="ICD9"/><TargetEntity id="10016080" type="MEDDRA"/><TargetEntity id="D006467" type="MeSH"/><TargetEntity id="-410021453" type="omicsDisease"/><TargetEntity id="330" type="siCondition"/></SourceEntity><SourceEntity id="115" type="Action"><TargetEntity id="6964" type="Mechanism">Coagulation Factor VIII Activators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>41</NumberOfSites><CompaniesSponsor><Company id="14112">Wyeth</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="115">Factor VIII agonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="968">Coagulation stimulator</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="74">Glycoprotein</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Adolescents (13-17 yrs)</Term><Term>Children (6-12 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Male</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Active Control</Term><Term>Multiple Blind</Term><Term>Prevention</Term><Term>Crossover Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Bioequivalence</Term><Term>Efficacy</Term><Term>Pharmacokinetics</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>100</PatientCountEnrollment><PatientCountEvaluable>124</PatientCountEvaluable><DateStart>2005-07-31T00:00:00Z</DateStart><DateEnd type="actual">2006-11-30T00:00:00Z</DateEnd><DateChangeLast>2016-11-28T10:31:43Z</DateChangeLast><DateAdded>2008-11-04T12:15:08Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Wyeth is now a wholly owned subsidiary of Pfizer</Affiliation><Name>Medical Monitor</Name></Contact><Contact type="Scientific contact"><Affiliation>For Germany, MedInfoDEU@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Italy, descresg@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Australia, New Zealand, medinfo@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Netherlands, trials-NL@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Sweden, Finland,MedInfoNord@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Hungary, WPBUMED@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Poland, WVWZMED@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact><Contact type="Scientific contact"><Affiliation>For Belgium, trials-BEL@wyeth.com</Affiliation><Name>Trial Manager</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Male subjects with severe or moderately severe hemophilia A&lt;/li&gt;&lt;li&gt;A negative past medical history of a Factor VIII inhibitor&lt;/li&gt;&lt;li&gt;Age &gt;/= 12 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;A history of Factor VIII inhibitors&lt;/li&gt;&lt;li&gt;Presence of a bleeding disorder in addition to hemophilia&lt;/li&gt;&lt;li&gt;Known hypersensitivity to hamster protein&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>To determine the incidence rate of Factor VIII inhibitors in the study patient population</Description></Measure><Measure><Description>To establish bioequivalence of ReFacto AF as compared to Advate using the one stage Factor VIII activity assay</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>To characterize the efficacy of ReFActo AF in preventing and treating bleeding episodes during prophylaxis</Description></Measure><Measure><Description>To characterize pharmacokinetics of ReFacto AF as compared to Advate over time</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study would consist of two parts: a safety and efficacy period in which all subjects would participate and a pharmacokinetic analysis period, in which 30 eligible subjects would participate to compare  &lt;ulink linkType="Drug" linkID="53695"&gt;ReFacto AF&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="31620"&gt;Advate&lt;/ulink&gt; bioequivalency and safety and efficacy of &lt;ulink linkType="Drug" linkID="53695"&gt;ReFacto AF&lt;/ulink&gt; in patients with hemophilia A.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results reported that in the first phase of the trial, &lt;ulink linkType="Drug" linkID="53695"&gt;ReFacto AF&lt;/ulink&gt; showed equivalence to &lt;ulink linkType="Drug" linkID="31620"&gt;Advate&lt;/ulink&gt;, with similar results recorded for the two products. In the efficacy phase 43 patients reported no bleeding and 61 reported no spontaneous bleeding; most bleeds (92%) resolved after one or two infusions. A transient and clinically silent factor VIII inhibitory activity was detected in two subjects, one of which was characterized as an anti-drug antibody. However, no antibodies or the peptide purification ligand were detected in CHO cells [&lt;ulink linkType="Reference" linkID="857877"&gt;857877&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="859201"&gt;859201&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;In the first phase (pharmacokinetics) of the trial, 30 subjects received 50 U of iv &lt;ulink linkType="Drug" linkID="53695"&gt;Refacto AF&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="31620"&gt;Advate&lt;/ulink&gt;. In the second (efficacy) phase, 94 patients received 25 to 35 U of &lt;ulink linkType="Drug" linkID="53695"&gt;ReFacto AF&lt;/ulink&gt; three times a week for 6 months as prophylaxis [&lt;ulink linkType="Reference" linkID="857877"&gt;857877&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="859201"&gt;859201&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;In the first phase of the trial, 30 subjects received 50 U of iv &lt;ulink linkType="Drug" linkID="53695"&gt;Refacto AF&lt;/ulink&gt; or &lt;ulink linkType="Drug" linkID="31620"&gt;Advate&lt;/ulink&gt;. In the second (efficacy) phase, 94 patients received 25 to 35 U of &lt;ulink linkType="Drug" linkID="53695"&gt;ReFacto AF&lt;/ulink&gt; three times a week for 6 months as prophylaxis [&lt;ulink linkType="Reference" linkID="857877"&gt;857877&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="859201"&gt;859201&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Australia"><Sites><Site><Address1>Perth</Address1><Address3>6000</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Belgium"><Sites><Site><Address1>Leuven</Address1><Address3>3000</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Germany"><Sites><Site><Address1>Berlin</Address1><Address3>10249</Address3><Contacts/></Site><Site><Address1>Muenster</Address1><Address3>48143</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Spain"><Sites><Site><Address1>Madrid</Address1><Address3>28046</Address3><Contacts/></Site><Site><Address1>Valencia</Address1><Address3>46009</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Finland"><Sites><Site><Address1>Helsinki</Address1><Address3>00029</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="France"><Sites><Site><Address1>Le Kremlin Bicêtre</Address1><Address3>94275</Address3><Contacts/></Site><Site><Address1>Rouen</Address1><Address3>76031</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Hungary"><Sites><Site><Address1>Budapest</Address1><Address3>H-1135</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Italy"><Sites><Site><Address1>Milano</Address1><Address3>20122</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Netherlands"><Sites><Site><Address1>Groningen</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="New Zealand"><Sites><Site><Address1>Auckland</Address1><Contacts/></Site><Site><Address1>Hamilton</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Poland"><Sites><Site><Address1>Lodz</Address1><Address3>95-510</Address3><Contacts/></Site><Site><Address1>Poznan</Address1><Contacts/></Site><Site><Address1>Warszawa</Address1><Address3>00-576</Address3><Contacts/></Site><Site><Address1>Wroclaw</Address1><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Sweden"><Sites><Site><Address1>Malmö</Address1><Contacts/></Site><Site><Address1>Stockholm</Address1><Address3>171 76</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="US"><Sites><Site><Address1>Atlanta</Address1><Address2>Georgia</Address2><Address3>30322</Address3><CountrySubDivision code="GA">Georgia</CountrySubDivision><Contacts/></Site><Site><Address1>Aurora</Address1><Address2>Colorado</Address2><Address3>80045</Address3><CountrySubDivision code="CO">Colorado</CountrySubDivision><Contacts/></Site><Site><Address1>Buffalo</Address1><Address2>New York</Address2><Address3>14215</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Address1>Chapel Hill</Address1><Address2>North Carolina</Address2><Address3>27599</Address3><CountrySubDivision code="NC">North Carolina</CountrySubDivision><Contacts/></Site><Site><Address1>Charlottesville</Address1><Address2>Virginia</Address2><Address3>22908</Address3><CountrySubDivision code="VA">Virginia</CountrySubDivision><Contacts/></Site><Site><Address1>Dayton</Address1><Address2>Ohio</Address2><Address3>45404</Address3><CountrySubDivision code="OH">Ohio</CountrySubDivision><Contacts/></Site><Site><Address1>East Lansing</Address1><Address2>Michigan</Address2><Address3>48823</Address3><CountrySubDivision code="MI">Michigan</CountrySubDivision><Contacts/></Site><Site><Address1>Hershey</Address1><Address2>Pennsylvania</Address2><Address3>17033</Address3><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Address1>Iowa City</Address1><Address2>Iowa</Address2><Address3>52242</Address3><CountrySubDivision code="IA">Iowa</CountrySubDivision><Contacts/></Site><Site><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37232</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Address1>New Brunswick</Address1><Address2>New Jersey</Address2><Address3>08903-0019</Address3><CountrySubDivision code="NJ">New Jersey</CountrySubDivision><Contacts/></Site><Site><Address1>New Hyde Park</Address1><Address2>New York</Address2><Address3>11040</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Address1>New Orleans</Address1><Address2>Louisiana</Address2><Address3>70112</Address3><CountrySubDivision code="LA">Louisiana</CountrySubDivision><Contacts/></Site><Site><Address1>Philadelphia</Address1><Address2>Pennsylvania</Address2><CountrySubDivision code="PA">Pennsylvania</CountrySubDivision><Contacts/></Site><Site><Address1>Phoenix</Address1><Address2>Arizona</Address2><Address3>85016</Address3><CountrySubDivision code="AZ">Arizona</CountrySubDivision><Contacts/></Site><Site><Address1>Sacramento</Address1><Address2>California</Address2><Address3>95817</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Address1>Salt Lake City</Address1><Address2>Utah</Address2><Address3>84113</Address3><CountrySubDivision code="UT">Utah</CountrySubDivision><Contacts/></Site><Site><Address1>San Diego</Address1><Address2>California</Address2><Address3>92123</Address3><CountrySubDivision code="CA">California</CountrySubDivision><Contacts/></Site><Site><Address1>St. Louis</Address1><Address2>Missouri</Address2><Address3>63014</Address3><CountrySubDivision code="MO">Missouri</CountrySubDivision><Contacts/></Site><Site><Address1>Worcester</Address1><Address2>Massachusetts</Address2><Address3>01605</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Hemophilia</Disease><PatientSegments><PatientSegment><PatientSegment id="9876">Subjects with Hemophilia A</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9883">Subjects with Moderate Hemophilia</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9884">Subjects with Severe Hemophilia</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00141843</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hemophilia" id="17998"><Endpoint>Assessment of Inhibitor Antibody Development</Endpoint><SubEndpoints><SubEndpoint disease="Hemophilia" id="17999">Assessment of development of factor VIII inhibitor</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hemophilia" id="17997"><Endpoint>Assessment of Hemostatic Efficacy</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Hemophilia" id="15917"><Criterion>Subjects with Hemophilia A</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15924"><Criterion>Subjects with Moderate Hemophilia</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15925"><Criterion>Subjects with Severe Hemophilia</Criterion></Inclusion><Inclusion disease="Hemophilia" id="15987"><Criterion>Subjects with Absence of Inhibitors</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Hemophilia" id="13198"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13213">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Hemophilia" id="13232"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion></Exclusion><Exclusion disease="Hemophilia" id="13255"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Hemophilia" id="13257">Subjects with factor VIII inhibitors</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2006-11-30T00:00:00Z</PrimaryCompletionDate><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-11-04T12:15:08Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="336484"><TitleDisplay>Tecentriq Drug Use Surveillance (NSCLC)</TitleDisplay><TitleOfficial>Tecentriq Drug Use Surveillance (Advanced or Recurrent Non-Small Cell Lung Cancer)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000031978</Identifier></Identifiers><Indications><Indication id="1262">Non-small-cell lung cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atezolizumab</Name><Drug id="72699">atezolizumab</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="72699">atezolizumab</Drug><IndicationsPioneer/><Companies><Company><Company id="15414">Chugai Pharmaceutical Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="72699" type="Drug"><TargetEntity id="745748" type="siDrug"></TargetEntity></SourceEntity><SourceEntity id="15414" type="Company"><TargetEntity id="4295876884" type="organizationId">Chugai Pharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1262" type="ciIndication"><TargetEntity id="10061873" type="MEDDRA"/><TargetEntity id="D002289" type="MeSH"/><TargetEntity id="-1730468577" type="omicsDisease"/><TargetEntity id="612" type="siCondition"/></SourceEntity><SourceEntity id="14007" type="Action"><TargetEntity id="4337" type="Mechanism">Anti-PD-L1 (CD274)</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="15414">Chugai Pharmaceutical Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="14007">Programmed cell death ligand 1 inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="393">Immunostimulant</Class><Class id="55685">Anticancer monoclonal antibody</Class><Class id="7761">T-lymphocyte stimulator</Class></Class><Technologies><Technology id="180">Antibody fragment</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="1263">Immuno-oncology</Technology><Technology id="573">Immunoglobulin-G</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology><Technology id="85">Protein recombinant</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>1000</PatientCountEnrollment><DateStart>2018-04-18T00:00:00Z</DateStart><DateChangeLast>2018-04-23T12:02:21Z</DateChangeLast><DateAdded>2018-04-20T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>Chugai Pharmaceutical Co. Ltd; Real world data science Dept</Affiliation><Email>shimizuayk@chugai-pharm.co.jp</Email><Name>Ayaka Shimizu</Name><Phone>03-3273-0905</Phone></Contact><Contact type="Scientific contact"><Affiliation>Chugai Pharmaceutical Co. Ltd; Real world data science Dept</Affiliation><Email>nemotomst@chugai-pharm.co.jp</Email><Name>Masatomi Nemoto</Name><Phone>03-3273-0905</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;All patients who are scheduled to receive  Tecentriq at contracted institutions during this surveillance's enrollment period&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The incidence of ADRs</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The incidence of ADRs for each patient baseline characteristic</Description></Measure><Measure><Description>The time of onset of ADRs</Description></Measure><Measure><Description>The treatment status and outcome of ADRs</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This surveillance study is conducted to confirm incidence of adverse drug reactions (ADRs) in Japanese clinical setting.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients who receive &lt;ulink linkType="Drug" linkID="72699"/&gt;&lt;ulink linkType="Drug" linkID="72699"&gt;Tecentriq&lt;/ulink&gt; (atezolizumab) will be observed and analyzed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>Chugai Pharmaceutical Co. Ltd; Real world data science Dept</Name><Address1>Tokyo</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Lung tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="3617">Subjects with Non Small Cell Lung Cancer (NSCLC)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="3623">Subjects with Advanced Stage Lung Cancer</PatientSegment><SubSegments><SubSegment id="3634">Subjects with metastatic/stage IV lung cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="3650">Subjects with Recurrent/Relapsed Lung Cancer</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000031978</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Lung tumor" id="8639"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Lung tumor" id="3900"><Criterion>Subjects with Non Small Cell Lung Cancer (NSCLC)</Criterion></Inclusion><Inclusion disease="Lung tumor" id="3925"><Criterion>Subjects with Protocol Specified Stages of Lung Cancer(TNM staging)</Criterion><SubCriteria><SubCriterion disease="Lung tumor" id="3936">Subjects with stage IV lung cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Lung tumor" id="3940"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Lung tumor" id="4000"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Lung tumor" id="4073"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion></InclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-04-20T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2018-04-24T00:00:00Z</Date><Reason id="302">Recruitment Status Changed</Reason></Change></ChangeHistory></Trial><Trial id="338194"><TitleDisplay>Identification of impacts of Proton Pump Inhibitors on the pharmacokinetic of Voriconazole</TitleDisplay><TitleOfficial>Identification of impacts of Proton Pump Inhibitors on the pharmacokinetic of Voriconazole</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800015710</Identifier></Identifiers><Indications><Indication id="124">Fungal infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>voriconazole</Name><Drug id="8714">voriconazole</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8714">voriconazole</Drug><IndicationsPioneer/><Companies><Company><Company id="1074897">The Second XiangYa Hospital of Central South University</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8714" type="Drug"><TargetEntity id="179738" type="siDrug">Voriconazole</TargetEntity></SourceEntity><SourceEntity id="1074897" type="Company"><TargetEntity id="5037943518" type="organizationId">Second Xiangya Hospital of Central South University</TargetEntity></SourceEntity><SourceEntity id="124" type="ciIndication"><TargetEntity id="10017533" type="MEDDRA"/><TargetEntity id="D009181" type="MeSH"/><TargetEntity id="-2109353222" type="omicsDisease"/><TargetEntity id="817" type="siCondition"/></SourceEntity><SourceEntity id="777" type="Action"><TargetEntity id="444" type="Mechanism">Lanosterol 14alpha-demethylase Inhibitors</TargetEntity><TargetEntity id="5607" type="Mechanism">Sterol 14-alpha Demethylase (CYP51) (Trypanosoma cruzi) Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1074897">The Second XiangYa Hospital of Central South University</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="777">Lanosterol-14 demethylase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15178">Systemic dermatological antifungal product</Class><Class id="161">Ergosterol synthesis inhibitor</Class><Class id="1748">Fungicide</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="585">Oral formulation</Technology><Technology id="593">Oral liquid formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Pharmacokinetics</Term></TermsEndpoint><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2018-04-23T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-20T00:00:00Z</DateEnd><DateChangeLast>2018-05-04T22:00:38Z</DateChangeLast><DateAdded>2018-05-11T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>The Second Xiangya Hospital of Central South University</Affiliation><Email>277938084@qq.com</Email><Name>Wu Zhufeng</Name><Phone>+86 15692004126</Phone></Contact><Contact type="Scientific contact"><Affiliation>The Second Xiangya Hospital of Central South University</Affiliation><Email>yan.miao@126.com</Email><Name>Yan Miao</Name><Phone>+86 13787783668</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Aged more than 18 years&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Simultaneous use of another antifungal agent&lt;/li&gt;&lt;li&gt;Combination of rifampicin,isoniazid,phenytoin and other potent CYP450 inducers and inhibitors&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Blood concentration</Description></Measure></MeasuresPrimary><MeasureSecondary/></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim is to evaluate impacts of proton pump inhibitors on the pharmacokinetic of &lt;ulink linkType="Drug" linkID="8714"&gt;voriconazole&lt;/ulink&gt;.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients will receive voriconazole.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>The Second Xiangya Hospital of Central South University</Name><Address2>Hu'nan</Address2><CountrySubDivision>Hu'nan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800015710</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-05-11T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="347641"><TitleDisplay>Donafenib in 131I-Refractory Differentiated Thyroid Cancer</TitleDisplay><TitleOfficial>A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03602495</Identifier><Identifier type="Organisational Study">ZGDD3</Identifier><Identifier type="Other">CTR20180191</Identifier></Identifiers><Indications><Indication id="1069">Metastasis</Indication><Indication id="1134">Thyroid tumor</Indication></Indications><BiomarkerNames><BiomarkerName id="75" role="Therapeutic effect marker" type="Genomic;Proteomic">Thyroglobulin</BiomarkerName><BiomarkerName id="5605" role="Therapeutic effect marker" type="Proteomic">Anti-thyroglobulin antibodies</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>donafenib tosylate (oral tablet, cancer), Suzhou Zelgen Biopharmaceutical</Name><Drug id="83537">donafenib tosylate (oral tablet, cancer), Suzhou Zelgen Biopharmaceutical</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="83537">donafenib tosylate (oral tablet, cancer), Suzhou Zelgen Biopharmaceutical</Drug><IndicationsPioneer/><Companies><Company><Company id="1065043">Suzhou Zelgen Biopharmaceuticals Co Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="1065043" type="Company"><TargetEntity id="5043322443" type="organizationId">Suzhou Zelgen Biopharmaceutical Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1069" type="ciIndication"><TargetEntity id="10062194" type="MEDDRA"/><TargetEntity id="D009362" type="MeSH"/><TargetEntity id="-1423187778" type="omicsDisease"/><TargetEntity id="618" type="siCondition"/></SourceEntity><SourceEntity id="1134" type="ciIndication"><TargetEntity id="C73" type="ICD10"/><TargetEntity id="193" type="ICD9"/><TargetEntity id="10066474" type="MEDDRA"/><TargetEntity id="D013964" type="MeSH"/><TargetEntity id="-845587053" type="omicsDisease"/><TargetEntity id="649" type="siCondition"/></SourceEntity><SourceEntity id="3520" type="Action"><TargetEntity id="1101" type="Mechanism">Receptor Tyrosine Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="4542" type="Action"><TargetEntity id="1212" type="Mechanism">Raf Kinase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>27</NumberOfSites><CompaniesSponsor><Company id="1065043">Suzhou Zelgen Biopharmaceuticals Co Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3520">Tyrosine kinase receptor inhibitor</Action><Action id="4542">Raf protein kinase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="61">Angiogenesis inhibitor</Class><Class id="62255">Anticancer protein kinase inhibitor</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>204</PatientCountEnrollment><DateStart>2018-06-26T00:00:00Z</DateStart><DateEnd type="estimated">2020-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T16:41:53Z</DateChangeLast><DateAdded>2018-07-30T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>linys@pumch.cn</Email><Name>Lin Yan Song, MD</Name><Phone>13671116837</Phone></Contact><Contact type="Scientific contact"><Affiliation>Peking Union Medical College Hospital</Affiliation><Name>Lin Yan Song, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Suzhou Zesheng Biological Pharmaceutical Co., Ltd</Affiliation><Name>Lu Huiping</Name></Contact><Contact type="Scientific contact"><Affiliation>West China Hospital of Sichuan University</Affiliation><Name>Liu Bin</Name></Contact><Contact type="Scientific contact"><Affiliation>Tianjin Medical University General Hospital</Affiliation><Name>Tan Jian</Name></Contact><Contact type="Scientific contact"><Affiliation>Yunnan Cancer Hospital</Affiliation><Name>Deng Zhiyong</Name></Contact><Contact type="Scientific contact"><Affiliation>Zhejiang Cancer Hospital</Affiliation><Name>Li Linfa</Name></Contact><Contact type="Scientific contact"><Affiliation>Third People's Liberation Army Hospital</Affiliation><Name>Ding Yong</Name></Contact><Contact type="Scientific contact"><Affiliation>Chinese Academy of Medical Sciences Cancer Hospital</Affiliation><Name>He Xiaohui</Name></Contact><Contact type="Scientific contact"><Affiliation>Jiangxi Cancer Hospital</Affiliation><Name>Chen Zhijun</Name></Contact><Contact type="Scientific contact"><Affiliation>The First Affiliated Hospital of Xi'an Jiaotong University</Affiliation><Name>Li Enxiao</Name></Contact><Contact type="Scientific contact"><Affiliation>Huazhong University of Science and Technology Union Hospital of Tongji Medical College</Affiliation><Name>Gao Zairong</Name></Contact><Contact type="Scientific contact"><Affiliation>Huazhong University of Science Tongji Hospital, Tongji Medical College</Affiliation><Name>Li Xingrui</Name></Contact><Contact type="Scientific contact"><Affiliation>Hebei Cancer Hospital</Affiliation><Name>Jing Shanghua</Name></Contact><Contact type="Scientific contact"><Affiliation>Jilin University Sino-Japanese Friendship Hospital</Affiliation><Name>Ma Qingjie</Name></Contact><Contact type="Scientific contact"><Affiliation>Shanxi Medical University First Hospital</Affiliation><Name>Lu Keyi</Name></Contact><Contact type="Scientific contact"><Affiliation>Shaoyifu Hospital, School of Medicine, Zhejiang University</Affiliation><Name>Fang Yong</Name></Contact><Contact type="Scientific contact"><Affiliation>Shanghai Sixth People's Hospital</Affiliation><Name>Shen Chan</Name></Contact><Contact type="Scientific contact"><Affiliation>Henan Provincial People's Hospital</Affiliation><Name>Gao Yongju</Name></Contact><Contact type="Scientific contact"><Affiliation>Beijing Union Medical College Hospital</Affiliation><Name>Lin Yansong, MD</Name></Contact><Contact type="Scientific contact"><Affiliation>Anhui Provincial Hospital</Affiliation><Name>Cheng Yizhuang</Name></Contact><Contact type="Scientific contact"><Affiliation>The Second Affiliated Hospital of Anhui Medical University</Affiliation><Name>Chen Zhendong</Name></Contact><Contact type="Scientific contact"><Affiliation>Beijing University First Hospital</Affiliation><Name>Wang Rongfu</Name></Contact><Contact type="Scientific contact"><Affiliation>First Affiliated Hospital of Fujian Medical</Affiliation><Name>Xie Xianhe</Name></Contact><Contact type="Scientific contact"><Affiliation>Fudan University Cancer Hospital</Affiliation><Name>Zhao Qinghai</Name></Contact><Contact type="Scientific contact"><Affiliation>Harbin Medical University Affiliated Tumor Hospital</Affiliation><Name>Cui Yali</Name></Contact><Contact type="Scientific contact"><Affiliation>Henan Cancer Hospital</Affiliation><Name>Yang Hui</Name></Contact><Contact type="Scientific contact"><Affiliation>Hunan Cancer Hospital</Affiliation><Name>Shi Feng</Name></Contact><Contact type="Scientific contact"><Affiliation>Jiangsu Provincial People's Hospital</Affiliation><Name>Bao Lihua</Name></Contact><Contact type="Scientific contact"><Affiliation>Southern Medical University Nanfang Hospital</Affiliation><Name>Lei Shangtong</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Advanced or metastasis thyroid cancer&lt;/li&gt;&lt;li&gt;Subjects must have histologically or cytologically confirmed diagnosis of one of the following differentiated thyroid cancer (DTC) subtypes: papillary thyroid cancer (PTC), follicular thyroid cancer (FTC) or Hurthle cell, poorly differentiated carcinoma&lt;/li&gt;&lt;li&gt;Subjects must show evidence of disease progression within 14 months prior to signing informed consent, according to RECIST 1.1 assessed and confirmed by central radio-graphic review of CT scans or magnetic resonance imaging (MRI); 6RAI refractory:&lt;ul&gt;&lt;li&gt;After clearing nails, in the absence of exogenous iodine load disturbance, thyroid stimulating hormone (TSH) (&gt; 30 mU/l) stimulation status can be diagnosed as iodine refractory thyroid cance&lt;/li&gt;&lt;li&gt;Not suitable for therapeutic surgery or radiotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Measurable disease meeting the following criteria and confirmed by central radiographic review:&lt;ul&gt;&lt;li&gt;At least one lesion of &gt;/= 1.0 cm in the longest diameter for a non-lymph node or &gt;/= 1.5 cm in the short-axis diameter for a lymph node which is serially measurable according to RECIST 1.1 using computerized tomography&lt;/li&gt;&lt;li&gt;Lesions that have had external beam radiotherapy (EBRT) or locoregional therapies such as radio-frequency (RF) ablation must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion&lt;/li&gt;&lt;li&gt;Bone metastasis lesion is non-measurable&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects must be 131I-refractory / resistant as defined by at least one of the following;&lt;ul&gt;&lt;li&gt;One or more measurable lesions that do not demonstrate iodine uptake on any radio-iodine scan&lt;/li&gt;&lt;li&gt;One or more measurable lesions that has progressed by RECIST 1.1 within 14 months of 131I therapy, despite demonstration of radio-iodine avidity at the time of that treatment by pre-treatment scanning&lt;/li&gt;&lt;li&gt;Cumulative activity of 131I of&amp;gt; 600 mCi or 22 gigabequerels (GBq)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects may have not received molecular targeted therapy&lt;/li&gt;&lt;li&gt;Subjects with known brain metastasis who have completed whole brain radiotherapy, stereotactic radiosurgery or complete surgical resection, will be eligible if they have remained clinically stable, asymptomatic and off of steroids for one month&lt;/li&gt;&lt;li&gt;Subjects must tolerate to thyroxin ,and TSH suppression (TSH&amp;lt; 0.5 mU/ml)&lt;/li&gt;&lt;li&gt;Before 14 days prior to study entry,(before laboratory examination for 14 days no blood transfusion,not use albumin and hematopoietic stimulating factor), Adequate laboratory examination:&lt;ul&gt;&lt;li&gt;Absolute neutrophil count (ANC) &gt;/= 1500/ mm3&lt;/li&gt;&lt;li&gt;Platelets &gt;/= 100,000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin &gt;/=  9.0 g/dl&lt;/li&gt;&lt;li&gt;Adequate blood coagulation function:International Normalized Ratio(INR) ≤ 2&lt;/li&gt;&lt;li&gt;Adequate liver function: bilirubin&amp;lt;/= 1.5 x the upper limit of normal(ULN); alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) &amp;lt;/= 2.5 x the upper limit of normal (ULN),for liver metastasis ALT and AST &amp;lt;/= 5.0 x the upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Serum creatinine less than or equal to 1.5 x the upper limit of normal (ULN);creatinine clearance&amp;lt; 50 ml/min:&lt;ul&gt;&lt;li&gt;Note: Ccr = (140 - age) x body weight (kg)/(72 x Scr [mg/dl]) or Ccr = ([140 - age] x body weight [kg])/[0.818 x Scr [micromol/l]) women's calculation results x 0.85&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Life expectancy of at least 3 months&lt;/li&gt;&lt;li&gt;All females must have a negative serum or urine pregnancy test. Females of childbearing potential and male subjects who are partners of women of childbearing potential must use or their partners must use a highly effective method of contraception&lt;/li&gt;&lt;li&gt;Voluntary provision of written informed consent and the willingness and ability to comply with all aspects of the protocol&lt;/li&gt;&lt;li&gt;Swallow oral drugs and keep them in the body&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years old, male or female&lt;/li&gt;&lt;li&gt;Patients with previous history of brain metastases must satisfy: Completed whole-brain radiotherapy, stereotactic radiosurgery, or complete surgical resection, and have received stable doses of glucocorticoid treatment at least 2 weeks prior to randomization (maximum dose of 16 mg daily Mesosone or equivalent dose), and can be stabilized after randomization, no symptoms of brain metastasis or subdural metastasis&lt;/li&gt;&lt;li&gt;Expected survival period &gt;/= 12 weeks&lt;/li&gt;&lt;li&gt;Female patients must satisfy:  menopause (defined as no menstruation for at least one year), or two have been surgically sterilized, or three have fertility but must meet: Blood pregnancy tests performed within 7 days prior to randomization must be negative, and agreeing to use appropriate contraceptive measures must include at least one barrier method of contraception (at least 28 days after the signing of the informed consent to the last dose of the test drug), and do not breastfeed&lt;/li&gt;&lt;li&gt;Male patients must agree to use appropriate contraceptive measures and must include at least one barrier method of contraception (from signing informed consent to at least 28 days after the last administration of the test drug)&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Other pathologic subtypes of the thyroid, undifferentiated carcinoma, medullary carcinoma,lymphoma and sarcoma etc&lt;/li&gt;&lt;li&gt;Prior treatment to TKI or other molecular targeted drugs&lt;/li&gt;&lt;li&gt;Subjects who have received any chemotherapy or extra radiotherapy (in addition to low dose chemotherapy for radiosensitization) within 30 days prior to the first dose of study drug and should have recovered from any toxicity related to previous anti-cancer treatment&lt;/li&gt;&lt;li&gt;Known or suspect to TKI food allergy;in the study be allergic to drugs&lt;/li&gt;&lt;li&gt;Active malignancy (except for differentiated thyroid carcinoma, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, or carcinoma in-situ of the cervix) within the past five years&lt;/li&gt;&lt;li&gt;Major surgery, open biopsy or severe trauma within 4 weeks prior to the first dose of study drug&lt;/li&gt;&lt;li&gt;An unhealed wound, ulcer, or fracture&lt;/li&gt;&lt;li&gt;Evidence of bleeding and coagulation disorders&lt;/li&gt;&lt;li&gt;Using the antiplatelet drugs (except for a small dose of aspirin which is&amp;lt; 100 mg)&lt;/li&gt;&lt;li&gt;The risk of Infiltration and bleeding of the trachea, bronchi and esophagus, not using topical treatment berore randomize&lt;/li&gt;&lt;li&gt;Bleeding of more than grade 3 within 3 months prior to the first dose of study drugs&lt;/li&gt;&lt;li&gt;Significant cardiovascular impairment: history of congestive heart failure greater than New York Heart Association (NYHA) Class II, unstable angina; myocardial infarction or stroke within 6 months of the first dose of study drug&lt;/li&gt;&lt;li&gt;Cardiac arrhythmia requiring medical treatment, QTc &gt; 480 ms; adequately controlled blood pressure with or without antihypertensive medications, defined as BP&amp;lt; 140/90 mmHg using at least 2 kinds of medicine&lt;/li&gt;&lt;li&gt;Venous or arterial thromboembolic events, cerebral blood-vessel accident, arterial thrombosis, pulmonary embolism, deep-venous thrombosis, within 6 months of the first dose of study drug&lt;/li&gt;&lt;li&gt;Active infection more than grade 2 (any infection requiring treatment)&lt;/li&gt;&lt;li&gt;All chemotherapy or radiation-related toxicities must have resolved to less than grade 2 severity, except alopecia neurotoxicity&lt;/li&gt;&lt;li&gt;HIV infectious, active infection of the HCV and HBV (HBV-DNA &gt; 1000 copise/ml, expect the chronic asymptomatic HBV carrier)&lt;/li&gt;&lt;li&gt;Epileptic seizure being drug treatment&lt;/li&gt;&lt;li&gt;Using the strong - acting CYP3A4 inducer (phenytoin, carbamazepine, rifampicin, rifapentine, phenobarbital) within 7 days of the first dose of study drug&lt;/li&gt;&lt;li&gt;Using biological reaction regulator(g-csf granulocyte colony stimulating factor) within 21 days of the first dose of study drug&lt;/li&gt;&lt;li&gt;The drug abuse, medicine, psychology and social disease which may be have an effect on study result&lt;/li&gt;&lt;li&gt;Any malabsorption disease&lt;/li&gt;&lt;li&gt;Any disease that is unstable or may endanger the patient's safety and research compliance&lt;/li&gt;&lt;li&gt;The disease which is unstable and harm to safty and research compliance of patient&lt;/li&gt;&lt;li&gt;Take the other clinical research treatment in the study and within 4 weeks of the first dose of study drug&lt;/li&gt;&lt;li&gt;Within 4 weeks prior to randomization, tyrosine kinase inhibitors, monoclonal antibodies targeting vascular endothelial growth factor or vascular endothelial growth factor or vascular endothelial growth factor receptor, or other targeted drugs&lt;/li&gt;&lt;li&gt;Known or suspected hypersensitivity to tyrosine kinase inhibitors or hypersensitivity to the drug administered during the trial; in the first five years prior to randomization, there have been cancers of primary site or histological type different from thyroid cancer, or cancers coexisting with thyroid cancer but with different primary sites or histological types, but cervix in situ cancer, treated basal cells except cancer and superficial bladder tumors (non-invasive tumors, carcinoma in situ and tumor invading intrinsic membrane)&lt;/li&gt;&lt;li&gt;A hemorrhagic/bleeding event with severity &gt;/= 3 (Adverse Event Terminology Standard Version 4.0 [CTCAE V4.03]) within the first 3 months of randomization&lt;/li&gt;&lt;li&gt;Clinically significant heart disease within the first 6 months of randomization, including congestive heart failure greater than New York Heart Association class II, unstable angina (angina at rest), and new angina (before randomization 3 months) or myocardial infarction&lt;/li&gt;&lt;li&gt;Need to receive antiarrhythmic drugs for ventricular arrhythmias; QTc &gt; 480 ms; hypertension that cannot be well controlled by &gt;/= 2 antihypertensive drugs (systolic blood pressure &gt; 140 mmHg or diastolic blood pressure &gt; 90 mmHg)&lt;/li&gt;&lt;li&gt;Thrombotic or embolic vein or arterial events such as cerebrovascular accidents, including transient ischemic attack, arterial thrombosis, deep vein thrombosis, and pulmonary embolism occurred within the first 6 months of randomization&lt;/li&gt;&lt;li&gt;During the trial or within 4 weeks prior to randomization, other clinical studies outside the scope of this trial were treated&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Progression-free Survival: PFS was defined as the time from date of randomization to disease progression radiological or death due to any cause, whichever occurs first. Subjects without progression or death at the time of analysis were censored at their last date of tumor evaluation</Description><Timeframe>From randomization of the first subject until the last subject complete 24 months treatment</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Disease control rate (DCR): DCR is defined as the percentage of subjects whose best response was not progressive disease (PD) according to Response Evaluation Criteria in Solid Tumors (RECIST) (= total number of complete response [CR]+ total number of partial response [PR] + total number of stable disease (SD); CR, PR, or SD had to be maintained for at least 28 days from the first demonstration of that rating)</Description><Timeframe>From randomization of the first subject until the last subject complete 24 months treatment</Timeframe></Measure><Measure><Description>Objective response rate (ORR): ORR is defined as the percentage of subjects with total number of complete response (CR) + total number of partial response (PR)</Description><Timeframe>From randomization of the first subject until the last subject complete 24 months treatment</Timeframe></Measure><Measure><Description>Overall survival: OS is defined as the time from date of randomization to death due to any cause. Subjects still alive at the time of analysis were censored at their last date of last contact</Description><Timeframe>From randomization of the first subject until the last subject complete 48 months treatment</Timeframe></Measure><Measure><Description>Time to disease progression (TTP): TTP was defined as the time from date of randomization to disease progression radiological. Subjects without progression at the time of analysis were censored at their last date of tumor evaluation</Description><Timeframe>From randomization of the first subject until the last subject complete 24 months treatment</Timeframe></Measure><Measure><Description>Thyroglobulin (Tg), thyroglobulin antibody (TgAb)</Description><Timeframe>During the double-blind treatment period, every 4 weeks; open treatment period, once every 12 weeks, until disease progression or death</Timeframe></Measure><Measure><Description>Cancer Patient Quality of Life Inventory (FACT-G)</Description><Timeframe>In the double-blind treatment period, every 4 weeks; open treatment period, every 12 weeks until the end of treatment</Timeframe></Measure><Measure><Description>Evaluate the donafenib group and continue to receive treatment after treatment with tofosyl tosylate for treatment of blindness</Description><Timeframe>Open treatment period every 12 weeks until disease progression or death</Timeframe></Measure><Measure><Description>Evaluation of the placebo group continued treatment after blindfolding Dopamine tosylate treatment, from the blind until after the disease progression PFS</Description><Timeframe>Open treatment period every 12 weeks until disease progression or death</Timeframe></Measure><Measure><Description>Adverse events; vital signs; physical examination; laboratory tests</Description><Timeframe>In the double-blind treatment period, every 4 weeks; open treatment period, every 12 weeks, until the end of treatment</Timeframe></Measure><Measure><Description>Blood pregnancy</Description><Timeframe>End of treatment</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The purpose of this randomized, multicenter, double-blind, placebo-controlled, phase III study of &lt;ulink linkType="Drug" linkID="83537"&gt;donafenib&lt;/ulink&gt; (CM-4307), an oral multikinase inhibitor that targets Raf kinase and      receptor tyrosine kinases, is to assess efficacy and safety in patients with      131I-refractory/resistant differentiated thyroid cancer.&lt;/para&gt;&lt;para&gt;The trial is to evaluate PFS for the treatment of locally advanced/metastatic radioactive iodine refractory differentiated thyroid cancer (RAIR-DTC) with donafenib tosylate. &lt;/para&gt;&lt;para&gt;Secondary objectives are to evaluate:&lt;br/&gt;Efficacy of donafenib in the treatment of RAIR-DTC in OS , TTP, DCR, ORR.&lt;br/&gt;Safety.&lt;br/&gt;Changes in patient's quality of life scores.&lt;br/&gt;Monitoring of Tg, TgAb levels changes.&lt;br/&gt;PFS of the two experimental groups from blinding until disease progression.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This trial consist of two treatment arms:&lt;br/&gt;Arm 1 (experimental: donafenib): patients will receive donafenib 300 mg bid for each 28 days cycle (100 mg/tablet, three tablets/time under fasting in double-blind period: if the patient is unable to tolerate toxic reactions and will not ease after dose adjustment, discontinue the drug, first appearance of imaging progress, uncovered by the researchers and decided whether to continue to give tonic acid tablets of tonamide treatment).  Open period: after continuing to intolerance or progress in double blind treatment period, for progress but tolerance into open therapy period for donafenib will be evaluated by investigator. The investigator will believe that the patient is still benefiting and, if voluntary, will continue to receive treatment with donafenib phenotype until progression or intolerability.&lt;br/&gt;Arm 2 (placebo-comparator): patients will receive  placebo 300 mg bid for each 28 days cycle (100 mg/tablet, three tablets/time under fasting in double-blind period: if the patient is unable to tolerate toxic reactions and will not ease after dose adjustment, discontinue the drug. If the patient  first showed radiologically confirmed disease progression [RECIST V1.1, confirmed by the IRC], the investigator will be uncovered the blindness). Open period: if the progress has been made and the patients, he or she will  be transferred to a treatment with donafenib until it progresses again or becomes intolerable.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Peking Union Medical College Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Name>Lin Yan Song, MD</Name></Contact></Contacts></Site><Site><Name>eijing Union Medical College Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Beijing University First Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Chinese Academy of Medical Sciences Cancer Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Third People's Liberation Army Hospital</Name><Address1>Beijing</Address1><Address2>Beijing</Address2><CountrySubDivision>Beijing</CountrySubDivision><Contacts/></Site><Site><Name>Jilin University Sino-Japanese Friendship Hospital</Name><Address1>Changchun</Address1><Address2>Jilin</Address2><CountrySubDivision>Jilin</CountrySubDivision><Contacts/></Site><Site><Name>Hunan Cancer Hospital</Name><Address1>Changsha</Address1><Address2>Henan</Address2><CountrySubDivision>Henan</CountrySubDivision><Contacts/></Site><Site><Name>West China Hospital of Sichuan University</Name><Address1>Chengdu</Address1><Address2>Sichuan</Address2><CountrySubDivision>Sichuan</CountrySubDivision><Contacts/></Site><Site><Name>First Affiliated Hospital of Fujian Medical University</Name><Address1>Fuzhou</Address1><Address2>Fujian</Address2><CountrySubDivision>Fujian</CountrySubDivision><Contacts/></Site><Site><Name>Southern Medical University Nanfang Hospital</Name><Address1>Guangzhou</Address1><Address2>Guangdong</Address2><CountrySubDivision>Guangdong</CountrySubDivision><Contacts/></Site><Site><Name>Shaoyifu Hospital, School of Medicine, Zhejiang University</Name><Address1>Hangzhou</Address1><Address2>Zhejiang</Address2><CountrySubDivision>Zhejiang</CountrySubDivision><Contacts/></Site><Site><Name>Zhejiang Cancer Hospital</Name><Address1>Hangzhou</Address1><Address2>Zhejiang</Address2><CountrySubDivision>Zhejiang</CountrySubDivision><Contacts/></Site><Site><Name>Harbin Medical University Affiliated Tumor Hospital</Name><Address1>Harbin</Address1><Address2>Heilongjiang</Address2><CountrySubDivision>Heilongjiang</CountrySubDivision><Contacts/></Site><Site><Name>Anhui Provincial Hospital</Name><Address1>Hefei</Address1><Address2>Anhui</Address2><CountrySubDivision>Anhui</CountrySubDivision><Contacts/></Site><Site><Name>The Second Affiliated Hospital of Anhui Medical University</Name><Address1>Hefei</Address1><Address2>Anhui</Address2><CountrySubDivision>Anhui</CountrySubDivision><Contacts/></Site><Site><Name>Yunnan Cancer Hospital</Name><Address1>Kunming</Address1><Address2>Yunnan</Address2><CountrySubDivision>Yunnan</CountrySubDivision><Contacts/></Site><Site><Name>Jiangxi Cancer Hospital</Name><Address1>Nanchang</Address1><Address2>Jiangxi</Address2><CountrySubDivision>Jiangxi</CountrySubDivision><Contacts/></Site><Site><Name>Jiangsu Provincial People's Hospital</Name><Address1>Nanjing</Address1><Address2>Jiangsu</Address2><CountrySubDivision>Jiangsu</CountrySubDivision><Contacts/></Site><Site><Name>Fudan University Cancer Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>Shanghai Sixth People's Hospital</Name><Address1>Shanghai</Address1><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site><Site><Name>Hebei Cancer Hospital</Name><Address1>Shijiazhuang</Address1><Address2>Hebei</Address2><CountrySubDivision>Hebei</CountrySubDivision><Contacts/></Site><Site><Name>Shanxi Medical University First Hospital</Name><Address1>Taiyuan</Address1><Address2>Shanxi</Address2><CountrySubDivision>Shanxi</CountrySubDivision><Contacts/></Site><Site><Name>Tianjin Medical University General Hospital</Name><Address1>Tianjin</Address1><Address2>Tianjin</Address2><CountrySubDivision>Tianjin</CountrySubDivision><Contacts/></Site><Site><Name>Huazhong University of Science Tongji Hospital, Tongji Medical College</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><CountrySubDivision>Hubei</CountrySubDivision><Contacts/></Site><Site><Name>Huazhong University of Science and Technology Union Hospital of Tongji Medical College</Name><Address1>Wuhan</Address1><Address2>Hubei</Address2><CountrySubDivision>Hubei</CountrySubDivision><Contacts/></Site><Site><Name>The First Affiliated Hospital of Xi'an Jiaotong University</Name><Address1>Xi'an</Address1><Address2>Shaanxi</Address2><CountrySubDivision>Shaanxi</CountrySubDivision><Contacts/></Site><Site><Name>Henan Cancer Hospital</Name><Address1>Zhengzhou</Address1><Address2>Henan</Address2><CountrySubDivision>Henan</CountrySubDivision><Contacts/></Site><Site><Name>Henan Provincial People's Hospital</Name><Address1>Zhengzhou</Address1><Address2>Henan</Address2><CountrySubDivision>Henan</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Thyroid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7969">Subjects with Differentiated Thyroid Cancer (DTC)</PatientSegment><SubSegments><SubSegment id="7970">Subjects with papillary thyroid cancer</SubSegment><SubSegment id="7971">Subjects with follicular thyroid cancer</SubSegment><SubSegment id="7972">Subjects with hurthle cell carcinoma of thyroid</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7977">Subjects with Locally Advanced Thyroid Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7978">Subjects with Metastatic Thyroid Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7979">Subjects with Resectable Thyroid Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="7984">Subjects with Treatment Resistant Disease</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03602495</Identifier></Identifiers></Registry><Registry><Name id="1039">Center for Drug Evaluation</Name><Identifiers><Identifier>CTR20180191</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thyroid tumor" id="12238"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thyroid tumor" id="12290"><Endpoint>Assessment of Disease Progression</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thyroid tumor" id="12301"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Thyroid tumor" id="12309"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Thyroid tumor" id="12310">Assessment of Efficacy</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Thyroid tumor" id="12235"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12238"><Endpoint>Assessment of Progression Free Survival (PFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12239"><Endpoint>Assessment of Survival</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12242"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Thyroid tumor" id="12243">Assessment of objective/overall response rate (ORR)</SubEndpoint><SubEndpoint disease="Thyroid tumor" id="12244">Assessment of Partial Response (PR)</SubEndpoint><SubEndpoint disease="Thyroid tumor" id="12245">Assessment of Complete Response</SubEndpoint><SubEndpoint disease="Thyroid tumor" id="12246">Assessment of Stable Disease</SubEndpoint><SubEndpoint disease="Thyroid tumor" id="12251">Assessment of disease control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12255"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Thyroid tumor" id="31768">Assessment by FACT-General (FACT-G)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12273"><Endpoint>Assessment of Antibodies</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12290"><Endpoint>Assessment of Disease Progression</Endpoint><SubEndpoints><SubEndpoint disease="Thyroid tumor" id="12291">Assessment of time to disease progression (TTP)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12292"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12294"><Endpoint>Assessment of adverse events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12301"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12304"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12305"><Endpoint>Assessment of Physical Examination</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12306"><Endpoint>Assessment of Vital Signs</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Thyroid tumor" id="12309"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Thyroid tumor" id="12310">Assessment of Efficacy</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thyroid tumor" id="8314"><Criterion>Subjects with Differentiated Thyroid Cancer (DTC)</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8315">Subjects with papillary thyroid cancer</SubCriterion><SubCriterion disease="Thyroid tumor" id="8316">Subjects with follicular thyroid cancer</SubCriterion><SubCriterion disease="Thyroid tumor" id="8317">Subjects with hurthle cell carcinoma of thyroid</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8322"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Thyroid tumor" id="8323"><Criterion>Subjects with Advanced/Metastatic Cancer</Criterion></Inclusion><Inclusion disease="Thyroid tumor" id="8324"><Criterion>Subjects with Resectable Thyroid Cancer</Criterion></Inclusion><Inclusion disease="Thyroid tumor" id="8326"><Criterion>Subjects with Measurable Disease</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8328">Subjects with disease measurable by imaging techniques</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8331"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8334">Subjects with life expectancy of three months or more</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8338"><Criterion>Subjects with Protocol Specified Performance Status </Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8339">Subjects with ECOG/WHO/Zubrod score performance status of 0</SubCriterion><SubCriterion disease="Thyroid tumor" id="8340">Subjects with ECOG/WHO/Zubrod score performance status of 1</SubCriterion><SubCriterion disease="Thyroid tumor" id="8341">Subjects with ECOG/WHO/Zubrod score performance status of 2</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8356"><Criterion>Subjects with Progressive/Treatment Refractory Disease</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="12903">Subjects with radioactive iodine refractory thyroid cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8357"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8358">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Thyroid tumor" id="8359">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8364"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8369">Subjects recovered from prior therapy/therapies</SubCriterion><SubCriterion disease="Thyroid tumor" id="8373">Protocol specified criteria for females</SubCriterion><SubCriterion disease="Thyroid tumor" id="8374">Subjects with ability to administer the medications as required</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="8383"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Thyroid tumor" id="34038"><Criterion>Subjects with Protocol Specified Renal Function</Criterion></Inclusion><Inclusion disease="Thyroid tumor" id="34119"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8371">Non Pregnant/Non lactating women</SubCriterion><SubCriterion disease="Thyroid tumor" id="8372">Subjects with adequate contraception</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="34425"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8366">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thyroid tumor" id="34898"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="8368">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thyroid tumor" id="9871"><Criterion>Subjects with Medullary Thyroid Cancer (MTC)</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9872"><Criterion>Subjects with Undifferentiated/Anaplastic Thyroid Cancer (ATC)</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9878"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9879"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9880"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9881">Subjects co-morbid with HIV infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="9889"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9893">Subjects with abnormal pulmonary functions</SubCriterion><SubCriterion disease="Thyroid tumor" id="9894">Subjects with abnormal hematological status</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="9898"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9900">Subjects with hypersensitivity/contraindication to targeted therapy agents</SubCriterion><SubCriterion disease="Thyroid tumor" id="9903">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="9906"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9907">Subjects with history of/scheduled for chemotherapy</SubCriterion><SubCriterion disease="Thyroid tumor" id="9908">Subjects with history of targeted therapy</SubCriterion><SubCriterion disease="Thyroid tumor" id="9911">Subjects with history of radiotherapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="9914"><Criterion>Subjects with History of Treatment with Non-chemotherapeutic Drugs</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9915"><Criterion>Subjects with Therapy Associated Toxicity</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="9918"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9922">Subjects with medical condition interfering with the study protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="25678"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9924">Subjects with prior/current participation in any investigational study</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="26345"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9892">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="26395"><Criterion>Subjects by disease severity</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="26823"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9909">Subjects with history of biologic therapy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="27487"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="27668"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Thyroid tumor" id="27971"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9921">Subjects with inability/unwillingness to comply with the protocol</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thyroid tumor" id="29410"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion><SubCriteria><SubCriterion disease="Thyroid tumor" id="9931">Subjects with history of drug/substance abuse</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2020-03-31T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-07-18T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-07-30T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="349425"><TitleDisplay>Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinic Characterization</TitleDisplay><TitleOfficial>Cohort of Patients With Pelvic Gynecological Cancer: Constitution of a Collection of Biological Samples With Radioclinic Characterization</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03622983</Identifier><Identifier type="Organisational Study">PELVIMASS2</Identifier><Identifier type="Secondary Organisational">2016-A00613-48</Identifier><Identifier type="Trial Acronym">PELVIMASS2</Identifier></Identifiers><Indications><Indication id="651">Cancer</Indication></Indications><BiomarkerNames><BiomarkerName id="36136" role="Disease marker" type="Genomic;Proteomic">Cytokines</BiomarkerName><BiomarkerName id="46244" role="Disease marker" type="Genomic">Circulating tumor DNA</BiomarkerName><BiomarkerName id="52234" role="Disease marker" type="Genomic">Circulating microRNA</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1065442" type="Company"><TargetEntity id="5037142499" type="organizationId">Centre Hospitalier Intercommunal Creteil</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1065442">Centre Hospitalier Intercommunal Creteil</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Female</Term></TermsPatientSelection><TrialCategories><Category>Pathophysiology</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Prospective</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>500</PatientCountEnrollment><DateStart>2017-05-01T00:00:00Z</DateStart><DateEnd type="estimated">2032-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T16:43:15Z</DateChangeLast><DateAdded>2018-08-14T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Email>cyril.touboul@chicreteil.fr</Email><Name>Cyril Touboul</Name><Phone>+33145175543</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Diagnosis of pelvic gynecological cancer posed on initial histological analysis or during recurrence&lt;/li&gt;&lt;li&gt;Age &gt;/= 18 years&lt;/li&gt;&lt;li&gt;Affiliation to the general social security scheme;&lt;/li&gt;&lt;li&gt;Consent signed&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Refusal of the patient&lt;/li&gt;&lt;li&gt;Non-affiliation to the general social security scheme&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Circulating tumor DNA</Description><Timeframe>Two years</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Tumoral DNA</Description><Timeframe>Day of surgery</Timeframe></Measure><Measure><Description>Circulating MicroRNA</Description><Timeframe>Ten years</Timeframe></Measure><Measure><Description>Circulating MicroRNA</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Circulating MicroRNA</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Circulating cytokines</Description><Timeframe>Ten years</Timeframe></Measure><Measure><Description>Circulating cytokines</Description><Timeframe>Two years</Timeframe></Measure><Measure><Description>Circulating cytokines</Description><Timeframe>Five years</Timeframe></Measure><Measure><Description>Circulating tumor DNA</Description><Timeframe>Ten years</Timeframe></Measure><Measure><Description>Circulating tumor DNA</Description><Timeframe>Five years</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study will permit to collect      biological samples and detailed clinical data that will allow to test hypothesis and develop      a personalized medicine based on clinical and biological characteristics of patients. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with pelvic gynecological cancer followed in the CHi creteil hospital will be included and observed in this study. Recovery of surgical waste during surgery will be planned in the current care and clinical data collection.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="France"><Sites><Site><Name>CHI Creteil</Name><Address1>Créteil</Address1><Address3>94000</Address3><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><Contacts><Contact type="Facility contact"><Email>cyril.touboul@chicreteil.fr</Email><Name>cyril Touboul, MD</Name><Phone>+33145175543</Phone></Contact></Contacts></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Solid tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="7966">Subjects with Relapsed/Recurrent Solid Tumors</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03622983</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Solid tumor" id="15254"><Endpoint>Assessment of Biomarkers</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Solid tumor" id="15245"><Endpoint>Assessment of Inflammatory &amp; Oxidative Stress Markers</Endpoint><SubEndpoints><SubEndpoint disease="Solid tumor" id="15246">Assessment of inflammatory/proinflammatory cytokine levels</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15254"><Endpoint>Assessment of Biomarkers</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Solid tumor" id="15270"><Endpoint>Pharmacogenetic/Pharmacogenomics Analysis</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Solid tumor" id="13128"><Criterion>Subjects with Relapsed/Recurrent Disease</Criterion></Inclusion><Inclusion disease="Solid tumor" id="13137"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Solid tumor" id="34423"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13138">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Solid tumor" id="34896"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="13140">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Solid tumor" id="10743"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Solid tumor" id="25667"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Solid tumor" id="10744">Subjects with inability/unwillingness to provide informed consent</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2022-04-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-08-01T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-08-14T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="353372"><TitleDisplay>A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide (NT-Pro BNP) in Acute Heart Failure</TitleDisplay><TitleOfficial>A Health Economic Evaluation of Using N-Terminal Pro Brain Natriuretic Peptide (NT-pro BNP) for Management of Acute Heart Failure in a Tertiary Referral Hospital in Jakarta, Indonesia</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03669198</Identifier><Identifier type="Organisational Study">HFBG</Identifier></Identifiers><Indications><Indication id="55">Cardiac failure</Indication></Indications><BiomarkerNames><BiomarkerName id="106" role="Therapeutic effect marker" type="Proteomic">N-terminal Pro Brain Natriuretic Peptide</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>biomarker's guided therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>diagnostic test</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1105220" type="Company"><TargetEntity id="5044363667" type="organizationId">Fakultas Kedokteran Universitas Indonesia</TargetEntity></SourceEntity><SourceEntity id="55" type="ciIndication"><TargetEntity id="I50" type="ICD10"/><TargetEntity id="10007554" type="MEDDRA"/><TargetEntity id="D006333" type="MeSH"/><TargetEntity id="-1323949873" type="omicsDisease"/><TargetEntity id="237" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1105220">Faculty of Medicine, University of Indonesia</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biomarker identification</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Single Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>56</PatientCountEnrollment><DateStart>2017-11-01T00:00:00Z</DateStart><DateEnd type="actual">2018-05-31T00:00:00Z</DateEnd><DateChangeLast>2018-10-12T02:37:16Z</DateChangeLast><DateAdded>2018-09-17T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Heart Failure Biomarker Group</Affiliation><Name>Prima Almazini, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients aged 18 to 75 years&lt;/li&gt;&lt;li&gt;The primary diagnosis at the Emergency Department (ED) is acute decompensated heart failure (ADHF)&lt;/li&gt;&lt;li&gt;Using the national health insurance&lt;/li&gt;&lt;li&gt;Willing to be followed for 3 months&lt;/li&gt;&lt;li&gt;Willing to sign informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Severe life-threatening comorbidities with a life expectancy of&amp;lt; 2 years&lt;/li&gt;&lt;li&gt;Acute heart failure other than ADHF such as acute pulmonary edema, acute heart failure in the setting of acute coronary syndrome, cardiogenic shock, right heart failure, and hypertensive heart failure&lt;/li&gt;&lt;li&gt;ADHF accompanied by sepsis, liver disease, lung disease with severe radiological findings, mechanical complications of acute myocardial infarction, aortic dissection, congenital heart disease, idiopathic pulmonary hypertension, lung emboli, severe respiratory failure, and severe burns&lt;/li&gt;&lt;li&gt;Patients admitted to ICVCU (Intensive Cardiovascular Care Unit)&lt;/li&gt;&lt;li&gt;Patients did not take medication regularly and controls routinely&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mortality rate: percentage of patients who are death post discharge (%)</Description><Timeframe>3 months after discharge</Timeframe></Measure><Measure><Description>Rehospitalization rate: percentage of patients who readmit and are hospitalized because of heart failure (%)</Description><Timeframe>3 months after discharge</Timeframe></Measure><Measure><Description>Emergency department visit: percentage of patients who readmit and are not hospitalized because of heart failure (%)</Description><Timeframe>3 months after discharge</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cost: total cost include cost of hospitalization, cost of rehospitalization and cost of emergency department visit (Rupiah)</Description><Timeframe>Admission to hospital until 3 months after discharge</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was a health economic evaluation of using N-Terminal Pro Brain Natriuretic Peptide (NT-pro BNP) for management of acute heart failure in a tertiary referral hospital in Jakarta, Indonesia. Investigators evaluate two alternative treatments which one that more cost-effective between biomarker's guided therapy and without biomarker.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study consist of two groups:&lt;br/&gt;Group 1: patients who be included in NT-pro BNP group would be examined NT-pro BNP in the ED to determine the baseline level and prior to discharge for determine the percent decline from baseline level. Patients in the NT-pro BNP group could be discharged if the NT-pro BNP level decreased &gt;/=  30% from baseline. If the target percent decline was not met, investigators would do intensification of therapy according to the algorithm. Randomized patients would be followed during treatment up to 90 days post-discharge to assess short-term outcomes and costs.&lt;br/&gt;Group 2: patients in the control group would be managed based on clinical judgment without use of NT-pro BNP testing. In the control group, the decision whether patient can be discharged or not would be determined by cardiologist in charge of the patient based on clinical assessment.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Indonesia"><Sites><Site><Name>Heart Failure Biomarker Group</Name><Address1>Jakarta</Address1><Address2>DKI Jakarta</Address2><Address3>10420</Address3><CountrySubDivision>DKI Jakarta</CountrySubDivision><Contacts/></Site><Site><Name>Tertiary Referral Hospital</Name><Address1>Jakarta</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Cardiac failure</Disease><PatientSegments><PatientSegment><PatientSegment id="59">Acute Decompensated Heart Failure (ADHF) Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03669198</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Cardiac failure" id="819"><Endpoint>Assessment of hospitalization</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="823">Hospitalization due to other cardiovascular events</SubEndpoint><SubEndpoint disease="Cardiac failure" id="830">Hospitalization due to heart failure</SubEndpoint><SubEndpoint disease="Cardiac failure" id="837">Assessment of Hospitalization Rates</SubEndpoint><SubEndpoint disease="Cardiac failure" id="838">Assessment of number of emergency department visits</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Cardiac failure" id="973"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Cardiac failure" id="28672"><Endpoint>Health Economic Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="28677">Cost of therapy/other medical costs</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Cardiac failure" id="641"><Endpoint>Assessment of Cardiac Markers</Endpoint><SubEndpoints><SubEndpoint disease="Cardiac failure" id="656">Plasma NT-pro-BNP</SubEndpoint></SubEndpoints></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Cardiac failure" id="261"><Criterion>Subjects with Decompensated Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="271"><Criterion>Subjects with Acute/Sub Acute Heart Failure</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="33672"><Criterion>Subjects Fulfilling Protocol Specific Diagnostic Criteria</Criterion></Inclusion><Inclusion disease="Cardiac failure" id="34444"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="485">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Cardiac failure" id="34921"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="499">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Cardiac failure" id="412"><Criterion>Subjects with Congestive Heart Failure (CHF)</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="1383">Right heart failure</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="437"><Criterion>Subjects with  Coronary Artery Disease (CAD)/Ischemic Heart Disease (IHD)</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="438">Subjects with acute coronary syndrome</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="469"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="474">Subjects co-morbid with cardiogenic shock</SubCriterion><SubCriterion disease="Cardiac failure" id="475">Subjects co-morbid with congenital heart disease</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="556"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Cardiac failure" id="640"><Criterion>Subjects co-morbid with infections</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="646">Subjects co-morbid with sepsis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="679"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="699">Conditions/co-morbidity that limit survival or Limited Life expectancy</SubCriterion><SubCriterion disease="Cardiac failure" id="802">Recent/current hospitalization</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="25073"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="581">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27043"><Criterion>Subjects with history of cardiovascular disease/disorder</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="441">Subjects with history of myocardial infarction</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27060"><Criterion>Subjects co-morbid with Respiratory Diseases/Disorders</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="572">Subjects co-morbid with pulmonary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Cardiac failure" id="27844"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Cardiac failure" id="823">Unwillingness/inability to comply with study requirements/protocol</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2018-02-15T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2018-09-11T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2018-09-17T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="359961"><TitleDisplay>A clinical study to assess TPST-1120 in the treatment of patients with advanced solid tumors</TitleDisplay><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers/><Indications><Indication id="3713">Advanced solid tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>TPST-1120</Name><Drug id="109918">TPST-1120</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="109918">TPST-1120</Drug><IndicationsPioneer/><Companies><Company><Company id="1162307">Tempest Therapeutics Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3034" type="Action"><TargetEntity id="890" type="Mechanism">PPARalpha Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="15">Planned</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1162307">Tempest Therapeutics Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="3034">PPAR alpha antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="1545">Anticancer</Class><Class id="1589">Apoptosis stimulator</Class><Class id="7293">Synergist</Class></Class><Technologies><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><DateChangeLast>2018-11-15T22:01:15Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with advanced solid tumors&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety</Description></Measure><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This is a clinical study to assess &lt;ulink linkType="Drug" linkID="109918"&gt;TPST-1120&lt;/ulink&gt; in the treatment of patients with advanced solid tumors [&lt;ulink linkType="Reference" linkID="2094256"&gt;2094256&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;As of November 2018, &lt;ulink linkType="Company" linkID="1162307"&gt;Tempest Therapeutics Inc&lt;/ulink&gt; planned to initiate a new clinical trial in early 2019 [&lt;ulink linkType="Reference" linkID="2094256"&gt;2094256&lt;/ulink&gt;].&lt;br/&gt;&lt;br/&gt;&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="365353"><TitleDisplay>RATLE da Vinci</TitleDisplay><TitleOfficial>A pilot study of robot-assisted esophagectomy with nodal dissection for esophageal cancer using the da Vinci Xi surgical system</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">UMIN000035364</Identifier></Identifiers><Indications><Indication id="1011">Esophagus tumor</Indication><Indication id="307">Squamous cell carcinoma</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Da Vinci Xi surgical system</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>lymphadenectomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>robotic esophagectomy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="25425" type="Company"><TargetEntity id="5035524271" type="organizationId">National Cancer Center</TargetEntity></SourceEntity><SourceEntity id="1011" type="ciIndication"><TargetEntity id="C15" type="ICD10"/><TargetEntity id="150" type="ICD9"/><TargetEntity id="10061882" type="MEDDRA"/><TargetEntity id="D004938" type="MeSH"/><TargetEntity id="-1694229607" type="omicsDisease"/><TargetEntity id="598" type="siCondition"/></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"/><TargetEntity id="D002294" type="MeSH"/><TargetEntity id="-1612557995" type="omicsDisease"/><TargetEntity id="676" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase Not Applicable</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="25425">Japanese National Cancer Center</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>10</PatientCountEnrollment><DateStart>2018-04-02T00:00:00Z</DateStart><DateChangeLast>2019-01-08T08:32:41Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>National Cancer Center Hospital ; Division of Esophageal Surgery</Affiliation><Email>jkanamor@ncc.go.jp</Email><Name>Jun Kanamori</Name><Phone>03-3542-2511</Phone></Contact><Contact type="Scientific contact"><Affiliation>National Cancer Center Hospital ; Division of Esophageal Surgery</Affiliation><Email>hdaiko@ncc.go.jp</Email><Name>Hiroyuki Daiko</Name><Phone>03-3542-2511</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Staging of tumor is performed according to the UICC/AJCC seventh edition of the TNM Classification of malignant tumors&lt;/li&gt;&lt;li&gt;To be eligible for this study, patients must fulfill all of the following criteria:&lt;ul&gt;&lt;li&gt;Histologically proven squamous cell carcinoma, adenosquamous carcinoma or basaloid cell carcinoma&lt;/li&gt;&lt;li&gt;Primary tumor located in thoracic esophagus. Tumor which is centrally located &gt;  2 cm below of the esophago-gastric junction is ineligible&lt;/li&gt;&lt;li&gt;Either single lesion or multiple lesions. Second tumors in cervical esophagus which is indicated for EMR/ESD are also eligible&lt;/li&gt;&lt;li&gt;Clinical stages I, II or III (excluding T4b) based on the seventh UICC-TNM classification&lt;/li&gt;&lt;li&gt;Aged 20 to 80 years&lt;/li&gt;&lt;li&gt;No prior lateral thoracotomy (or thoracoscopic surgery) on right side or no prior lobectomy or more extended surgery on left side was performed&lt;/li&gt;&lt;li&gt;No prior treatment against esophageal cancer except for:&lt;ul&gt;&lt;li&gt;Non-curative resection for primary tumor by EMR/ESD&lt;/li&gt;&lt;li&gt;Clinical stage IB, II or III esophageal cancer patients who received&amp;lt;/= two courses   of cisplatin plus fluorouracil&lt;/li&gt;&lt;li&gt;Curative resection had been achieved by EMR/ESD against metachronous multiple cancer&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No prior treatment of chemotherapy or radiation therapy against any other malignancies. History of adjuvant hormonal therapy after &gt;  one year from the last administration is eligible&lt;/li&gt;&lt;li&gt;No prior gastrectomy&lt;/li&gt;&lt;li&gt;Sufficient organ functions:&lt;ul&gt;&lt;li&gt;WBC&amp;gt;/= 3000/mm3&lt;/li&gt;&lt;li&gt;Platelet&amp;gt;/= 100000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin&amp;gt;/= 10mg/dl&lt;/li&gt;&lt;li&gt;AST&amp;lt;/= 100 IU/l , ALT &amp;lt;/= 100 IU/l&lt;/li&gt;&lt;li&gt;T.Bil&amp;lt;/= 2.0 mg/dl&lt;/li&gt;&lt;li&gt;Creatinine&amp;lt;/= 1.5 mg/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Synchronous or metachronous (within five years) malignancies except for carcinoma in situ or mucosal tumors curatively treated with local therapy&lt;/li&gt;&lt;li&gt;Pregnancy or breast-feeding&lt;/li&gt;&lt;li&gt;Severe psychiatric disease&lt;/li&gt;&lt;li&gt;Continuous systemic steroid or immune-suppressive drug therapy&lt;/li&gt;&lt;li&gt;Unstable angina pectoris, or history of myocardial infarction within 6 months&lt;/li&gt;&lt;li&gt;Poorly controlled hypertension&lt;/li&gt;&lt;li&gt;Poorly controlled diabetes mellitus in spite of continuous use of insulin&lt;/li&gt;&lt;li&gt;BMI  &gt;/= 30&lt;/li&gt;&lt;li&gt;Other reasons of not to perform robotic esophagectomy&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The achievement rate of robotic esophagectomy</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The incidence of post-operative laryngeal nerve palsy and other complications</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study would aim to elucidate the safety of robotic esophagectomy with lymphadenectomy for resectable esophageal cancer.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients robotic would undergo esophagectomy with lymphadenectomy for treating resectable esophageal cancer.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Name>National Cancer Center Hospital</Name><Address1>Tokyo</Address1><Address3>104-0045</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Esophagus tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="9473">Subjects with Squamous Cell Carcinoma of Esophagus</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9480">Subjects with Locally Advanced Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="9490">Subjects with Resectable Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10854">Subjects with Stage I Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10855">Subjects with Stage II Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10856">Subjects with Stage III Esophageal Cancer</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="19058">Treatment Naive Subjects</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1003">University Hospital Medical Information Network (UMIN)</Name><Identifiers><Identifier type="Secondary Organisational">UMIN000035364</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Esophagus tumor" id="12035"><Endpoint>Protocol Specified Other Endpoints</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Esophagus tumor" id="12015"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="12040">Assessment of complication rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="12035"><Endpoint>Protocol Specified Other Endpoints</Endpoint><SubEndpoints><SubEndpoint disease="Esophagus tumor" id="12045">Assessment of neurological status</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Esophagus tumor" id="45199"><Endpoint>Clinical Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Esophagus tumor" id="7747"><Criterion>Subjects with Squamous Cell Carcinoma of Esophagus</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7751"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7753"><Criterion>Subjects with Stage I Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7756"><Criterion>Subjects with Stage II Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7759"><Criterion>Subjects with Stage III Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7768"><Criterion>Subjects with Resectable Esophageal Cancer</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7801"><Criterion>Subjects with Normal/Acceptable Organ Function</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7802">Subjects with normal/acceptable hematological functions</SubCriterion><SubCriterion disease="Esophagus tumor" id="7803">Subjects with normal/acceptable liver function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="7808"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="7826"><Criterion>Subjects with Protocol Specified Laboratory Values</Criterion></Inclusion><Inclusion disease="Esophagus tumor" id="34025"><Criterion>Subjects with Protocol Specified Renal Function</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7804">Subjects with normal/acceptable renal function</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="34406"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7809">Subjects willing/able to provide informed consent/assent</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="34879"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="7811">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Esophagus tumor" id="35115"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="35116">Chemotherapy naive subjects</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Esophagus tumor" id="9329"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9330"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="9369"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9379">Protocol specified exclusion criteria for females</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="9384"><Criterion>Subjects with abnormal/unacceptable anthropometric assessment</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="26149"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="26360"><Criterion>Subjects with Abnormal Organ Function</Criterion><SubCriteria><SubCriterion disease="Esophagus tumor" id="9343">Subjects with abnormal/unacceptable cardiac function</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Esophagus tumor" id="26840"><Criterion>Subjects with History of/Scheduled for Disease Specific Pharmacological Therapy</Criterion></Exclusion><Exclusion disease="Esophagus tumor" id="29277"><Criterion>Subjects with history of psychiatric disease/disorder</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="365484"><TitleDisplay>Oral Direct Factor Xa Inhibitor (Rivaroxaban) in Patients With Post-thrombotic Syndrome (PTS) after Stent Implantation</TitleDisplay><TitleOfficial>Oral Direct Factor Xa Inhibitor (Rivaroxaban) in Patients With Post-thrombotic Syndrome (PTS) after Stent Implantation</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Other">ChiCTR1800020395</Identifier></Identifiers><Indications><Indication id="574">Deep vein thrombosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>rivaroxaban</Name><Drug id="32677">rivaroxaban</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>warfarin</Name><Drug id="44375">warfarin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="32677">rivaroxaban</Drug><IndicationsPioneer/><Companies><Company><Company id="1085780">Shanghai 9th People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44375">warfarin</Drug><IndicationsPioneer/><Companies><Company><Company id="1085780">Shanghai 9th People's Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="32677" type="Drug"><TargetEntity id="307796" type="siDrug">Rivaroxaban</TargetEntity></SourceEntity><SourceEntity id="44375" type="Drug"><TargetEntity id="91527" type="siDrug">Warfarin sodium</TargetEntity></SourceEntity><SourceEntity id="1085780" type="Company"><TargetEntity id="5040056106" type="organizationId">Shanghai Ninth People's Hospital Shanghai Jiaotong University School of Medicine</TargetEntity></SourceEntity><SourceEntity id="574" type="ciIndication"><TargetEntity id="10051055" type="MEDDRA"/><TargetEntity id="321" type="siCondition"/></SourceEntity><SourceEntity id="10583" type="Action"><TargetEntity id="2845" type="Mechanism">Vitamin K Epoxide Reductase (VKER, VKOR) Inhibitors</TargetEntity><TargetEntity id="6689" type="Mechanism">Vitamin K Epoxide Reductase (VKER, VKOR) (Bacterial) Inhibitors</TargetEntity></SourceEntity><SourceEntity id="111" type="Action"><TargetEntity id="502" type="Mechanism">Thrombin Inhibitors</TargetEntity><TargetEntity id="4384" type="Mechanism">Anti-Thrombin</TargetEntity></SourceEntity><SourceEntity id="113" type="Action"><TargetEntity id="1624" type="Mechanism">Anti-Factor IXa</TargetEntity><TargetEntity id="2667" type="Mechanism">Coagulation Factor IXa Inhibitors</TargetEntity><TargetEntity id="3316" type="Mechanism">Anti-Factor IX</TargetEntity></SourceEntity><SourceEntity id="114" type="Action"><TargetEntity id="3317" type="Mechanism">Anti-Factor VII</TargetEntity></SourceEntity><SourceEntity id="119" type="Action"><TargetEntity id="5807" type="Mechanism">Anti-Factor X</TargetEntity></SourceEntity><SourceEntity id="120" type="Action"><TargetEntity id="679" type="Mechanism">Coagulation Factor Xa Inhibitors</TargetEntity><TargetEntity id="6421" type="Mechanism">Anti-Factor Xa</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="1">Not yet recruiting</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="1085780">Shanghai 9th People's Hospital</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="10583">Vitamin K epoxide reductase inhibitor</Action><Action id="111">Factor IIa antagonist</Action><Action id="113">Factor IX antagonist</Action><Action id="114">Factor VII antagonist</Action><Action id="119">Factor X antagonist</Action><Action id="120">Factor Xa antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2953">Anti-inflammatory</Class><Class id="449">Antiarrhythmic agent</Class><Class id="659">Coagulation inhibitor</Class></Class><Technologies><Technology id="751">Film coating</Technology><Technology id="898">Formulation powder</Technology><Technology id="743">Granule</Technology><Technology id="585">Oral formulation</Technology><Technology id="594">Oral suspension formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category><Category>Medical device</Category></TrialCategories><TermsDesign><Term>Cohort</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>200</PatientCountEnrollment><DateStart>2019-01-01T00:00:00Z</DateStart><DateEnd type="estimated">2021-12-31T00:00:00Z</DateEnd><DateChangeLast>2019-04-15T11:37:22Z</DateChangeLast><DateAdded>2019-01-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine</Affiliation><Email>luxinwu@aliyun.com</Email><Name>Lu Xin-wu</Name><Phone>+86 13651839016</Phone></Contact><Contact type="Public contact"><Affiliation>Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine</Affiliation><Email>cinder_13@126.com</Email><Name>Yang Xin-rui</Name><Phone>+86 15921515302</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Past history of objectively documented deep vein thrombosis for a minimum of 6 months&lt;/li&gt;&lt;li&gt;Villalta score of &gt;  10&lt;/li&gt;&lt;li&gt;Patients with iliac-femoral vein stenosis or occlusion and treated with stent implantation successfully &lt;/li&gt;&lt;li&gt;Followed by VKA or&lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt; treatment&lt;/li&gt;&lt;li&gt;Age &gt; 18 years old&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Episode of objectively documented deep vein thrombosis occurred&amp;lt; 6 months before recruitment&lt;/li&gt;&lt;li&gt;Childbearing potential without proper contraceptive measures, pregnancy or breast feeding&lt;/li&gt;&lt;li&gt;Active bleeding, recent (&amp;lt;3mo) gastro intestinal(GI) bleeding ,active peptic ulcer, severe liver dysfunction, bleeding diathesis&lt;/li&gt;&lt;li&gt;Recent (&amp;lt; 3 month) internal eye surgery or hemorrhagic retinopathy; recent (&amp;lt; 10 days) major surgery, cataract surgery, trauma, cardio pulmonary resuscitation (CPR), obstetrical delivery, or other invasive procedure&lt;/li&gt;&lt;li&gt;History of stroke or intracranial/intra spinal bleed, tumor, vascular malformation, aneurysm&lt;/li&gt;&lt;li&gt;Active cancer (metastatic, progressive, or treated within the last 6 months)&lt;/li&gt;&lt;li&gt;Uncontrolled hypertension defined as systolic &gt; 175 mmHg and a diastolic &gt; 110 mmHg&lt;/li&gt;&lt;li&gt;Platelet count&amp;lt; 100,000 cells/mm3 or &gt; 700,000 cells/mm3&lt;/li&gt;&lt;li&gt;Life expectancy&amp;lt; 1 year&lt;/li&gt;&lt;li&gt;Anticipated in other clinical study&lt;/li&gt;&lt;li&gt;In the judgment of the clinician, the subject isnt suitable for this study&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Patency: US, CTV, DSA</Description><Timeframe>180 days</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Major bleeding</Description></Measure><Measure><Description>Incidence of deep vein thrombosis</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The objective of this study  is to evaluate the oral direct Factor Xa Inhibitor (&lt;ulink linkType="Drug" linkID="32677"&gt;rivaroxaban&lt;/ulink&gt;) in patients with Post-thrombotic Syndrome (PTS) after stent implantation. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients with PTS (post-thrombotic syndrome) who received stent implantation and completed 6 or 12 months of treatment with rivaroxaban or &lt;ulink linkType="Drug" linkID="44375"&gt;warfarin&lt;/ulink&gt;, VKA (vitamin K antagonist) are eligible for this trial (Einstein-Special study).  &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="China"><Sites><Site><Name>Shanghai Ninth People’s Hospital</Name><Address2>Shanghai</Address2><CountrySubDivision>Shanghai</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Thrombosis</Disease><PatientSegments><PatientSegment><PatientSegment id="7323">Subjects with Venous Thrombosis</PatientSegment><SubSegments><SubSegment id="7396">Subjects with deep vein thrombosis</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Peripheral vascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="10151">Subjects with Venous Thrombosis</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="10157">Subjects with History of PAD Interventions</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1007">Chinese Clinical Trials Registry (ChiCTR)</Name><Identifiers><Identifier>ChiCTR1800020395</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Thrombosis" id="10265"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10273">Assessment of patency of vessel</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21925"><Endpoint>Assessment of Vessel Patency</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Peripheral vascular disease" id="21954"><Endpoint>Imaging/Radiological Assessments</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="22143">Assessment by angiography</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Thrombosis" id="45419"><Endpoint>Imaging/Radiological Assessments</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Thrombosis" id="10242"><Endpoint>Assessment of Thrombotic/Thromboembolic Events</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10243">Assessment of venous thrombosis/thromboembolism</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Thrombosis" id="10256"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Thrombosis" id="10257">Assessment of major bleeding events</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="21834"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21839">Assessment of deep vein thrombosis</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Peripheral vascular disease" id="44794"><Endpoint>Assessment of Hemorrhagic Complications</Endpoint><SubEndpoints><SubEndpoint disease="Peripheral vascular disease" id="21853">Assessment of bleeding complications</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Thrombosis" id="5942"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="6192">Subjects with deep vein thrombosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="5993"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="5995">Subjects on prior/concurrent anticoagulants</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Thrombosis" id="6027"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19226"><Criterion>Subjects with Inclusion Based On Location/Anatomy of Vessel</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="19282"><Criterion>Subjects with History of/Scheduled for Cardiac Surgery/Intervention</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19286">Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19301"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19306">Subjects on antithrombotic agents</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Peripheral vascular disease" id="19315"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Peripheral vascular disease" id="35066"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="19211">Subjects with Venous Thrombosis</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Thrombosis" id="7560"><Criterion>Subjects with Diagnosis of Thrombosis</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7562">Subjects with venous thrombosis</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7578"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7579">Subjects co-morbid with cerebrovascular disease/stroke</SubCriterion><SubCriterion disease="Thrombosis" id="7581">Subjects with malignancy/tumors</SubCriterion><SubCriterion disease="Thrombosis" id="7582">Subjects with ocular diseases/disorders</SubCriterion><SubCriterion disease="Thrombosis" id="7588">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion><SubCriterion disease="Thrombosis" id="7590">Subjects co-morbid with hematological disease/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7584"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7585"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7587"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7596"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7597">Subjects with abnormal hematological tests</SubCriterion><SubCriterion disease="Thrombosis" id="7599">Subjects with abnormal cardiac function tests</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7608"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7612">Subjects with life expectancy of one year or less</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="7637"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7652"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Thrombosis" id="7668"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7670">Protocol specific criteria for exclusion of females</SubCriterion><SubCriterion disease="Thrombosis" id="7673">Subjects not suitable for study as per investigator’s opinion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15950"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15941">Subjects with deep vein thrombosis</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16003">Subjects co-morbid with aneurysm</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15959"><Criterion>Subjects co-morbid with hypertension</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15960"><Criterion>Subjects co-morbid with Hematological/Coagulation Disorders</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15967">Subjects with bleeding</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15968"><Criterion>Subjects co-morbid with Cerebrovascular Disorders/Diseases</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="15973">Subjects co-morbid with stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="15976"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15977"><Criterion>Subjects co-morbid with gastrointestinal diseases/disorders</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15978"><Criterion>Subjects co-morbid with Ocular Disorders/Diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="15989"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16008"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16019">Subjects with abnormal hematology</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="16045"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="16065"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="25354"><Criterion>Subjects with Protocol Specified Life Expectancy</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="25632"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16089">Subjects not suitable to participate as per investigator's discretion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="25676"><Criterion>Subjects with Protocol Specified Participation Status</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7677">Subjects with history of/current participation in other clinical trials</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25761"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16095">Pregnant/lactating women</SubCriterion><SubCriterion disease="Peripheral vascular disease" id="16109">Subjects without adequate contraception</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="25907"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16007">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="26295"><Criterion>Subjects with Abnormal/Unacceptable Clinical Assessments</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16018">Subjects with abnormal vital signs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Peripheral vascular disease" id="26937"><Criterion>Subjects co-morbid with vascular disorders/diseases</Criterion></Exclusion><Exclusion disease="Peripheral vascular disease" id="27932"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Peripheral vascular disease" id="16070">Subjects with inability to comply with the protocol/follow up</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="27969"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Thrombosis" id="7674">Subjects unwilling or unable to comply with the protocol/study requirements</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Thrombosis" id="28355"><Criterion>Subjects with Protocol Specified Reproductive Status</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-01-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="374379"><TitleDisplay>A randomized study to assess whether such site-specific therapy improves outcome compared with empirical chemotherapy in previously untreated patients with cancer of unknown primary site (CUP)</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="651">Cancer</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>standard site-specific therapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="duo"><Interventions><Intervention type="InterventionPrimary"><Name>carboplatin</Name><Drug id="44383">carboplatin</Drug></Intervention><Intervention type="InterventionPrimary"><Name>paclitaxel</Name><Drug id="3803">paclitaxel</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="3803">paclitaxel</Drug><IndicationsPioneer/><Companies><Company><Company id="1059313">West Japan Oncology Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1107695">Japan Agency for Medical Research and Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="44383">carboplatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1059313">West Japan Oncology Group</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="1107695">Japan Agency for Medical Research and Development</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="3803" type="Drug"><TargetEntity id="101438" type="siDrug">Paclitaxel</TargetEntity></SourceEntity><SourceEntity id="44383" type="Drug"><TargetEntity id="125568" type="siDrug">Carboplatin</TargetEntity></SourceEntity><SourceEntity id="1059313" type="Company"><TargetEntity id="5035560630" type="organizationId">West Japan Oncology Group</TargetEntity></SourceEntity><SourceEntity id="1107695" type="Company"><TargetEntity id="5045823858" type="organizationId">Japan Agency for Medical Research and Development</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>0</NumberOfSites><CompaniesSponsor><Company id="1059313">West Japan Oncology Group</Company><Company id="1107695">Japan Agency for Medical Research and Development</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Class><Class id="140">DNA synthesis inhibitor</Class><Class id="1545">Anticancer</Class><Class id="2576">Microtubule stabilizer</Class><Class id="2660">Vasoprotectant</Class><Class id="50">Anticancer alkylating agent</Class><Class id="767">Cell cycle inhibitor</Class></Class><Technologies><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="1647">Natural product</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="746">Solution</Technology></Technologies><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Medical device</Category><Category>Medical procedure</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>130</PatientCountEnrollment><PatientCountEvaluable>130</PatientCountEvaluable><DateChangeLast>2019-04-26T22:01:05Z</DateChangeLast><DateAdded>2019-04-29T00:00:00Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with CUP&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Survival rate</Description><Timeframe>For one-year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Comprehensive gene expression profiling was performed by microarray analysis, and an established algorithm was applied to predict tumor origin</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to to assess whether such site-specific therapy improves outcome compared with empirical chemotherapy in previously untreated patients with cancer of unknown primary site (CUP) [&lt;ulink linkType="Reference" linkID="2132755"&gt;2132755&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In March 2019, results were published. Pancreatic (21%), gastric (21%), and lymphoma (20%) were cancer types most commonly predicted. The one-year survival rate was found to be 44.0 and 54.9% for site-specific treatment and empirical PC (p = 0.264), respectively.  For site-specific treatment versus 12.5 and 4.8 months for empirical PC, median overall and progression-free survival were 9.8 and 5.1 months (p = 0.896 and 0.550, respectively). Median overall survival (16.7 versus 10.6 months; p = 0.116) and progression-free survival (5.5 versus 3.9 months; p = 0.018) were better for predicted more-responsive than less-responsive tumor types [&lt;ulink linkType="Reference" linkID="2132755"&gt;2132755&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients with CUP were randomly assigned (1:1) to receive standard site-specific therapy or empirical &lt;ulink linkType="Drug" linkID="3803"&gt;paclitaxel&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="44383"&gt;carboplatin&lt;/ulink&gt; (PC) [&lt;ulink linkType="Reference" linkID="2132755"&gt;2132755&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries/><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Government</Type><Type>Others</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-29T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="375777"><TitleDisplay>Intestinal Microbiota and Arterial Stiffness</TitleDisplay><TitleOfficial>Intestinal Microbiota and Its Relationship With Vascular Structure and Function and Cardiovascular Risk, Phase I (MIVAS Study)</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="NCT">NCT03900338</Identifier><Identifier type="Organisational Study">GRS 1820/B/18</Identifier><Identifier type="Trial Acronym">MIVAS</Identifier></Identifiers><Indications><Indication id="57">Cardiovascular disease</Indication></Indications><BiomarkerNames><BiomarkerName id="113" role="Disease marker" type="Anthropomorphic">Body Mass Index</BiomarkerName><BiomarkerName id="141" role="Disease marker" type="Structural (imaging)">Carotid artery intima-media</BiomarkerName><BiomarkerName id="146" role="Disease marker" type="Physiological">Ankle-brachial index</BiomarkerName><BiomarkerName id="160" role="Disease marker" type="Physiological">Pulse wave velocity</BiomarkerName><BiomarkerName id="419" role="Disease marker" type="Anthropomorphic">Waist to Hip Ratio</BiomarkerName><BiomarkerName id="2095" role="Disease marker" type="Physiological">Mean arterial pressure</BiomarkerName><BiomarkerName id="3057" role="Disease marker" type="Biochemical">Bile acids and salts</BiomarkerName><BiomarkerName id="11071" role="Disease marker" type="Biochemical">Fatty acids</BiomarkerName><BiomarkerName id="12058" role="Disease marker" type="Anthropomorphic">Total body mass</BiomarkerName><BiomarkerName id="15633" role="Disease marker" type="Biochemical">Ursodeoxycholic acid</BiomarkerName><BiomarkerName id="19068" role="Disease marker" type="Physiological">Cardio ankle vascular index</BiomarkerName></BiomarkerNames><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1074680" type="Company"><TargetEntity id="5038078619" type="organizationId">Consejeria de Sanidad de la Junta de Castilla y Leon</TargetEntity></SourceEntity><SourceEntity id="1096283" type="Company"><TargetEntity id="5042933391" type="organizationId">Fundacion para la Investigacion y Formacion en Ciencias de la Salud en Castilla y Leon</TargetEntity></SourceEntity><SourceEntity id="57" type="ciIndication"><TargetEntity id="10007649" type="MEDDRA"/><TargetEntity id="D002318" type="MeSH"/><TargetEntity id="-1500764314" type="omicsDisease"/><TargetEntity id="182" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 1 Clinical</Phase><RecruitmentStatus id="2">Recruiting</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1096283">Fundacion para la Investigacion y Formacion en Ciencias de la Salud</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1074680">Castilla-León Health Service</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Healthy volunteers accepted</Term></TermsPatientSelection><TrialCategories><Category>Dietary supplement</Category></TrialCategories><TermsDesign><Term>Cross-sectional</Term><Term>Case Control</Term><Term>Observational</Term></TermsDesign><PatientCountEnrollment>324</PatientCountEnrollment><DateStart>2019-04-03T00:00:00Z</DateStart><DateEnd type="estimated">2019-12-30T00:00:00Z</DateEnd><DateChangeLast>2019-06-07T02:04:27Z</DateChangeLast><DateAdded>2019-04-08T00:00:00Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>rimary Care Research Unit - The Alamedilla Center for Health</Affiliation><Name>Luis Garcia-Ortiz</Name></Contact><Contact type="Scientific contact"><Affiliation>Life and Health Sciences Research Institute in Minho University</Affiliation><Name>Pedro Guimaraes Cunha</Name></Contact><Contact type="Scientific contact"><Affiliation>rimary Care Research Unit - The Alamedilla Center for Health</Affiliation><Name>Rita Salvado Martins</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients with &gt; 40 years old who agree to participate in the study and do not meet any of the exclusion criteria&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Participants who are in terminal condition&lt;/li&gt;&lt;li&gt;Participants with a history of cardiovascular disease (ischaemic heart disease or stroke, peripheral arterial disease or Heart Failure)&lt;/li&gt;&lt;li&gt;People with diabetes&lt;/li&gt;&lt;li&gt;Diagnosed renal failure in terminal stages (glomerular filtration rate&amp;lt; 30%)&lt;/li&gt;&lt;li&gt;Chronic inflammatory disease or acute inflammatory process in the past 3 months&lt;/li&gt;&lt;li&gt;Patients treated with oestrogens, testosterone or growth hormone&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Pulse wave velocity: measurement by SphygmoCor System (meters/seg)</Description><Timeframe>One year</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Cardio ankle vascular index: measurement by Vasera device 2000 (not units)</Description><Timeframe>One year</Timeframe></Measure><Measure><Description>Carotid intima-media thickness: measurement by ultrasonography (Sonosite Micromax) (mm)</Description><Timeframe>One year</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of this observational, case-control is to analyze the differences in      intestinal microbiota between patients with and without arterial stiffness, measured by pulse      wave velocity (PWV).&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The investigators      will select 324 subjects, between 30 to 75 years-old, from a database that combine data from      four different studies: Triple A, Early vascular Aging (EVA) and Improving interMediAte Risk      management (MARK) that took place in the Research Unit of La Alamedilla Primary Care Center,      and Guimaraes/ Vizela Study promoted by the Life and Health Sciences Research Institute in      Minho University.&lt;br/&gt;Measurements: 162 Cases will be defined by a Carotid-femoral Pulse Wave Velocity (cf-PWV) &amp;gt; 10      mm/s determined using the SphygmoCor System. 162 controls will be selected by the propensity      score. The composition of the gut microbiome in faecal samples will be determined by      ribosomal ribonucleic acid (16S rRNA) gene sequencing. Other measurements: demographic data,      lifestyle assessment (physical activity, adherence to the Mediterranean diet, alcohol and      tobacco consumption). Anthropometric Variables: Weight, body composition by bioimpedance,      size, body mass index (BMI), waist and hip perimeter, peripheral and central arterial      pressure. Analysis of structure and vascular function and organ lesions target: pulse wave      velocity, cardio-ankle vascular index and ankle-brachial index; Intimal median carotid      thickness, central and peripheral rate of increase, renal and cardiac organic lesion. Blood      analysis: short chain fatty acids, total bile acids, ursodeoxycholic acid. Patients with PWV &gt; 10 and &amp;lt;10 in two different measurements will be observed.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Spain"><Sites><Site><Name>Primary Care Research Unit - The Alamedilla Center for Health</Name><Address1>Salamanca</Address1><Address3>37006</Address3><Contacts/></Site></Sites></SitesByCountry><SitesByCountry country="Portugal"><Sites><Site><Name>Life and Health Sciences Research Institute in Minho University</Name><Address1>Braga</Address1><Address3>4700</Address3><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Other cardiovascular disease</Disease><PatientSegments><PatientSegment><PatientSegment id="16529">Others</PatientSegment><SubSegments><SubSegment id="14550">Healthy Subjects</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT03900338</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Other cardiovascular disease" id="48042"><Endpoint>Assessment of Cardiac Function</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="46647"><Endpoint>Assessment of Vascular Indices or Parameters</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="48042"><Endpoint>Assessment of Cardiac Function</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Other cardiovascular disease" id="48051"><Endpoint>Imaging/Radiological Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Other cardiovascular disease" id="42989"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="43505"><Endpoint>Assessment of Vital Signs</Endpoint><SubEndpoints><SubEndpoint disease="Other cardiovascular disease" id="43507">Blood pressure assessment</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="43649"><Endpoint>Clinical Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="46468"><Endpoint>Protocol Specified Other Endpoints</Endpoint></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="48042"><Endpoint>Assessment of Cardiac Function</Endpoint></OtherEndpoint><OtherEndpoint disease="Other cardiovascular disease" id="48045"><Endpoint>Anthropometric Assessments</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Other cardiovascular disease" id="32809"><Criterion>Protocol Specified Other Inclusion Criteria</Criterion></Inclusion><Inclusion disease="Other cardiovascular disease" id="34636"><Criterion>Subjects with Normal/Adequate Systemic and Physical Function Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="32811">Healthy Subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Other cardiovascular disease" id="35436"><Criterion>Subjects with Protocol Specified Compliance Status</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="35437">Subjects able to comply with the study protocol procedures/ requirements</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Other cardiovascular disease" id="23962"><Criterion>Subjects with Co-morbid Conditions</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="24099"><Criterion>Protocol Specified Other Exclusion Criteria</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="25146"><Criterion>Subjects co-morbid with Endocrine/Metabolic Disorders</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="24456">Subjects co-morbid with diabetes mellitus</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="26092"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27027"><Criterion>Subjects with History of Cerebrovascular Events</Criterion><SubCriteria><SubCriterion disease="Other cardiovascular disease" id="23708">Subjects with history of stroke</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Other cardiovascular disease" id="27423"><Criterion>Subjects with History of/Scheduled for Pharmacological Therapy for Other Indication</Criterion></Exclusion><Exclusion disease="Other cardiovascular disease" id="27740"><Criterion>Subjects with Abnormal Laboratory Findings</Criterion></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Anticipated">2019-12-30T00:00:00Z</PrimaryCompletionDate><DateFirstReceived>2019-03-29T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2019-04-08T00:00:00Z</Date><Reason id="301">Clinical trial added</Reason></Change></ChangeHistory></Trial><Trial id="49483"><TitleDisplay>An open-label, non-randomized study to evaluate the safety, tolerability and efficacy of  Avonex, Betaferon, Rebif and Copaxone in RRMS patients</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="213">Multiple sclerosis</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>glatiramer acetate</Name><Drug id="8710">glatiramer acetate</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>interferon beta-1a, Biogen</Name><Drug id="3360">interferon beta-1a, Biogen</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>interferon beta-1b, Bayer</Name><Drug id="3362">interferon beta-1b, Bayer</Drug></Intervention></Interventions></InterventionsControlByRegimen><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>recombinant interferon beta-1a, Merck Serono</Name><Drug id="9702">recombinant interferon beta-1a, Merck Serono</Drug></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="8710">glatiramer acetate</Drug><IndicationsPioneer/><Companies><Company><Company id="20348">Teva Pharmaceutical Industries Ltd</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>CURRENT</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="8710" type="Drug"><TargetEntity id="199999" type="siDrug">Glatiramer acetate</TargetEntity></SourceEntity><SourceEntity id="20348" type="Company"><TargetEntity id="4295875158" type="organizationId">Teva Pharmaceutical Industries Ltd</TargetEntity></SourceEntity><SourceEntity id="213" type="ciIndication"><TargetEntity id="G35" type="ICD10"/><TargetEntity id="10028245" type="MEDDRA"/><TargetEntity id="D009103" type="MeSH"/><TargetEntity id="-1241225595" type="omicsDisease"/><TargetEntity id="112" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20348">Teva Pharmaceutical Industries Ltd</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>Yes</IsCommerciallySignificant><Class><Class id="1596">Immunomodulator</Class><Class id="1615">Neuroprotectant</Class><Class id="284">Nootropic agent</Class><Class id="2953">Anti-inflammatory</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="111">Cloning technology</Technology><Technology id="898">Formulation powder</Technology><Technology id="750">Freeze drying</Technology><Technology id="74">Glycoprotein</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="894">Liquid formulation</Technology><Technology id="744">Liquid-based formulation technology</Technology><Technology id="80">Peptide</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TrialCategories><Category>Biological</Category></TrialCategories><TermsDesign><Term>Non-Randomized</Term><Term>Active Control</Term><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>283</PatientCountEnrollment><PatientCountEvaluable>283</PatientCountEvaluable><DateStart>2005-06-08T00:00:00Z</DateStart><DateChangeLast>2009-03-26T06:16:56Z</DateChangeLast><DateAdded>2009-03-26T06:16:56Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;RRMS patients treated for at least 6 months&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Annualized relapse rates compared to pre-treatment baseline and across the four treatment arms</Description></Measure><Measure><Description>Number of relapse-free patients</Description></Measure><Measure><Description>Mean EDSS score changes</Description></Measure><Measure><Description>Progression rate (number of patients with a change of one step or more on EDSS)</Description></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Adverse events</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;There were no major side effects observed with &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; when compared to &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt;. Highest discontinuation rates between 6 and 24 months were observed, 32.9% (26 patients) with &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt; and 8.9% (7 patients; p &amp;lt; 0.001) with &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="606499"&gt;606499&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The study was designed to evaluate the safety, tolerability and efficacy of &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; in relapsing-remitting multiple sclerosis (RRMS) patients [&lt;ulink linkType="Reference" linkID="606499"&gt;606499&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;Results by month 6 showed that all treatments produced statistically significant reductions in annualized relapse rates relative to baseline. No differences were seen in the clinical onset of action among the therapies. By 12 months, &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; achieved a statistically greater relapse-rate reduction than &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt;, and at 24 months after initiation of treatment, relapse-rate reductions were greater with &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; (-0.81, p &amp;lt; 0.001) compared to all beta interferons. The percentage of relapse-free patients, 24 months after treatment initiation, was 58.2% for &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt;, compared to 35.4, 45.5, and 45.8% for &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt; , respectively. More patients remaining progression-free with &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt;  (based on a less than one point increase in EDSS); 87.5% of &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt;  patients compared to 74.5, 71.7, and 73.3% for &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt;, and &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt;, respectively [&lt;ulink linkType="Reference" linkID="606499"&gt;606499&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients received one of the following &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt; (n = 79), &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt; (n = 77), &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt; (n = 48) or &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; (n = 79). Tolerability to study medications was assessed based on dropouts due to absence of perceived efficacy or adverse reactions [&lt;ulink linkType="Reference" linkID="606499"&gt;606499&lt;/ulink&gt;].&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received one of the following &lt;ulink linkType="Drug" linkID="3360"&gt;Avonex&lt;/ulink&gt; (n = 79), &lt;ulink linkType="Drug" linkID="3362"&gt;Betaferon&lt;/ulink&gt; (n = 77), &lt;ulink linkType="Drug" linkID="9702"&gt;Rebif&lt;/ulink&gt; (n = 48) or &lt;ulink linkType="Drug" linkID="8710"&gt;Copaxone&lt;/ulink&gt; (n = 79). Tolerability to study medications was assessed based on dropouts due to absence of perceived efficacy or adverse reactions [&lt;ulink linkType="Reference" linkID="606499"&gt;606499&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Jewish Hospital</Name><Address1>Berlin</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-03-26T06:16:56Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="51236"><TitleDisplay>A phase IIa, open-label study to evaluate the safety and efficacy of NBI-30775 in patients with major depressive disorder</TitleDisplay><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers/><Indications><Indication id="93">Depression</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>CRF-1 antagonists, Neurocrine/Janssen</Name><Drug id="16713">CRF-1 antagonists, Neurocrine/Janssen</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="16713">CRF-1 antagonists, Neurocrine/Janssen</Drug><IndicationsPioneer><Indication id="93">Depression</Indication></IndicationsPioneer><Companies><Company><Company id="18501">Neurocrine Biosciences Inc</Company><RelationshipDirect>FORMER</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="16713" type="Drug"><TargetEntity id="255011" type="siDrug">R-121919</TargetEntity></SourceEntity><SourceEntity id="18501" type="Company"><TargetEntity id="4295907381" type="organizationId">Neurocrine Biosciences Inc</TargetEntity></SourceEntity><SourceEntity id="93" type="ciIndication"><TargetEntity id="10012378" type="MEDDRA"/><TargetEntity id="D003863" type="MeSH"/><TargetEntity id="-508468160" type="omicsDisease"/><TargetEntity id="53" type="siCondition"/></SourceEntity><SourceEntity id="7875" type="Action"><TargetEntity id="119" type="Mechanism">CRF1 Receptor Antagonists</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2a Clinical</Phase><RecruitmentStatus id="12">Status not specified</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="18501">Neurocrine Biosciences Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="7875">CRF-1 receptor antagonist</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2941">Antidepressant</Class><Class id="2942">Anxiolytic</Class></Class><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>20</PatientCountEnrollment><PatientCountEvaluable>20</PatientCountEvaluable><DateStart>1999-06-15T00:00:00Z</DateStart><DateChangeLast>2018-11-29T07:48:21Z</DateChangeLast><DateAdded>2009-04-27T06:55:42Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Max Planck Institute for Psychiatry</Affiliation><Name>Florian Holsboer</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Major depressive disorder&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Safety and tolerability particularly related to effects on the stress hormone system</Description></Measure><Measure><Description>Antidepressant efficacy measurements (Hamilton Depression Scores [HAMD] and patient Beck Depression Index [BDI] rating scales)</Description></Measure><Measure><Description>Anti-anxiety efficacy measurements (Hamilton Anxiety Scores [HAMA])</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;A phase IIa, open-label study was conducted to evaluate the safety and efficacy of &lt;ulink linkType="Drug" linkID="16713"&gt;NBI-30775&lt;/ulink&gt; in patients with major depressive disorder [&lt;ulink linkType="Reference" linkID="328888"&gt;328888&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="333018"&gt;333018&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="348946"&gt;348946&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="375602"&gt;375602&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 1999, preliminary results indicated a statistically significant improvement in widely accepted measures of anxiety and depression [&lt;ulink linkType="Reference" linkID="348946"&gt;348946&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2000, data showed &lt;ulink linkType="Drug" linkID="16713"&gt;NBI-30775&lt;/ulink&gt; to be safe and well tolerated in all patients throughout the 30 day treatment period, with no endocrinological side effects. Blockade of CRF1 receptors did not impair secretory activity of  corticotropin and cortisol, either during treatment or following exogenously administered CRF. These  results supported the hypothesis that suppression of the stress hormone system is not required to produce efficacy with this  mechanism.  Significant anti-depressant activity was seen, defined by reduction in Hamilton Depression Scores (HAMD). Treatment response, defined by &amp;gt; 50% reduction in HAMD, was seen in 50% of the patients in the low dose group and 80%  in the high dose group. Anxiety reductions of equal proportion were also seen. The majority of patients experienced a rebound effect or return of depressive symptoms following cessation of treatment [&lt;ulink linkType="Reference" linkID="375602"&gt;375602&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients were given &lt;ulink linkType="Drug" linkID="16713"&gt;NBI-30775&lt;/ulink&gt; qd for 30 days in one of two dose ranges: 5 to 40 mg and  40 to 80 mg [&lt;ulink linkType="Reference" linkID="375602"&gt;375602&lt;/ulink&gt;]. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients were given &lt;ulink linkType="Drug" linkID="16713"&gt;NBI-30775&lt;/ulink&gt; qd for 30 days in one of two dose ranges: 5 to 40 mg and  40 to 80 mg [&lt;ulink linkType="Reference" linkID="375602"&gt;375602&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="118773">CRF-1 antagonists, Neurocrine/Janssen</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route></Route></Treatment><Treatment><Dose>40 milligram</Dose><Route></Route></Treatment><Treatment><Dose>80 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Germany"><Sites><Site><Name>Max Planck Institute of Psychiatry</Name><Address1>Munich</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms/><TrialRegistries/><OutcomeMeasureTerms/><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2009-04-27T06:55:42Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="6844"><TitleDisplay>A Double-Blind, Group-Comparison, Phase III Study With Zolpidem MR Using Placebo and Nitrazepam in Insomnia Patients</TitleDisplay><TitleOfficial>FK-199B (Zolpidem MR Tablet) Phase III Clinical Study- A Double-Blind, Placebo- and Nitrazepam-Controlled, Group-Comparison Study in Patients With Insomnia Associated With Schizophrenia and Manic-Depressive Psychosis</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>No</EndpointsAchieved><Identifiers><Identifier type="Secondary Organisational">JapicCTI-060330</Identifier><Identifier type="Organisational Study">6199-CL-0008</Identifier><Identifier type="NCT">NCT00374777</Identifier></Identifiers><Indications><Indication id="299">Schizophrenia</Indication><Indication id="653">Bipolar disorder</Indication><Indication id="750">Insomnia</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>zolpidem (controlled-release, insomnia), Sanofi</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens><InterventionsControlByRegimen regimenType="single"><Interventions><Intervention type="InterventionControl"><Name>nitrazepam</Name></Intervention></Interventions></InterventionsControlByRegimen></InterventionsControlByRegimens><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="1013295" type="Company"><TargetEntity id="4295876965" type="organizationId">Astellas Pharma Inc</TargetEntity></SourceEntity><SourceEntity id="299" type="ciIndication"><TargetEntity id="F20" type="ICD10"/><TargetEntity id="10039626" type="MEDDRA"/><TargetEntity id="D012559" type="MeSH"/><TargetEntity id="-729613619" type="omicsDisease"/><TargetEntity id="65" type="siCondition"/></SourceEntity><SourceEntity id="653" type="ciIndication"><TargetEntity id="F31" type="ICD10"/><TargetEntity id="296" type="ICD9"/><TargetEntity id="10057667" type="MEDDRA"/><TargetEntity id="D001714" type="MeSH"/><TargetEntity id="-1667300745" type="omicsDisease"/><TargetEntity id="47" type="siCondition"/></SourceEntity><SourceEntity id="750" type="ciIndication"><TargetEntity id="G47.0" type="ICD10"/><TargetEntity id="10022437" type="MEDDRA"/><TargetEntity id="76" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase 3 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="1013295">Astellas Pharma Inc</Company></CompaniesSponsor><CompaniesCollaborator/><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term><Term>Japanese Ancestry</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Placebo Control</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>450</PatientCountEnrollment><PatientCountEvaluable>451</PatientCountEvaluable><DateStart>2006-08-31T00:00:00Z</DateStart><DateEnd type="actual">2008-06-30T00:00:00Z</DateEnd><DateChangeLast>2018-09-21T12:23:14Z</DateChangeLast><DateAdded>2008-01-14T14:39:33Z</DateAdded><Contacts><Contact type="Public contact"><Affiliation>The clinical management</Affiliation><Email>clinicaltrials_info@jp.astellas.com</Email><Name>Astellas Pharma Inc.</Name></Contact><Contact type="Scientific contact"><Affiliation>Astellas Pharma Inc</Affiliation><Name>Use Central Contact</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;At primary registration:&lt;ul&gt;&lt;li&gt;Patients with nonorganic insomnia as defined by the International Classification of Diseases, 10th edition (ICD-10) who were diagnosed to have nonorganic insomnia associated with schizophrenia and manic-depressive psychosis&lt;/li&gt;&lt;li&gt;Patients complaining of insomnia continuously for 4 weeks or longer&lt;/li&gt;&lt;li&gt;Patients whose time for bed was usually between 9 pm and 1  am, and who slept for between 6 and 9 h within 4 weeks before the start of the run-in period according to the health check sheet&lt;/li&gt;&lt;li&gt;Patients who usually slept for a total of between 3 and 6 h within 4 weeks before the start of the run-in period according to the health check sheet&lt;/li&gt;&lt;li&gt;Patients whose wake time after sleep onset was usually &gt;/=  45 min per night within 4 weeks before the start of the run-in period according to the health check sheet&lt;/li&gt;&lt;li&gt;Patients who had a washout period before the start of the run-in period, when given antihistamine (H1 blocker only, including combination cold remedy, except for eye-drops, nose drops or external medicine), hypnotics, or anxiolytic or antidepressant drugs for sleep&lt;/li&gt;&lt;li&gt;Patients aged between 20 and 65  years  when their informed consent was obtained&lt;/li&gt;&lt;li&gt;Patients who had an ability to fill in the sleep check sheet&lt;/li&gt;&lt;li&gt;It does not matter whether the patients are inpatients or outpatients (they were not allowed to change this status for 1 week before the start of the run-in period)&lt;/li&gt;&lt;li&gt;Patients who provided written informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;At secondary registration:&lt;ul&gt;&lt;li&gt;Patients whose time for bed was between 9 pm and 1 am, and who slept for between 6 and 9 h during the run-in period according to the sleep check sheet&lt;/li&gt;&lt;li&gt;Patients who on average slept for a total of between 3 and 6 h during the run-in period according to the sleep check sheet on the day of administration of the study drug&lt;/li&gt;&lt;li&gt;Patients whose wake time after sleep onset during the run-in period was &gt;/= 45 min per night &gt;/= 3 nights and mean wake time after sleep onset during the run-in period is &gt;/= 30 min/night, according to the sleep check sheet on the day of administration of the study drug&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;At primary registration:&lt;ul&gt;&lt;li&gt;Patients in acute or exacerbating phase of the primary disease who show unstable symptoms&lt;/li&gt;&lt;li&gt;Patients with insomnia caused by physical diseases including chronic obstructive pulmonary disease, bronchial asthma, fibrositis syndrome, chronic fatigue syndrome, rheumatic disease, climacteric disturbance, and dermatitis atopic&lt;/li&gt;&lt;li&gt;Patients with circadian rhythm sleep disorder&lt;/li&gt;&lt;li&gt;Patients with alcoholic sleep disorder&lt;/li&gt;&lt;li&gt;Patients with alcohol or drug dependence or a history of these&lt;/li&gt;&lt;li&gt;Patients with insomnia related with drugs including antiparkinson, antihypertensive, or steroid drugs&lt;/li&gt;&lt;li&gt;Patients with sleep apnea syndrome, restless legs syndrome, and periodic limb movement disorder&lt;/li&gt;&lt;li&gt;Patients with epileptic insomnia&lt;/li&gt;&lt;li&gt;Patients who had gone on an overseas trip to a place with a time difference of &gt;/= 5  h within 12 weeks before the start of the run-in period&lt;/li&gt;&lt;li&gt;Patients who used&lt;ulink linkType="Drug" linkID="4723"&gt;zolpidem&lt;/ulink&gt; or nitrazepam within 2 weeks before the start of the run-in period&lt;/li&gt;&lt;li&gt;Patients with a history of allergy to&lt;ulink linkType="Drug" linkID="4723"&gt;zolpidem&lt;/ulink&gt; or nitrazepam&lt;/li&gt;&lt;li&gt;Patients with myasthenia gravis&lt;/li&gt;&lt;li&gt;Patients with acute closed-angle glaucoma&lt;/li&gt;&lt;li&gt;Patients with highly impaired respiratory function, eg, in the acute phase of cor pulmonale, emphysema, bronchial asthma, and cerebrovascular disease&lt;/li&gt;&lt;li&gt;Patients with organic brain disorder&lt;/li&gt;&lt;li&gt;Patients with scores in Module C 'Suicidality' of the Mini-International Neuropsychiatric Interview (MINI)&lt;/li&gt;&lt;li&gt;Patients with serious heart disease, liver disease, renal disease, and hematological disorder  grade 3 according to the 'Criteria for Classification of Seriousness of Adverse Reactions to Pharmaceuticals, etc&lt;/li&gt;&lt;li&gt;Patients who are engaged in potentially hazardous machine operations such as driving cars&lt;/li&gt;&lt;li&gt;Pregnant women, women with an intention of pregnancy during the study period, and nursing mothers&lt;/li&gt;&lt;li&gt;Patients with clinical conditions that are judged to be inappropriate for a safe conduct of the clinical study by the investigator or subinvestigator&lt;/li&gt;&lt;li&gt;Patients who participated in other clinical studies or post-marketing clinical studies within 12 weeks before providing the informed consent&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;At secondary registration:&lt;ul&gt;&lt;li&gt;Patients who were given prohibited concomitant drugs or therapies during the run-in period&lt;/li&gt;&lt;li&gt;Patients with a compliance of&amp;lt; 50% during the run-in period&lt;/li&gt;&lt;li&gt;Patients who changed their inpatient/outpatient status during the run-in period&lt;/li&gt;&lt;li&gt;Patients judged to be inappropriate as subjects for this study by the investigator or subinvestigator on the basis of laboratory test results or such like at the start of the run-in period&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Mean wake time after sleep onset during the double-blind period</Description><Timeframe>2 Weeks</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Mean total sleep time during the double-blind period</Description><Timeframe>2 Weeks</Timeframe></Measure><Measure><Description>Mean number of nightly awakenings during the double-blind period</Description><Timeframe>2 Weeks</Timeframe></Measure><Measure><Description>Mean sleep latency during the double-blind period</Description><Timeframe>2 Weeks</Timeframe></Measure><Measure><Description>Patient impression during the double-blind period</Description><Timeframe>2 Weeks</Timeframe></Measure><Measure><Description>Mean subjective wake time after sleep onset without bed out latency during the double-blind period</Description></Measure><Measure><Description>Mean subjective number of awakenings without bed out latency during the double-blind period</Description></Measure><Measure><Description>Mean subjective bed out latency during the double-blind period</Description></Measure><Measure><Description>Safety</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;In November 2008, results were published. The incidence of adverse events (AEs)  was 31,   35.1, 31.5 and 33.6% in the placebo,  &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg, &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg  and  nitrazepam 5 mg groups, respectively. There were no severe AEs   reported in any of the treatment groups. Common AEs reported  in the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25  and   12.5 mg groups, respectively, were    nasopharyngitis (8.8 and 6.3%), headache (4.4  and 0.9%), somnolence (1.8 and 3.6%), alanine aminotransferase increased (1.8  and 1.8%), diarrhea (0.9 and 1.8%), dizziness and eczema (both 1.8 and 0.9%), constipation, nausea, feeling abnormal, aspartate aminotransferase increased and anterograde amnesia (all 0   and 1.8%), and eosinophil count increased (1.8 and 0%). Most of these events were mild. No deaths occured during this   study. Serious AE included  one case of depression in one subject (0.9%) receiving &lt;ulink linkType="Drug" linkID="4723"&gt;FK199B&lt;/ulink&gt;   12.5 mg and  was considered possibly related to treatment    [&lt;ulink linkType="Reference" linkID="1267771"&gt;1267771&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study was designed to investigate the effects of &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; in adult Japanese patients with insomnia associated with schizophrenia and manic-depressive psychosis. The main objective of this study was to verify the superiority of &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5   and 6.25 mg to placebo   [&lt;ulink linkType="Reference" linkID="1267771"&gt;1267771&lt;/ulink&gt;].&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2008, results were published. In the full analysis set (FAS [n = 451]), the mean subjective wake time after sleep onset in the double-blind period  decreased (improved) in the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25   and  12.5 mg groups with   increase in the dose, when compared with  placebo (inter-group difference of the adjusted means: -1.95 and -6.72 min, respectively). However, superiority of &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg group to the placebo was not shown (p = 0.116).    There was no  statistically significant difference  in mean wake time after sleep onset in the nitrazepam 5 mg group  and  &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg group  (inter-group difference in the adjusted mean: 0.71 min, p = 0.867).   Sleep parameters  (mean subjective total sleep time, mean subjective number of awakenings, mean subjective sleep onset latency, mean subjective wake time after sleep onset without bed out latency, and mean subjective number of awakenings without bed out latency in the double-blind period) were statistically significantly superior in the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg group, when  compared with the placebo (p = 0.007,  0.004,  0.034,  0.006,  &amp;lt; 0.001, respectively; analysis of covariance using the means in the run-in period and primary disease as covariates). There was  a statistically significant improvement in mean subjective sleep onset latency  in the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg group, when compared with   placebo  (p = 0.021). There was  no statistically significant difference in mean subjective bed out latency   between the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 or  6.25 mg group and the placebo    [&lt;ulink linkType="Reference" linkID="1267771"&gt;1267771&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;Results were also published from a   subgroup analysis for the mean subjective wake time after sleep onset in the double-blind period. The inter-group difference in the adjusted mean between the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg group and the placebo was -12.38 min in the female patients, when compared with  2.21 min in the male patients; and was -19.84 min  in the duration of insomnia &amp;lt; 12 months, when  compared with -0.61 min in that &amp;gt; 12 months. In the subgroup analysis for the mean subjective total sleep time in the double-blind period, the inter-group difference in the adjusted mean between the &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg group and the placebo was 22.36 min in the female patients, when compared   with 13.23 min in  male patients; and was  47.01 min  in the duration of insomnia &amp;lt; 12 months, when  compared with 6.11 min in those  &amp;gt; 12 months; and was 29.98 min in the absence of pretreatment for insomnia, when compared with 12.13 min in  presence of pretreatment     [&lt;ulink linkType="Reference" linkID="1267771"&gt;1267771&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><Regimens>&lt;Regimens&gt;&lt;para&gt;This  triple-dummy study consisted of a  run-in period, double-blind period and post-treatment period:&lt;br/&gt;Run-in period: patients received one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg placebo tablet, one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg placebo tablet, and one nitrazepam 5 mg placebo tablet po qd before bedtime, for 1 week, in a single-blind manner.&lt;br/&gt;Double-blind period: patients received treatment   orally once-daily before bedtime for a period of 2 weeks in the following regimens:&lt;br/&gt;&lt;ulink linkType="Drug" linkID="89931"&gt;Zolpidem&lt;/ulink&gt; 6.25 mg group: one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg tablet +  one  &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg placebo tablet + one nitrazepam 5 mg placebo tablet.&lt;br/&gt;&lt;ulink linkType="Drug" linkID="89931"&gt;Zolpidem&lt;/ulink&gt; 12.5 mg group: one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg placebo tablet + one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg tablet + one nitrazepam 5 mg placebo tablet.&lt;br/&gt;Nitrazepam 5 mg group: one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg placebo tablet + one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg placebo tablet + one nitrazepam 5 mg tablet.&lt;br/&gt;Placebo group: one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg placebo tablet + one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg placebo tablet + one nitrazepam 5 mg placebo tablet.&lt;br/&gt;Post-treatment period :  patients received one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 6.25 mg placebo tablet, one &lt;ulink linkType="Drug" linkID="89931"&gt;zolpidem&lt;/ulink&gt; 12.5 mg placebo tablet, and one nitrazepam 5 mg placebo tablet po qd before bedtime, for 1 week, in a single-blind manner    [&lt;ulink linkType="Reference" linkID="1267771"&gt;1267771&lt;/ulink&gt;].&lt;br/&gt; &lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>zolpidem (controlled-release, insomnia), Sanofi</Name><Dose unit="milligram dose">6.25</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>0.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="109">Eczema</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication><CountPatientsAffectedPercentage>4.4</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>8.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention><AdverseEventsByIntervention><Intervention type="InterventionPrimary"><Name>zolpidem (controlled-release, insomnia), Sanofi</Name><Dose unit="milligram dose">12.5</Dose></Intervention><AdverseEvents><AdverseEvent><Indication id="102">Diarrhea</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="109">Eczema</Indication><CountPatientsAffectedPercentage>0.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="148">Headache</Indication><CountPatientsAffectedPercentage>0.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="226">Nausea</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="2274">Rhinopharyngitis</Indication><CountPatientsAffectedPercentage>6.3</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3073">Drowsiness</Indication><CountPatientsAffectedPercentage>3.6</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="3454">Dizziness</Indication><CountPatientsAffectedPercentage>0.9</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="404">Constipation</Indication><CountPatientsAffectedPercentage>1.8</CountPatientsAffectedPercentage></AdverseEvent><AdverseEvent><Indication id="93">Depression</Indication><CountPatientsAffectedPercentage>0.9</CountPatientsAffectedPercentage></AdverseEvent></AdverseEvents></AdverseEventsByIntervention></AdverseEventsByInterventions><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="6027">nitrazepam</Intervention><Treatments><Treatment><Dose>5 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="5923">zolpidem (controlled-release, insomnia), Sanofi</Intervention><Treatments><Treatment><Dose>6.25 milligram</Dose><Route>Oral</Route></Treatment><Treatment><Dose>12.5 milligram</Dose><Route>Oral</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Japan"><Sites><Site><Address1>Hokkaido region</Address1><Contacts/></Site><Site><Address1>Kanto region</Address1><Contacts/></Site><Site><Address1>Chubu region</Address1><Contacts/></Site><Site><Address1>Kansai region</Address1><Contacts/></Site><Site><Address1>Shikoku region</Address1><Contacts/></Site><Site><Address1>Kyushu region</Address1><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Schizophrenia</Disease><PatientSegments><PatientSegment><PatientSegment id="7167">Subjects with Other Neuro-psychiatric Diseases/Disorders</PatientSegment><SubSegments><SubSegment id="7168">Subjects with other psychotic disorders</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="7176">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="7169">Subjects with mood disorders</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Insomnia</Disease><PatientSegments><PatientSegment><PatientSegment id="11067">Subjects with comorbid conditions</PatientSegment><SubSegments><SubSegment id="11068">Subjects co-morbid with mood disorders</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00374777</Identifier></Identifiers></Registry><Registry><Name id="1006">Japanese Pharmaceutical Information Center - Clinical Trials Information (JapicCTI)</Name><Identifiers><Identifier type="Secondary Organisational">JapicCTI-060330</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Bipolar disorder" id="9989"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9991">Assessment of mean wake time</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Schizophrenia" id="10104"><Endpoint>Assessment of Sleep</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Insomnia" id="23572"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23581">Assessment of early morning awakening</SubEndpoint></SubEndpoints></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Bipolar disorder" id="9989"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="9990">Assessment of total sleep time</SubEndpoint><SubEndpoint disease="Bipolar disorder" id="9992">Assessment of night awakenings</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Schizophrenia" id="10100"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Schizophrenia" id="10104"><Endpoint>Assessment of Sleep</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23572"><Endpoint>Assessment of Sleep</Endpoint><SubEndpoints><SubEndpoint disease="Insomnia" id="23574">Assessment of sleep onset latency (SOL)</SubEndpoint><SubEndpoint disease="Insomnia" id="23577">Assessment of number of awakenings</SubEndpoint><SubEndpoint disease="Insomnia" id="23579">Assessment of total sleep time (TST)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Insomnia" id="23612"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Bipolar disorder" id="33272"><Endpoint>Patient Reported Outcomes/Quality of Life Assessments</Endpoint></SecondaryEndpoint></SecondaryEndpoints><OtherEndpoints><OtherEndpoint disease="Bipolar disorder" id="10006"><Endpoint>Anthropometric Assessments</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10007"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10013"><Endpoint>Assessment of Cardiac Function</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10009">Assessment of blood pressure</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10016"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint><SubEndpoints><SubEndpoint disease="Bipolar disorder" id="10021">Assessment of hematological parameters</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10026"><Endpoint>Assessment of adverse events</Endpoint></OtherEndpoint><OtherEndpoint disease="Bipolar disorder" id="10045"><Endpoint>Assessment of Mortality/Death Rates</Endpoint></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="10116"><Endpoint>Assessment of Safety and Tolerability</Endpoint><SubEndpoints><SubEndpoint disease="Schizophrenia" id="10117">Assessment of adverse events(AEs)/side effects</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10118">Assessment of serious adverse events</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10123">Assessment of neuropsychiatric adverse events</SubEndpoint><SubEndpoint disease="Schizophrenia" id="10126">Assessment of discontinuations due to adverse events</SubEndpoint></SubEndpoints></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="37184"><Endpoint>Assessment of Vital Signs</Endpoint></OtherEndpoint><OtherEndpoint disease="Schizophrenia" id="37187"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></OtherEndpoint></OtherEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Schizophrenia" id="5492"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="5493">Subjects with other psychotic disorders</SubCriterion><SubCriterion disease="Schizophrenia" id="5494">Subjects with mood disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Bipolar disorder" id="5787"><Criterion>Subjects with Bipolar Disorder</Criterion></Inclusion><Inclusion disease="Bipolar disorder" id="5822"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="5825">Subjects with psychotic disorders</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insomnia" id="20420"><Criterion>Subjects Based on Etiology of Insomnia</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="20422">Subjects with secondary insomnia</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Insomnia" id="20444"><Criterion>Subjects co-morbid with psychiatric disease/disorders</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="20445">Subjects with psychotic disorders</SubCriterion><SubCriterion disease="Insomnia" id="20446">Subjects with mood disorders</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Schizophrenia" id="7036"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Schizophrenia" id="7040"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Schizophrenia" id="7072"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="7077">History of/scheduled to receive anti anxiety drugs</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7439"><Criterion>Subjects with Co-morbid Conditions</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7444">Subjects co-morbid with hepatobiliary diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Bipolar disorder" id="7441"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7445"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Bipolar disorder" id="7470"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="Bipolar disorder" id="7476">Subjects with hypersensitivity/contraindication to any investigational agents</SubCriterion><SubCriterion disease="Bipolar disorder" id="7478">Hypersensitivity/Contraindication to sedatives and hypnotics</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insomnia" id="18229"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion></Exclusion><Exclusion disease="Insomnia" id="18231"><Criterion>Subjects co-morbid with renal disease/disorder</Criterion></Exclusion><Exclusion disease="Insomnia" id="18262"><Criterion>Subjects with History of/Scheduled to Receive Therapy</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="18269">Subjects with history of/scheduled to receive an investigational drug</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insomnia" id="18272"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="18277">Subjects with history/scheduled to cardiovascular medications</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Insomnia" id="26052"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Insomnia" id="18232">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Schizophrenia" id="26078"><Criterion>Subjects co-morbid with hepatobiliary disorders/diseases</Criterion><SubCriteria><SubCriterion disease="Schizophrenia" id="7037">Subjects co-morbid with hepatic diseases/disorders</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2008-05-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2008-01-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>17.03 Months</EnrollmentPeriod><EnrollmentRate>26.42 Patients/Month</EnrollmentRate><DateFirstReceived>2006-09-08T00:00:00Z</DateFirstReceived><FundersType><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2008-01-14T14:39:33Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="70601"><TitleDisplay>Virtual Histology Findings and Effects of Varying Doses of Atorvastatin Treatment</TitleDisplay><TitleOfficial>A Prospective, Double-blinded, Randomized Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">UW 07-266 (IRB HKU)</Identifier><Identifier type="NCT">NCT01200056</Identifier><Identifier type="Secondary Organisational">HKUCTR-517</Identifier><Identifier type="Other">UW 07-266</Identifier><Identifier type="Trial Acronym">VENUS</Identifier></Identifiers><Indications><Indication id="1625">Coronary arteriosclerosis</Indication></Indications><BiomarkerNames><BiomarkerName id="137" role="Therapeutic effect marker" type="Structural (imaging)">Atherosclerotic plaque</BiomarkerName></BiomarkerNames><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>atorvastatin</Name><Drug id="2807">atorvastatin</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="2807">atorvastatin</Drug><IndicationsPioneer/><Companies><Company><Company id="1048099">Queen Mary Hospital</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="18767">Pfizer Inc</Company><RelationshipDirect>CURRENT</RelationshipDirect><RelationshipInDirect>FORMER</RelationshipInDirect></Company><Company><Company id="22487">The University of Hong Kong</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="2807" type="Drug"><TargetEntity id="180072" type="siDrug">Atorvastatin calcium</TargetEntity></SourceEntity><SourceEntity id="1048099" type="Company"><TargetEntity id="5035546989" type="organizationId">Queen Mary Hospital</TargetEntity></SourceEntity><SourceEntity id="18767" type="Company"><TargetEntity id="4295904722" type="organizationId">Pfizer Inc</TargetEntity></SourceEntity><SourceEntity id="22487" type="Company"><TargetEntity id="4296686394" type="organizationId">University of Hong Kong</TargetEntity></SourceEntity><SourceEntity id="1625" type="ciIndication"><TargetEntity id="D003324" type="MeSH"/><TargetEntity id="2048" type="siCondition"/></SourceEntity><SourceEntity id="205" type="Action"><TargetEntity id="437" type="Mechanism">HMG-CoA Reductase Inhibitors</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 4 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>2</NumberOfSites><CompaniesSponsor><Company id="22487">The University of Hong Kong</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1048099">Queen Mary Hospital</Company><Company id="18767">Pfizer Inc</Company></CompaniesCollaborator><IsCommerciallySignificant>Yes</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="205">HMG CoA reductase inhibitor</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="2667">Antiarteriosclerotic</Class><Class id="71">Antihypercholesterolemic agent</Class><Class id="72">Antihyperlipidemic agent</Class></Class><Technologies><Technology id="680">Buccal formulation systemic</Technology><Technology id="585">Oral formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="595">Tablet formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Randomized</Term><Term>Multiple Blind</Term><Term>Treatment</Term><Term>Parallel Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>40</PatientCountEnrollment><PatientCountEvaluable>40</PatientCountEvaluable><DateStart>2007-08-31T00:00:00Z</DateStart><DateEnd type="actual">2010-06-30T00:00:00Z</DateEnd><DateChangeLast>2019-04-15T06:30:09Z</DateChangeLast><DateAdded>2010-09-29T07:33:07Z</DateAdded><Contacts><Contact type="Scientific contact"><Email>leewls@ha.org.hk</Email><Name>Dr. Wai Luen Stephen Lee</Name><Phone>2855 5409</Phone></Contact><Contact type="Public contact"><Affiliation>Queen Mary Hospital</Affiliation><Email>hkuctreg@hku.hk</Email><Name>HKUCTR Administrator</Name><Phone>2255 4667 / 2255 4679</Phone></Contact><Contact type="Scientific contact"><Affiliation>Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority</Affiliation><Email>leewls@ha.org.hk</Email><Name>Prof. Stephen WL LEE, MD FRCP FACC</Name><Phone>2855 5409</Phone></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patient aged 18 to 85 years (not pregnant) requiring percutaneous intervention to coronary             stenosis&lt;/li&gt;&lt;li&gt;Statin naive patient&lt;/li&gt;&lt;li&gt;No history of myocardial infarction. Angina free for at least 8 weeks&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Any history of previous statin treatment and myocardial infarction&lt;/li&gt;&lt;li&gt;Current acute coronary syndrome or in cardiogenic shock&lt;/li&gt;&lt;li&gt;Recommended coronary artery bypass graft surgery&lt;/li&gt;&lt;li&gt;Chronic total occlusion and very tortuous calcified arteries precluding safe IVUS             examination&lt;/li&gt;&lt;li&gt;Patient refused to give written informed consent&lt;/li&gt;&lt;li&gt;Congestive heart failure&lt;/li&gt;&lt;li&gt;Chronic renal failure &lt;/li&gt;&lt;li&gt;Serious hepatic disease or had obstructive hepatobiliary disease &lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>The primary endpoint would be the 6-month angiographical and VH-IVUS re-study findings (our hypothesis was plaque regression and virtual histology intravascular ultrasound [VH-IVUS] plaque modification with statin therapy could be statin dose dependent, and may affect clinical outcomes. Two clinically realistic doses of atorvastatin 10 and 40 mg were chosen in statin-naive patients without previous myocardial infarction. The primary endpoint of this study would therefore be the 6 months angiographical and IVUS follow-up, looking at the volumetric gray-scale IVUS and VH-IVUS findings at 6 months for the whole cohort as well as the differences between the two groups)</Description><Timeframe>6 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>The secondary endpoint would be the occurrence of any major adverse cardiac events at 6 months (including any death, myocardial infarction or need for revascularization) as routinely monitored after all percutaneous interventional procedures (as described in the 'title' above)</Description><Timeframe>Throughout the 6 months study period</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;Occurrence of major adverse cardiac events was not observed in &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 40 mg group when compared to six patients in the 10 mg group, p = 0.020) [&lt;ulink linkType="Reference" linkID="1357651"&gt;1357651&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This study  was the first prospective, randomized, double-blinded pilot study  designed to      investigate the varying statin dose effects on plaque regression and virtual histology composition      modulation by volumetric      virtual histology intravascular ultrasound (VH-IVUS).In this  study, statin-naive patients with      stable angina requiring percutaneous coronary intervention (PCI) were randomized to receive      6 months of either &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 10  or 40 mg daily. VH-IVUS was performed in all non-PCI      lesions at baseline and 6 months; all analyses were performed by core laboratory. &lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In November 2012, results were published. Patients who received &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 40 mg showed more lesions with heavier plaque burden and on larger vessel segments, resulting in a bigger baseline absolute plaque volume and fibrous volume (98.47 +/- 70.84 mm3 versus 144.17 +/- 154.46 mm3, p = 0.047, and 37.04 +/- 0.41 mm3 versus 54.90 +/- 58.05 mm3, p = 0.044, respectively). Percentage plaque volume and all of the four relative % VH volumes were similar between the two groups. A reduction in overall absolute plaque volume of 5.10 +/- 14.93 mm3 or 4.28%, p &amp;lt; 0.001, absolute VH-IVUS fibrous volume of 10.54% (-4.87 +/- 10.74 mm3, p &amp;lt; 0.001), absolute fibro-fatty volume of 6.26% reduction (-0.92 +/- 6.65 mm3, p = 0.150), and increase in absolute dense calcium volume of 12.8% (0.52 +/- 2.38 mm3, p = 0.024), absolute necrotic core volume of 5.02% (0.50 +/- 7.81 mm3, p = 0.498) was observed. Significantly more percentage plaque volume regression of -1.50 +/- 3.85% was observed in higher dose (40 mg) group when compared to 0.38 +/- 4.05% increase in the 10 mg group, p = 0.014), less relative percentage necrotic core expansion (1.68 +/- 7.57 versus 4.78 +/- 7.82% in the 10 mg group, p = 0.037). No significant correlation was observed between lowered LDL-cholesterol levels, the percentage plaque volumes and relative percentage necrotic core compositions, presumably due to the small sample size used or other pleiotropic effects of statin treatment, like anti-inflammatory actions not mediating through LDL-cholesterol lowering [&lt;ulink linkType="Reference" linkID="1357651"&gt;1357651&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;The study included only statin-naive patients without previous history of myocardial infarction (MI), aiming to show the 'pure' effects of varying doses of statin and to      better reveal the subtle differences in the changes. The study involved two arms. Patients received either &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 10 or 40 mg/day for 6 months, respectively. The primary endpoint of 6 months VH-IVUS findings and clinical outcomes were monitored and compared. &lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;Patients received either &lt;ulink linkType="Drug" linkID="2807"&gt;atorvastatin&lt;/ulink&gt; 10 (low dose) or 40 mg/day (moderate dose) for 6 months [&lt;ulink linkType="Reference" linkID="1357651"&gt;1357651&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="171551">atorvastatin</Intervention><Treatments><Treatment><Dose>10 milligram</Dose><Route></Route></Treatment><Treatment><Dose>40 milligram</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="Hong Kong"><Sites><Site><Name>Queen Mary Hospital</Name><Contacts/></Site><Site><Name>Departement of Medicine, Queen Mary Hospital</Name><Contacts/></Site><Site><Name>Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority</Name><Address1>Hong Kong SAR</Address1><Address2>Hong Kong</Address2><CountrySubDivision>Hong Kong</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Coronary artery disease</Disease><PatientSegments><PatientSegment><PatientSegment id="182">Subjects with Angina</PatientSegment><SubSegments><SubSegment id="188">Subjects with Stable Angina</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="189">Treatment Naive Subjects</PatientSegment><SubSegments><SubSegment id="197">Statin naive subjects</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="201">Subjects Undergoing/Underwent Percutaneous Coronary Intervention (PCI)</PatientSegment></PatientSegment><PatientSegment><PatientSegment id="243">Subjects with Abnormal Angiographic Findings</PatientSegment><SubSegments><SubSegment id="251">Stenosis/Narrowing of vessel</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT01200056</Identifier></Identifiers></Registry><Registry><Name id="1009">HKClinicalTrials.com</Name><Identifiers><Identifier type="Secondary Organisational">HKUCTR-517</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Coronary artery disease" id="2504"><Endpoint>Detection of Coronary Artery Disease (CAD)</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2511">Significant coronary lesion on angiogram</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2656"><Endpoint>Assessment of Artery Plaque /Atheroma</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2658">Change in Atheroma/Plaque volume</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Coronary artery disease" id="2666"><Endpoint>Assessment of Procedure and Procedure Related Events</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Coronary artery disease" id="2491"><Endpoint>Assessment of Cardiovascular Events</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2492">Acute/New Myocardial infarction (MI)/MI (Q-wave and non-Q wave)</SubEndpoint><SubEndpoint disease="Coronary artery disease" id="2619">Assessment of major adverse cardiac events (MACEs)</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2621"><Endpoint>Assessment of Mortality/Death Rates</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2623">Assessment of all cause mortality</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2634"><Endpoint>Assessment of Adverse Events</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Coronary artery disease" id="2689"><Endpoint>Assessment of Reperfusion/Revascularization</Endpoint><SubEndpoints><SubEndpoint disease="Coronary artery disease" id="2700">Need for a revascularization procedure</SubEndpoint></SubEndpoints></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Coronary artery disease" id="1068"><Criterion>Subjects with Coronary Artery Disease (CAD)</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1069">Subejcts with coronary artery stenosis</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1085"><Criterion>Subjects with angina</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1091">Subjects with stable angina / angina pectoris / exertional angina</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1155"><Criterion>Treatment Naive Subjects</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1162">Statin naive subjects</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1169"><Criterion>Subjects with History of /Scheduled for Coronary Revascularization Therapy</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1171">PTCA (percutaneous transluminal coronary angioplasty)/Stent placement</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Coronary artery disease" id="1201"><Criterion>Coronary Angiogram Findings Suggestive of/Confirmed CAD/CHD</Criterion></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Coronary artery disease" id="1602"><Criterion>Subjects with Myocardial Infarction (MI)</Criterion></Exclusion><Exclusion disease="Coronary artery disease" id="1609"><Criterion>Subjects with Specific Coronary Angiographic Findings</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1617">Chronic total occlusion/TIMI flow 0 or TIMI flow 1 prior to wire crossing</SubCriterion><SubCriterion disease="Coronary artery disease" id="1620">Excessive tortuosity/angulation proximal to or within the lesion</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="1651"><Criterion>Subjects co-morbid with cardiovascular diseases/disorders</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1652">Subjects co-morbid with acute coronary syndrome</SubCriterion><SubCriterion disease="Coronary artery disease" id="1657">Subjects co-morbid with cardiogenic shock</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Coronary artery disease" id="26090"><Criterion>Subjects with History of/Scheduled for Intervention/Surgery</Criterion><SubCriteria><SubCriterion disease="Coronary artery disease" id="1846">Subjects with CABG (Coronary artery bypass graft) surgery</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><DateFirstReceived>2010-09-09T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Company</Type></FundersType><ChangeHistory><Change type="added"><Date>2010-09-29T07:33:07Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="75686"><TitleDisplay>Adjuvant Chemoradiotherapy and Interferon Alfa in Treating Patients With Resected Pancreatic Cancer</TitleDisplay><TitleOfficial>A Phase II Study of Interferon-based Chemoradiation in Patients With Resected Pancreatic Adenocarcinoma</TitleOfficial><OutcomesAvailable>Yes</OutcomesAvailable><EndpointsAchieved>Unspecified</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">CDR0000298776</Identifier><Identifier type="NCT">NCT00059826</Identifier><Identifier type="Secondary Organisational">ACOSOG-Z05031</Identifier></Identifiers><Indications><Indication id="249">Pancreas tumor</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>Chemoradiotherapy</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsPrimaryByRegimen regimenType="combo"><Interventions><Intervention type="InterventionPrimary"><Name>5-fluorouracil</Name></Intervention><Intervention type="InterventionPrimary"><Name>cisplatin</Name></Intervention><Intervention type="InterventionPrimary"><Name>interferon alfa-2b</Name><Drug id="45998">interferon alfa-2b</Drug></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary><DrugAsInterventionPrimary><Drug id="45998">interferon alfa-2b</Drug><IndicationsPioneer/><Companies><Company><Company id="1040381">Cancer and Leukemia Group B</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company><Company><Company id="20519">National Cancer Institute</Company><RelationshipDirect>NONE</RelationshipDirect><RelationshipInDirect>NONE</RelationshipInDirect></Company></Companies></DrugAsInterventionPrimary></DrugsAsInterventionPrimary><CrossReferences><SourceEntity id="45998" type="Drug"><TargetEntity id="165805" type="siDrug">Interferon alfa-2b</TargetEntity></SourceEntity><SourceEntity id="1040381" type="Company"><TargetEntity id="5035559663" type="organizationId">Alliance for Clinical Trials in Oncology Foundation</TargetEntity></SourceEntity><SourceEntity id="20519" type="Company"><TargetEntity id="4296539077" type="organizationId">National Cancer Institute</TargetEntity></SourceEntity><SourceEntity id="249" type="ciIndication"><TargetEntity id="C25" type="ICD10"/><TargetEntity id="10033609" type="MEDDRA"/><TargetEntity id="D010190" type="MeSH"/><TargetEntity id="-670361033" type="omicsDisease"/><TargetEntity id="630" type="siCondition"/></SourceEntity><SourceEntity id="917" type="Action"><TargetEntity id="1953" type="Mechanism">Interferon alpha Receptor (IFNAR) Ligands</TargetEntity><TargetEntity id="2945" type="Mechanism">IFN-alpha Modulators</TargetEntity></SourceEntity></CrossReferences><Phase>Phase 2 Clinical</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>14</NumberOfSites><CompaniesSponsor><Company id="1040381">Cancer and Leukemia Group B</Company></CompaniesSponsor><CompaniesCollaborator><Company id="20519">National Cancer Institute</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><ActionsPrimaryInterventionsPrimary><Action id="917">Interferon alpha ligand modulator</Action></ActionsPrimaryInterventionsPrimary><Class><Class id="15190">Systemic dermatological antiviral product</Class><Class id="1545">Anticancer</Class><Class id="991">Antiviral</Class></Class><Technologies><Technology id="761">Biological therapeutic</Technology><Technology id="898">Formulation powder</Technology><Technology id="740">Infusion</Technology><Technology id="651">Intramuscular formulation</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="85">Protein recombinant</Technology><Technology id="746">Solution</Technology><Technology id="647">Subcutaneous formulation</Technology></Technologies><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Biological</Category><Category>Small molecule</Category><Category>Radiation therapy</Category></TrialCategories><TermsDesign><Term>Open Label</Term><Term>Treatment</Term><Term>Single Group Assignment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term><Term>Safety</Term></TermsEndpoint><PatientCountEnrollment>89</PatientCountEnrollment><PatientCountEvaluable>89</PatientCountEvaluable><DateStart>2003-03-31T00:00:00Z</DateStart><DateEnd type="actual">2011-02-28T00:00:00Z</DateEnd><DateChangeLast>2018-05-12T07:23:28Z</DateChangeLast><DateAdded>2011-03-22T04:21:52Z</DateAdded><Contacts><Contact type="Scientific contact"><Affiliation>Floyd &amp; Delores Jones Cancer Institute at Virginia Mason Medical Center</Affiliation><Name>Vincent J. Picozzi, MD</Name></Contact></Contacts><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Disease characteristics:&lt;ul&gt;&lt;li&gt;Histologically confirmed adenocarcinoma of the head of the pancreas:&lt;ul&gt;&lt;li&gt;Stage I, II, or III (T1-4, N0-1, M0)&lt;/li&gt;&lt;li&gt;No recurrent pancreatic cancer&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Must have undergone a potentially curative gross total resection by             pancreaticoduodenectomy within the past 56 days&lt;ul&gt;&lt;li&gt;Must have R0 (no residual tumor) or R1 (microscopic residual tumor) grade                  disease post-resection&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No pancreaticoduodenectomy histopathology indicating any of the following types:&lt;ul&gt;&lt;li&gt;Adenosquamous carcinoma&lt;/li&gt;&lt;li&gt;Ampullary carcinoma&lt;/li&gt;&lt;li&gt;Carcinoid tumor&lt;/li&gt;&lt;li&gt;Cystadenocarcinoma&lt;/li&gt;&lt;li&gt;Cystadenoma&lt;/li&gt;&lt;li&gt;Distal common bile duct carcinoma&lt;/li&gt;&lt;li&gt;Duodenal carcinoma&lt;/li&gt;&lt;li&gt;Islet cell carcinoma&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;No metastatic disease by CT scan of the chest and CT scan with intravenous contrast             (or MRI) of abdomen/pelvis&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patient  characteristics:&lt;ul&gt;&lt;li&gt;Age&gt;/= 18 years&lt;/li&gt;&lt;li&gt;Performance status:&lt;ul&gt;&lt;li&gt;ECOG 0 to 1&lt;/li&gt;&lt;li&gt;Zubrod 0 to 1&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Life expectancy: not specified&lt;/li&gt;&lt;li&gt;Hematopoietic:&lt;ul&gt;&lt;li&gt;WBC at least 3000/mm3&lt;/li&gt;&lt;li&gt;Absolute neutrophil count &gt; 1500/mm3&lt;/li&gt;&lt;li&gt;Platelet count at least 100,000/mm3&lt;/li&gt;&lt;li&gt;Hemoglobin &gt; 9.5 g/dl&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Hepatic:&lt;ul&gt;&lt;li&gt;Bilirubin no &gt; 3 mg/dl&lt;/li&gt;&lt;li&gt;AST and ALT no &gt; 2 x upper limit of normal (ULN)&lt;/li&gt;&lt;li&gt;Alkaline phosphatase no &gt; 2 x ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Renal:&lt;ul&gt;&lt;li&gt;Creatinine no &gt; 1.5 x ULN&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Not pregnant or nursing&lt;/li&gt;&lt;li&gt;Negative pregnancy test&lt;/li&gt;&lt;li&gt;Fertile patients must use effective contraception&lt;/li&gt;&lt;li&gt;Stable or increasing weight within 14 days before start of study treatment (otherwise             supplemental nutrition, such as feeding jejunostomy, percutaneous endoscopic             gastrostomy, or total parenteral nutrition, must be initiated)&lt;/li&gt;&lt;li&gt;No evidence of recurrence of any prior malignancy&lt;/li&gt;&lt;li&gt;No other malignancies within the past five years except successfully treated carcinoma             in situ of the cervix, lobular carcinoma in situ of the breast, or nonmelanoma skin             cancer&lt;/li&gt;&lt;li&gt;No preexisting psychiatric condition (especially depression) or a history of severe             psychiatric disorders&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior concurrent therapy:&lt;ul&gt;&lt;li&gt;Biological therapy:&lt;ul&gt;&lt;li&gt;No prior biological or immunological therapies&lt;/li&gt;&lt;li&gt;No concurrent biological response modifiers for pancreatic cancer&lt;/li&gt;&lt;li&gt;No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF)&lt;/li&gt;&lt;li&gt;No concurrent oprelvekin&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Chemotherapy&lt;ul&gt;&lt;li&gt;No prior systemic chemotherapy for pancreatic cancer&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Endocrine therapy&lt;ul&gt;&lt;li&gt;No concurrent dexamethasone&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Radiotherapy&lt;ul&gt;&lt;li&gt;No prior radiotherapy for pancreatic cancer&lt;/li&gt;&lt;li&gt;No prior external beam photon (x-ray) therapy to the chest, abdomen, or pelvis&lt;/li&gt;&lt;li&gt;No concurrent intensity modulated radiotherapy&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Surgery:&lt;ul&gt;&lt;li&gt;See disease characteristics&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Other:&lt;ul&gt;&lt;li&gt;Underwent potentially curative therapy for any prior malignancies&lt;/li&gt;&lt;li&gt;No prior chronic immunosuppressive therapy (eg, prednisone or methotrexate) for             collagen vascular disease or other chronic immunological abnormality&lt;/li&gt;&lt;li&gt;No concurrent theophylline&lt;/li&gt;&lt;li&gt;No concurrent aminoglycoside antibiotics&lt;/li&gt;&lt;li&gt;No concurrent halogenated antiviral agents (eg, sorivudine)&lt;/li&gt;&lt;li&gt;No other concurrent investigational drugs for pancreatic cancer&lt;/li&gt;&lt;li&gt;No other concurrent systemic or loco-regional therapy for pancreatic cancer&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><MeasuresOutcome><MeasuresPrimary><Measure><Description>Overall survival</Description><Timeframe>At 18 months</Timeframe></Measure></MeasuresPrimary><MeasureSecondary><Measure><Description>Toxicity</Description><Timeframe>At 18 months</Timeframe></Measure><Measure><Description>Disease-free survival</Description><Timeframe>At 18 months</Timeframe></Measure><Measure><Description>Local-regional disease control</Description><Timeframe>At 18 months</Timeframe></Measure><Measure><Description>Distant disease control</Description><Timeframe>At 18 months</Timeframe></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AdverseEvents>&lt;AdverseEvents&gt;&lt;para&gt;A total of 84 patients were assessable for toxicity. During therapy, the all-cause grade &gt;/= 3 toxicity rate was 95% (n = 80). There was no long-term toxicity or toxicity-related deaths [&lt;ulink linkType="Reference" linkID="1175983"&gt;1175983&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdverseEvents&gt;</AdverseEvents><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;This phase II trial was designed to study the effectiveness of adjuvant chemoradiotherapy and      &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa&lt;/ulink&gt; in treating patients who had resected stage I,  II or  III      pancreatic cancer.&lt;/para&gt;&lt;para&gt;The objectives of the study were:&lt;br/&gt;To determine the disease-free and overall survival of patients with resected pancreatic           adenocarcinoma treated with adjuvant chemoradiotherapy comprising fluorouracil,           cisplatin, and &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa-2b&lt;/ulink&gt;.&lt;br/&gt;To determine the rate and severity of acute and late toxic effects in patients treated           with this regimen.&lt;br/&gt;To determine the local-regional disease control and distant disease control in patients           treated with this regimen.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><Outcomes>&lt;Outcomes&gt;&lt;para&gt;In February 2011, results were published. At 36-month median follow-up, the OS18 was 69%; the median disease-free survival was14.1 months and overall survival was 25.4 months, respectively [&lt;ulink linkType="Reference" linkID="1175983"&gt;1175983&lt;/ulink&gt;].&lt;/para&gt;&lt;/Outcomes&gt;</Outcomes><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;This would be a multicenter study.A total of 89 patients would be accrued for this study within two years.&lt;br/&gt;Chemoradiotherapy (CRT): patients would receive fluorouracil 175 mg/m2/day iv continuous infusion for 38 consecutive days, unless toxicity occurs;           cisplatin iv over 1 h on days 1, 8, 15, 22, 29, and 36; and &lt;ulink linkType="Drug" linkID="45998"&gt;interferon alfa-2b&lt;/ulink&gt;           3 million units sc on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, 33, 36, and           38. Patients also undergo radiotherapy (XRT) 5040 cGy total, in 28 fractions, at 180 cGy/fraction on days 1 to 5, 8 to 12, 15 to 19, 22 to 26, 29 to 33, and           36 to 38.&lt;br/&gt;Post-CRT chemotherapy: beginning 4 to 6 weeks after the completion of CRT, patients           would receive fluorouracil iv continuously on days 1 to 42. Treatment repeats every 56 days for           a total of two courses in the absence of disease progression or unacceptable toxicity.5-fluorouracil continuous infusion via an ambulatory infusion pump into a central venous catheter at 200 mg/m2/day for 6 weeks followed by 2 weeks of rest.&lt;/para&gt;&lt;para&gt;Patients would be followed every 2 months for two years, every 3 months for one year, every 4 months      for one year, every 6 months for one year, and then annually thereafter.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription><Regimens>&lt;Regimens&gt;&lt;para&gt;The primary end point of the study was 18-month overall survival from protocol enrollment (OS18); an OS18 &gt;/= 65% was considered a positive study outcome. Patients received 3 MU &lt;ulink linkType="Drug" linkID="45998"&gt;interferon-alfa-2b&lt;/ulink&gt; sc on days 1, 3, and 5 of each week for 5.5 weeks, 30 mg/m2 cisplatin iv weekly for 6 weeks, and continuous infusion of 175 mg/m2/day of 5-fluorouracil for 38 days concurrently with external-beam radiation (50.4 Gy). Chemoradiation was followed by two 6-week courses of continuous infusion 5-FU (200 mg/m2/day) [&lt;ulink linkType="Reference" linkID="1175983"&gt;1175983&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regimens&gt;</Regimens></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions><DoseRouteByIntervention><Intervention id="184713">5-fluorouracil</Intervention><Treatments><Treatment><Dose>175 milligram/m2</Dose><Route></Route></Treatment><Treatment><Dose>200 milligram/m2</Dose><Route></Route></Treatment></Treatments></DoseRouteByIntervention><DoseRouteByIntervention><Intervention id="184712">cisplatin</Intervention><Treatments><Treatment><Dose>30 milligram/m2</Dose><Route>Intravenous</Route></Treatment></Treatments></DoseRouteByIntervention></DoseRouteByInterventions><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>University of Florida Shands Cancer Center</Name><Address1>Gainesville</Address1><Address2>Florida</Address2><Address3>32610-0232</Address3><CountrySubDivision code="FL">Florida</CountrySubDivision><Contacts/></Site><Site><Name>Rush University Medical Center</Name><Address1>Chicago</Address1><Address2>Illinois</Address2><Address3>60612</Address3><CountrySubDivision code="IL">Illinois</CountrySubDivision><Contacts/></Site><Site><Name>James Graham Brown Cancer Center at University of Louisville</Name><Address1>Louisville</Address1><Address2>Kentucky</Address2><Address3>40202</Address3><CountrySubDivision code="KY">Kentucky</CountrySubDivision><Contacts/></Site><Site><Name>Brigham and Women's Hospital</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02115</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Massachusetts General Hospital Cancer Center</Name><Address1>Boston</Address1><Address2>Massachusetts</Address2><Address3>02114</Address3><CountrySubDivision code="MA">Massachusetts</CountrySubDivision><Contacts/></Site><Site><Name>Fairview University Medical Center - University Campus</Name><Address1>Minneapolis</Address1><Address2>Minnesota</Address2><Address3>55455</Address3><CountrySubDivision code="MN">Minnesota</CountrySubDivision><Contacts/></Site><Site><Name>Roswell Park Cancer Institute</Name><Address1>Buffalo</Address1><Address2>New York</Address2><Address3>14263-0001</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Memorial Sloan-Kettering Cancer Center</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>James P. Wilmot Cancer Center at University of Rochester Medical Center</Name><Address1>Rochester</Address1><Address2>New York</Address2><Address3>14642</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site><Site><Name>Vanderbilt-Ingram Cancer Center</Name><Address1>Nashville</Address1><Address2>Tennessee</Address2><Address3>37232</Address3><CountrySubDivision code="TN">Tennessee</CountrySubDivision><Contacts/></Site><Site><Name>Presbyterian Hospital of Dallas</Name><Address1>Dallas</Address1><Address2>Texas</Address2><Address3>75231</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Baylor University Medical Center - Houston</Name><Address1>Houston</Address1><Address2>Texas</Address2><Address3>77030</Address3><CountrySubDivision code="TX">Texas</CountrySubDivision><Contacts/></Site><Site><Name>Medical College of Wisconsin Cancer Center</Name><Address1>Milwaukee</Address1><Address2>Wisconsin</Address2><Address3>53226</Address3><CountrySubDivision code="WI">Wisconsin</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>Pancreas tumor</Disease><PatientSegments><PatientSegment><PatientSegment id="8071">Subjects with Localized Pancreatic Cancer</PatientSegment><SubSegments><SubSegment id="8082">TNM Stage I pancreatic cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="8072">Subjects with Locally Advanced Pancreatic Cancer</PatientSegment><SubSegments><SubSegment id="8083">TNM Stage II pancreatic cancer</SubSegment><SubSegment id="8084">TNM Stage III pancreatic cancer</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="11424">Subjects with Adenocarcinoma of Pancreas</PatientSegment></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00059826</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pancreas tumor" id="13344"><Endpoint>Assessment of Overall Survival (OS)</Endpoint></PrimaryEndpoint></PrimaryEndpoints><SecondaryEndpoints><SecondaryEndpoint disease="Hypertension" id="1"><Endpoint>Assessment of Blood Pressure (BP)</Endpoint><SubEndpoints><SubEndpoint disease="Hypertension" id="2">BP control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13345"><Endpoint>Assessment of Disease Free Survival (DFS)</Endpoint></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13356"><Endpoint>Assessment of Response Rates (RR)</Endpoint><SubEndpoints><SubEndpoint disease="Pancreas tumor" id="13374">Assessment of disease control rate</SubEndpoint></SubEndpoints></SecondaryEndpoint><SecondaryEndpoint disease="Pancreas tumor" id="13433"><Endpoint>Assessment of Safety and Tolerability</Endpoint></SecondaryEndpoint></SecondaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="Pancreas tumor" id="8812"><Criterion>TNM Stage I pancreatic cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8813"><Criterion>TNM Stage II pancreatic cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8814"><Criterion>TNM Stage III pancreatic cancer</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8816"><Criterion>Subjects with Locally Advanced Cancer/Tumor</Criterion></Inclusion><Inclusion disease="Pancreas tumor" id="8845"><Criterion>Subjects with History of Anti Cancer Therapy</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="8850">Subjects with history of surgery/procedure for Pancreatic cancer</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pancreas tumor" id="13495"><Criterion>Subjects with Histological Subtypes of Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="13496">Subjects with Pancreatic adenocarcinoma</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="Pancreas tumor" id="10370"><Criterion>Subjects with Advanced/Metastatic/Stage IV Pancreatic Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="10371"><Criterion>Subjects with Pancreatic Endocrine Tumors (PETs)</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="10373">Subjects with Islet cell tumor</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pancreas tumor" id="10414"><Criterion>Subjects with Relapsed/Recurrent Pancreatic Cancer</Criterion></Exclusion><Exclusion disease="Pancreas tumor" id="11232"><Criterion>Subjects With Histological Subtypes Of Pancreatic Cancer</Criterion><SubCriteria><SubCriterion disease="Pancreas tumor" id="11233">Subjects with pancreatic adenosquamous carcinoma</SubCriterion><SubCriterion disease="Pancreas tumor" id="11234">Subjects with Cystadenocarcinoma</SubCriterion><SubCriterion disease="Pancreas tumor" id="11238">Subjects with Cystadenoma</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><PrimaryCompletionDate type="Actual">2007-07-31T00:00:00Z</PrimaryCompletionDate><DateEnrollmentEnd type="actual">2006-03-31T00:00:00Z</DateEnrollmentEnd><EnrollmentPeriod>36.03 Months</EnrollmentPeriod><EnrollmentRate>2.47 Patients/Month</EnrollmentRate><DateFirstReceived>2003-05-06T00:00:00Z</DateFirstReceived><FundersType><Type>Academic</Type><Type>Government</Type></FundersType><ChangeHistory><Change type="added"><Date>2011-03-22T04:21:52Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial><Trial id="92307"><TitleDisplay>A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART</TitleDisplay><TitleOfficial>A Study to Investigate the Potential of Thalidomide Treatment to Enhance Immune Responses in HIV-Infected Individuals Who Are Receiving Highly Active Antiretroviral Therapy</TitleOfficial><OutcomesAvailable>No</OutcomesAvailable><EndpointsAchieved>Unknown</EndpointsAchieved><Identifiers><Identifier type="Organisational Study">279A</Identifier><Identifier type="NCT">NCT00002392</Identifier></Identifiers><Indications><Indication id="158">HIV infection</Indication></Indications><BiomarkerNames/><InterventionsPrimaryByRegimen regimenType="single"><Interventions><Intervention type="InterventionPrimary"><Name>thalidomide</Name></Intervention></Interventions></InterventionsPrimaryByRegimen><InterventionsControlByRegimens/><DrugsAsInterventionPrimary/><CrossReferences><SourceEntity id="20670" type="Company"><TargetEntity id="4296485220" type="organizationId">Rockefeller University</TargetEntity></SourceEntity><SourceEntity id="158" type="ciIndication"><TargetEntity id="B20" type="ICD10"/><TargetEntity id="042" type="ICD9"/><TargetEntity id="10020161" type="MEDDRA"/><TargetEntity id="D015658" type="MeSH"/><TargetEntity id="-841965209" type="omicsDisease"/><TargetEntity id="862" type="siCondition"/></SourceEntity></CrossReferences><Phase>Phase not specified</Phase><RecruitmentStatus id="4">Completed</RecruitmentStatus><NumberOfSites>1</NumberOfSites><CompaniesSponsor><Company id="20670">Rockefeller University</Company></CompaniesSponsor><CompaniesCollaborator><Company id="1073245">NIH AIDS Clinical Trials Information Service</Company></CompaniesCollaborator><IsCommerciallySignificant>No</IsCommerciallySignificant><Technologies/><TermsPatientSelection><Term>Aged Adults (65-79 yrs)</Term><Term>Elderly Adults (80 and over)</Term><Term>Middle-aged Adults (45-64 yrs)</Term><Term>Young Adults (18-44 yrs)</Term></TermsPatientSelection><TrialCategories><Category>Small molecule</Category></TrialCategories><TermsDesign><Term>Placebo Control</Term><Term>Treatment</Term><Term>Interventional</Term></TermsDesign><TermsEndpoint><Term>Efficacy</Term></TermsEndpoint><PatientCountEnrollment>12</PatientCountEnrollment><DateStart>1999-11-02T00:00:00Z</DateStart><DateChangeLast>2013-09-13T17:48:28Z</DateChangeLast><DateAdded>2012-09-27T07:54:32Z</DateAdded><Contacts/><CriteriaInclusion>&lt;Inclusion&gt;&lt;ul&gt;&lt;li&gt;Patients must have:&lt;ul&gt;&lt;li&gt;Documented HIV infection&lt;/li&gt;&lt;li&gt;CD4+ cell count between 300 and 500 cells/mm3&lt;/li&gt;&lt;li&gt;HIV-1 RNA&amp;lt; 500 by the branched-chain DNA assay (bDNA assay, Chiron) within 21 days of             study entry (As per amendment 11/25/98)&lt;/li&gt;&lt;li&gt;Undetectable-plasma HIV titers (as defined by the FDA) by the branched-chain DNA             test]&lt;/li&gt;&lt;li&gt;Established B cell lines (deleted as per amendment  11/25/98)&lt;/li&gt;&lt;li&gt;Response to at least one recall antigen in an in vitro assay of lymphocyte             proliferative responses&lt;/li&gt;&lt;li&gt;Life expectancy&amp;gt; 6 months (deleted as per amendment 11/25/98)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Inclusion&gt;</CriteriaInclusion><CriteriaExclusion>&lt;Exclusion&gt;&lt;ul&gt;&lt;li&gt;Co-existing condition:&lt;ul&gt;&lt;li&gt;Patients with the following conditions or symptoms are excluded:&lt;ul&gt;&lt;li&gt;Active opportunistic infection or HIV-related malignancy (HIV-related malignancy             deleted as per amendment 11/25/98)&lt;/li&gt;&lt;li&gt;Peripheral neuropathy of grade 2 or higher by Division of AIDS toxicity criteria&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Concurrent medication:&lt;ul&gt;&lt;li&gt;Excluded:&lt;ul&gt;&lt;li&gt;Other investigational HIV-drugs&lt;/li&gt;&lt;li&gt;Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids,             hematopoietins, interleukin-2, interferon, or pentoxifylline&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Patients with the following prior conditions are excluded:&lt;ul&gt;&lt;li&gt;History of serious hypersensitivity to tetanus toxoid or any of the vaccine components&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Prior Medication:&lt;ul&gt;&lt;li&gt;Excluded:&lt;ul&gt;&lt;li&gt;Previous immunization with pneumococcal polysaccharide vaccine (or, as per amendment             11/25/98, keyhole limpet hemocyanin vaccine)&lt;/li&gt;&lt;li&gt;Tetanus toxoid booster within five years (deleted as per amendment 11/25/98)&lt;/li&gt;&lt;li&gt;Other investigational HIV-drugs within 6 weeks of enrollment&lt;/li&gt;&lt;li&gt;Immunomodulatory or potentially immunomodulatory drugs, such as glucocorticoids,             hematopoietins, interleukin-2, interferon, or pentoxifylline within 6 weeks of             enrollment&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Risk behavior:&lt;ul&gt;&lt;li&gt;Excluded:&lt;ul&gt;&lt;li&gt;Active drug or alcohol abuse&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;li&gt;Required:&lt;ul&gt;&lt;li&gt;Effective combination antiretroviral therapy including two nucleoside analog agents (ZDV,        3TC, ddI, ddC, or d4T) and nelfinavir or indinavir, for at least one month prior to study        entry.  (As per amendment 11/25/98:On stable, effective, highly-active antiretroviral therapy with combinations of any             FDA-approved anti-HIV drugs for &gt;/= 3 months prior to entry)&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/li&gt;&lt;/ul&gt;&lt;/Exclusion&gt;</CriteriaExclusion><MeasuresOutcome><MeasuresPrimary/><MeasureSecondary><Measure><Description>Efficacy</Description></Measure></MeasureSecondary></MeasuresOutcome><ProtocolAndOutcomes><AimsAndScope>&lt;AimAndScope&gt;&lt;para&gt;The aim of the study was to ascertain the effect of &lt;ulink linkType="Drug" linkID="8050"&gt;thalidomide&lt;/ulink&gt; on immune responses to vaccination with polyvalent      pneumococcal polysaccharide vaccine and tetanus toxoid in HIV-infected patients,      particularly on markers of immune activation and parameters of specific, anti-HIV cellular      immunity.&lt;/para&gt;&lt;/AimAndScope&gt;</AimsAndScope><ProtocolDescription>&lt;ProtocolDescription&gt;&lt;para&gt;Patients would receive oral &lt;ulink linkType="Drug" linkID="8050"&gt;thalidomide&lt;/ulink&gt; in a blinded, placebo-controlled study.&lt;/para&gt;&lt;/ProtocolDescription&gt;</ProtocolDescription></ProtocolAndOutcomes><AdverseEventsByInterventions/><DoseRouteByInterventions/><SitesByCountries><SitesByCountry country="US"><Sites><Site><Name>Aaron Diamond AIDS Rsch Ctr / Rockefeller Univ</Name><Address1>New York</Address1><Address2>New York</Address2><Address3>10021</Address3><CountrySubDivision code="NY">New York</CountrySubDivision><Contacts/></Site></Sites></SitesByCountry></SitesByCountries><PatientSegmentTerms><PatientSegmentByDisease><Disease>HIV infection</Disease><PatientSegments><PatientSegment><PatientSegment id="7108">Subjects on Prior/Concurrent Antiretroviral Therapy</PatientSegment><SubSegments><SubSegment id="7112">Subjects on prior/concurrent HAART</SubSegment></SubSegments></PatientSegment><PatientSegment><PatientSegment id="19022">Subjects with HIV Infection</PatientSegment><SubSegments><SubSegment id="7126">Subjects with HIV-1 Infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease><PatientSegmentByDisease><Disease>Pneumococcal Vaccine</Disease><PatientSegments><PatientSegment><PatientSegment id="8346">Subjects with History of/Suspected Infectious Disorders</PatientSegment><SubSegments><SubSegment id="8349">Subjects with history of/suspected HIV infection</SubSegment></SubSegments></PatientSegment></PatientSegments></PatientSegmentByDisease></PatientSegmentTerms><TrialRegistries><Registry><Name id="1000">NLM ClinicalTrials.gov</Name><Identifiers><Identifier type="NCT">NCT00002392</Identifier></Identifiers></Registry></TrialRegistries><OutcomeMeasureTerms><PrimaryEndpoints><PrimaryEndpoint disease="HIV infection" id="9218"><Endpoint>Assessment of Immune Response</Endpoint></PrimaryEndpoint><PrimaryEndpoint disease="Pneumococcal Vaccine" id="15078"><Endpoint>Assessment of Immune Response</Endpoint><SubEndpoints><SubEndpoint disease="Pneumococcal Vaccine" id="15079">Assessment of anti-pneumococcal antibody concentration</SubEndpoint></SubEndpoints></PrimaryEndpoint><PrimaryEndpoint disease="Pneumococcal Vaccine" id="15094"><Endpoint>Assessment of Laboratory/Diagnostic Measures</Endpoint></PrimaryEndpoint></PrimaryEndpoints></OutcomeMeasureTerms><EligibilityCriteriaTerms><InclusionCriteria><Inclusion disease="HIV infection" id="5278"><Criterion>Subjects with HIV Infection</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5418">Subjects with HIV-1 infection</SubCriterion></SubCriteria></Inclusion><Inclusion disease="HIV infection" id="5311"><Criterion>Subjects with Specific HIV Test Results</Criterion></Inclusion><Inclusion disease="HIV infection" id="5317"><Criterion>Subjects with Protocol Specified HIV Viral Load</Criterion></Inclusion><Inclusion disease="HIV infection" id="5322"><Criterion>Subjects with Protocol Specified CD4+ T Cell Counts </Criterion></Inclusion><Inclusion disease="HIV infection" id="5344"><Criterion>Subjects on Prior/Concurrent Antiretroviral Therapy</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="5345">Subjects on prior/concurrent nucleoside reverse transcriptase inhibitors</SubCriterion><SubCriterion disease="HIV infection" id="5347">Subjects on prior/concurrent protease inhibitors</SubCriterion><SubCriterion disease="HIV infection" id="5348">Subjects on prior/concurrent HAART (Highly Active Anti Retroviral Therapy)</SubCriterion></SubCriteria></Inclusion><Inclusion disease="Pneumococcal Vaccine" id="13704"><Criterion>Subjects with History of/Suspected Infectious Disorders</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="13707">Subjects with history of/suspected HIV infection</SubCriterion></SubCriteria></Inclusion></InclusionCriteria><ExclusionCriteria><Exclusion disease="HIV infection" id="6820"><Criterion>Subjects with Opportunistic/Other Infections</Criterion></Exclusion><Exclusion disease="HIV infection" id="6850"><Criterion>Subjects with History of/Active Malignancy/Cancer</Criterion></Exclusion><Exclusion disease="HIV infection" id="6866"><Criterion>Subjects with Hypersensitivity/Contraindications to Drugs/Excipients</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="7809">Hypersensitivity/contraindications to vaccines</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6892"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6896">Subjects with history of/schedule for corticosteroids for other indication</SubCriterion><SubCriterion disease="HIV infection" id="6963">Subjects with history/scheduled to receive immunomodulators for other indication</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="6967"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6969">Subjects with prior other vaccination</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11828"><Criterion>Subjects with Prior History of/Scheduled for Pneumococcal Vaccination</Criterion></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11837"><Criterion>Subjects with history of/scheduled to receive therapy for other indication</Criterion></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11849"><Criterion>Subjects with Contraindication to Vaccine/Vaccine Ingredients</Criterion></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11858"><Criterion>Subjects at Risk/History of Infections</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="11861">Subjects at risk/history of human immunodeficiency virus (HIV) infection</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11865"><Criterion>Subjects co-morbid with CNS disorders</Criterion></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="11875"><Criterion>Subjects with Autoimmune/Immunological Disorders</Criterion></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="25884"><Criterion>Immunocompromised Subjects</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="11891">Subjects immunocompromised with cancer/malignancy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="HIV infection" id="25989"><Criterion>Subjects co-morbid with neurological disorders/diseases</Criterion><SubCriteria><SubCriterion disease="HIV infection" id="6833">Subjects co-morbid with peripheral neuropathy</SubCriterion></SubCriteria></Exclusion><Exclusion disease="Pneumococcal Vaccine" id="26537"><Criterion>Subjects with Prior Vaccination</Criterion><SubCriteria><SubCriterion disease="Pneumococcal Vaccine" id="11836">Subjects with Prior Other Vaccination</SubCriterion></SubCriteria></Exclusion></ExclusionCriteria></EligibilityCriteriaTerms><FundersType><Type>Academic</Type></FundersType><ChangeHistory><Change type="added"><Date>2012-09-27T07:54:32Z</Date><Reason id="301">Clinical trial added</Reason></Change><Change type="updated"><Date>2013-08-04T13:54:02Z</Date><Reason id="305">Change history start date</Reason></Change></ChangeHistory></Trial></trialRecordsOutput>